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Current cartilage regeneration techniques are ineffective in directly restoring the 
mechanical and biological functions of native hyaline cartilage.  Therefore, using the 
paracrine actions of stem cell therapies to stimulate endogenous cartilage regeneration 
has gained momentum.  Adipose stem cells (ASCs) are an attractive option for this 
endeavor because of their accessibility, chondrogenic potential, and secretion of factors 
that promote connective tissue repair.  In order to use the factors secreted by ASCs to 
stimulate cartilage regeneration, the molecular signaling mechanisms that affect postnatal 
cartilage development and changes in morphology need to be understood.  Next, 
approaches need to be developed to tailor the secretory profile of ASCs and to evaluate 
their effect on cartilage regeneration.  Finally, delivery methods that localize ASCs 
within a defect site while facilitating paracrine factor secretion need to be optimized.   
The growth plate is a unique model for understanding cartilage development 
because the different temporal stages of chondrogenesis are spatially organized in 
hierarchical zones within this tissue.  Counter-intuitively though, X-ray opaque tethers 
that link the epiphysis and metaphysis have previously been observed in rat tibial growth 
plates and increase with age as the growth plate (GP) becomes thinner.  To determine if 
tether formation is a regulated process of GP maturation, we tested the hypotheses that 
tether properties and distribution can be quantified by CT, that rachitic growth plates 
typical of vitamin D receptor knockout (VDR-/-) mice have fewer tethers and altered 
tether distribution, and that tether formation is regulated by signaling via the VDR.  
Distal femoral GPs from VDR+/+ and VDR-/- 8-week old C57Bl/6 mice were analyzed 
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with CT and then processed for decalcified and undecalcified histomorphometry.  A 
wide range of parameters that assessed GP and tether geometry and morphology, along 
with tether distribution, was measured using both CT and histology.  Growth plates of 
10 week old VDR+/+ and VDR-/- mice on a high calcium, phosphorus, lactose, and 
vitamin D3 rescue diet were also analyzed.  Both microCT and histology showed tethers 
present throughout normal mice GPs, while reduction in tether number and volume 
percentage occurred in VDR-/- GPs with localization to the central region.  Decreased 
shrinkage in the axial direction during decalcified histological processing correlated with 
tether formation, suggesting mechanical stability due to tethers.  Tether formation 
increased greatly between 8 and 10 weeks.  Rescue diets restored VDR-/- GP size but not 
tether volume percentage.  Overall, these results demonstrated CT imaging’s utility for 
analyzing tether formation and suggested that signaling via the vitamin D receptor plays a 
pivotal role in tether formation.  
Although observed in the growth plate, it is unknown if tethers are present in 
other growth centers, if they are regulated in a comparable manner, or if they have a 
functional role in skeletal development or stability.  To address this, distal femoral 
growth plates (GPs) and spheno-occipital synchondroses (SOSs) of wild-type C57Bl/6 
mice from 2 to 15 weeks of age were analyzed using CT scans.  The GPs and SOSs of 
VDR+/+ and VDR-/- mice fed regular or rescue diets to restore mineral homeostasis until 
10 weeks of age were also scanned.  Tethers in GPs and SOSs both thickened and 
accumulated in number as these growth centers decreased in size.  Ablating the VDR 
made GPs and SOSs rachitic and nearly eliminated tether formation.  Rescue diets 
restored the volume of both growth centers but only partially restored growth center 
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thickness and tether formation, suggesting that l,25-dihydroxy vitamin-D3 partially 
regulates tether formation in these growth centers via its receptor.  In VDR+/+ mice 2-15 
weeks in age, growth center thickness was inversely correlated to animal weight whereas 
tether phenotype (tether volume/growth center volume, tether number/mm, tether width, 
tether spacing) was significantly related to animal weight.  In both 2-15 week old 
VDR+/+ and 10 week old VDR+/+ and VDR-/- mice on normal and rescue diets, tether 
phenotype (tether number/mm, tether spacing) had strikingly similar relationships to 
growth center thickness.  These results showed that tethers are present in growth centers 
in different anatomic and undergo developmental changes in a comparable manner; in 
both sites, VDR-regulated tether formation is strongly linked to growth center 
morphology; and tether formation is associated with body weight, suggesting a role in 
maintaining growth plate stability during growth. 
After developing a better intuition of the signaling mechanisms that regulate 
cartilage formation, effective strategies are needed to direct the secretion of multiple 
growth factors from ASCs.  ASCs differentiated in chondrogenic medium have 
previously been used to directly replace chondrocytes, but it is unknown if chondrogenic 
treatment alone can optimize ASC growth factor secretion for cartilage regeneration.  The 
objective of this next study was to determine the effects chondrogenic medium and its 
components have on growth factor production from ASCs in order to promote cartilage 
regeneration.  ASCs isolate from male Sprague Dawley rats and cultured in monolayer or 
alginate microbeads were treated with growth (GM) or chondrogenic medium (CM) for 5 
days.  In subsequent studies, ASC monolayers were treated with GM supplemented with 
different combinations of 50 μg/mL ascorbic acid-2-phosphate (AA2P), 100 nM 
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dexamethasone (Dex), 10 ng/mL TGF-β1, and 100 ng/mL BMP-6 or CM excluding 
different combinations of AA2P, Dex, TGF-β1, and BMP-6.  Gene expression 8 hours 
after the last media change and growth factor production over 24 hours were quantified.  
Gene array analysis showed that ASCs had high mRNA levels of signaling molecules in 
the TGF-β and MAPK signaling pathways compared to liver mRNA.  CM increased 
mRNA levels and secretion of TGF- β2, TGF- β3, and IGF-I, and decreased mRNA 
levels and secretion of VEGF-A and FGF-2 while microencapsulation in GM increased 
production of IGF-I, TGF- β2, and VEGF-A.  In both GM and CM, AA2P increased IGF-
I and TGF-β2 secretion and decreased FGF-18 mRNA levels and VEGF-A secretion, Dex 
increased BMP-2 and FGF-18 mRNA levels and decreased VEGF-A secretion, TGF-β1 
increased FGF-2 and VEGF-A secretion and decreased IGF-I and PTHrP mRNA levels, 
and  BMP-6 increased noggin and FGF-18 gene mRNA levels and TGF-β2 secretion.   
These results showed that differentiation media components have distinct effects on 
ASCs and can be used to tailor ASC trophic factor secretion to regenerate different 
musculoskeletal tissues. 
After observing these findings in rat-derived ASCs, human ASCs were 
investigated.  Microencapsulating human ASCs in injectable microbeads can enhance the 
delivery and localization of these therapies, but their ability to act as growth factor 
production sources are still unknown.  To address this concern, the effects of 
microencapsulation in both GM and CM on ASC growth factor expression and secretion 
from 6 donors were studied.  Additionally, the effects of crosslinking and alginate 
compositions on growth factor expression and production were determined.  For ASCs 
derived from different donors, microencapsulation increased PTHrP mRNA levels and 
 xxii 
secretion of IGF-I and TGF-β3.  Meanwhile, CM decreased FGF-2 mRNA levels and 
VEGF-A secretion from ASC microbeads derived from the same donor population.  
Crosslinking microbeads in BaCl2 instead of CaCl2 did not eliminate the beneficial 
effects of microencapsulation, but did decrease IGF-I mRNA levels and production.  
Increasing the guluronate content of the alginate microbead increased TGF-β3 mRNA 
levels and IGF-I maintained within the microbeads.  Decreasing the molecular weight of 
the alginate used eliminated the effects microencapsulation had on increasing IGF-I 
secretion while increasing the molecular weight of alginate used decreased PTHrP 
mRNA levels.  This study demonstrated that microbeads can enhance growth factor 
secretion from human ASCs and may serve as a reliable source for delivering multiple 
growth factors to regenerate cartilage. 
After thorough characterization of ASCs’ secretory profiles under different 
preconditioning treatments, a better understanding of how ASCs and their secreted 
factors influence cartilage regeneration was needed.  Therefore, the effects ASC-secreted 
factors have in repairing chondral defects were studied.  ASCs isolated from male 
Sprague Dawley rats were cultured in monolayer or alginate microbeads supplemented 
with GM or CM.  Subsequent co-culture, conditioned media, and in vivo cartilage defect 
studies were performed.  ASC monolayers and microbeads cultured in CM had decreased 
FGF-2 mRNA levels and VEGF-A secretion compared to ASCs cultured in GM.  
Chondrocytes co-cultured with GM-cultured ASCs for 7 days had decreased mRNAs for 
col2, comp, and runx2.  Chondrocytes treated for 12 or 24 hours with conditioned 
medium from GM-cultured ASCs had reduced sox9, acan, and col2 mRNAs; reduced 
proliferation and proteoglycan synthesis; and increased apoptosis.  ASC-conditioned 
 xxiii 
medium also increased endothelial cell tube lengthening whereas conditioned medium 
from CM-cultured ASCs had no effect.  Treating ASCs with CM reduced or abolished 
these deleterious effects while adding a neutralizing antibody for VEGF-A eliminated 
ASC-conditioned medium induced chondrocyte apoptosis and restored proteoglycan 
synthesis.  FGF-2 also mitigated the deleterious effects VEGF-A had on chondrocyte 
apoptosis and phenotype.  When GM-grown ASC pellets were implanted in 1 mm non-
critical hyaline cartilage defects in vivo, cartilage regeneration was inhibited as evaluated 
by radiographic and equilibrium partitioning of an ionic contrast agent via μCT imaging.  
Histology revealed that defects with GM-cultured ASCs had no tissue ingrowth from the 
edges of the defect whereas empty defects and defects with CM-grown ASCs had similar 
amounts of neocartilage formation.  Based on these findings, ASCs must be treated to 
reduce the secretion of VEGF-A and other factors that inhibit cartilage regeneration, 
which can significantly influence how ASCs are used for repairing hyaline cartilage. 
Before the modified paracrine actions of ASCs can be used to repair cartilage, 
delivery within alginate microbeads needs to be optimized.  Alginate calcification has 
been previously reported clinically and during preclinical studies; however no study has 
investigated the mechanism, extensively characterized the mineral, or evaluated multiple 
methods to regulate or eliminate mineralization.  In the present study, alginate 
calcification was first studied in vitro: calcium-crosslinked alginate beads sequestered 
surrounding phosphate while forming traces of hydroxyapatite.  Calcification in vivo was 
then examined in nude mice using alginate microbeads with and without ASCs.  
Variables included the delivery method, site of delivery, sex of the animal, time in vivo, 
crosslinking solution, and method of storage prior to delivery.  Calcium-crosslinked 
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alginate microbeads mineralized when injected subcutaneously or implanted 
intramuscularly after 1 to 6 months.  More extensive analysis with histology, μCT, FTIR, 
XRD, and EDS showed calcium phosphate deposits throughout the microbeads with 
surface mineralization that closely matched hydroxyapatite found in bone.  Incorporating 
25M bisphosphonate reduced alginate calcification whereas using barium chloride 
eliminated mineralization.  Buffering the crosslinking solution with HEPES at pH 7.3 
while washing and storing samples in basal media prior to implantation also eliminated 
calcification in vivo.  This study showed that alginate processing prior to implantation can 
significantly influence bulk hydroxyapatite formation and presents a method to regulate 
alginate calcification. 
Finally, once the formulation of alginate microbeads was optimized, the method 
in which they were delivered into cartilage focal defects needed to be modified to 
promote cartilaginous tissue infiltration.  ASC microbeads preconditioned with GM and 
CM were implanted into 3 mm critically-sized xiphoid defects.  In a separate study, ASC 
microbeads preconditioned in GM and CM and immobilized in an RGD-conjugated 
hydrogel mixture were implanted into 2 mm critically-sized defects.  ASC microbeads 
implanted without the hydrogel mixture did not promote cartilage regeneration within the 
defect after 35 days and performed no better than empty microbeads.  ASC microbeads 
preconditioned with GM and immobilized within a RGD-conjugated hydrogel promoted 
limited tissue infiltration and perichondrium formation after 35 days.  Meanwhile, ASC 
microbeads preconditioned with CM and immobilized within a RGD-conjugated 
hydrogel promoted tissue infiltration from the edges of the defect and perichondrium.  
The RGD-conjugated hydrogel alone did not promote any tissue deposition within the 
 xxv 
defect.  The results from this study showed that both the paracrine actions of ASC 
microbeads and a biomimetic scaffold that facilitates cell migration may be needed to 
facilitate focal cartilage defect regeneration. 
This work was innovative because it developed a novel micro-CT evaluation 
method to study 3D tether morphology within anatomically distinct growth centers.  This 
work also established a new set of criteria to investigate the therapeutic potential of stem 
cell therapies while developing methods to control the paracrine actions of ASCs for 
cartilage regeneration.  Furthermore, this work created new formulations and methods to 
control the extent of alginate calcification in vivo and tissue infiltration within a focal 
cartilage defect.  This work was significant because it determined the molecular 
mechanism that regulates tether formation within the growth plate and proposed the 
functional role these mineralized structures may have in cartilage and bone development.  
Additionally, this work showed that VEGF-A secreted by ASCs can inhibit cartilage 
regeneration and that preconditioning methods can reduce secretion of this angiogenic 
growth factor while increasing secretion of chondrogenic growth factors.  Finally, this 
work showed that alginate can form hydroxyapatite in vivo via its calcium crosslinks and 
that both paracrine actions of ASCs and biomaterials that promote cell migration are 







Current cartilage repair methods are ineffective in restoring the mechanical and 
biological functions of native hyaline cartilage.  Therefore, using the paracrine actions of 
stem cell therapies to stimulate endogenous cartilage regeneration has gained momentum.  
Adipose stem cells (ASCs) are an attractive option for this endeavor because of their 
accessibility, chondrogenic potential, and secretion of factors that promote connective 
tissue repair.  In order to use the factors secreted by ASCs to stimulate cartilage 
regeneration, the signaling pathways that affect postnatal cartilage development and 
morphology need to be understood.  Next, approaches need to be developed to tailor the 
secretory profile of ASCs to promote cartilage regeneration.  Finally, delivery methods 
that localize ASCs within a defect site while facilitating paracrine factor secretion need to 
be optimized.   
The overall objective of this thesis was to develop an ASC therapy that could be 
effectively delivered in cartilage defects and stimulate regeneration via its paracrine 
actions.  The general hypothesis was that the secretory profile of ASCs can be tailored to 
enhance cartilage regeneration and be effectively delivered to regenerate cartilage in vivo.  
The overall approach used the growth plate as an initial model to study changes in 
postnatal cartilage morphology and the molecular mechanisms that regulate it, different 
media treatments and microencapsulation to tailor growth factor production, and alginate 
microbeads to deliver ASCs in vivo to repair cartilage focal defects.    
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SPECIFIC AIM 1: Determine the molecular mechanism that regulates morphology 
of a model cartilaginous tissue. 
The growth plate is a well-defined model for understanding the molecular 
mechanisms involved in post-natal cartilage development and may elucidate the paracrine 
factors needed for cartilage regeneration.  However, the three-dimensional temporal 
morphology of the growth plate and the signaling pathways involved in regulating 
morphology are not well-characterized.  Previous studies described the presence of 
tethers that link the epiphysis and metaphysis of the growth plate, but it is not known if 
tether formation is a regulated process of growth plate maturation and needs to be taken 
into account when designing regeneration therapies.  The objectives were to determine 
how the three dimensional morphology of the growth plate changes over time and to 
determine the molecular mechanism that regulates morphology.  The hypothesis was that 
the decrease in growth plate size is correlated to the increase in tether formation with 
time and that tether formation is regulated, in part, by vitamin D receptor-mediated 
signaling.  Histology and μCT reconstructions were used to study growth plate 
morphology and tether formation in different murine models. 
 
SPECIFIC AIM 2: Determine if ASCs can be manipulated to secrete paracrine 
factors that can promote cartilage regeneration.  
ASCs produce a wide array of growth factors and it is unknown what effects these 
molecules may have in cartilage regeneration.  Additionally, techniques that enhance 
secretion of favorable growth factors and inhibit production of unfavorable ones can 
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improve the therapeutic potential of ASCs.  The objectives were to determine what 
growth factors ASCs produce, to determine how microencapsulation and media 
treatments can be used to tailor growth factor secretion, and to investigate how the 
paracrine actions of these ASCs may affect chondrocytic behavior and cartilage 
regeneration.  The hypotheses were that media treatments and microencapsulation have 
distinct effects on ASC growth factor production and that these secreted factors can 
enhance chondrocytic behavior and cartilage regeneration.  Gene expression and protein 
production of growth factors from ASCs under different treatments were quantified, the 
influence ASC secreted factors had on chondrocytic behavior were studied in a series of 
co-culture and conditioned media experiments, and the effect ASCs had on cartilage 
regeneration was studied in a non-critical focal cartilage defect. 
  
SPECIFIC AIM 3: Determine if ASC microbeads can be effectively delivered to 
regenerate cartilage in vivo.  
A delivery method that localizes ASCs within a defect site, facilitates the long-
term secretion of ASC-produced factors, and promotes cartilage infiltration is needed to 
effectively use the paracrine actions of ASCs to regenerate cartilage.  We have previously 
developed an injectable microbead technology that can localize ASCs inside the body, 
however, it is unknown if it can facilitate mass transfer of therapeutic factors or promote 
tissue ingrowth into defects.  The objective was to determine if ASC microbeads can 
facilitate the secretion of ASC-produced therapeutic factors to promote cartilage 
regeneration in a defect.  The hypothesis was that microbeads can be used to deliver 
ASCs into cartilage defects and promote cartilage regeneration.  The performance of 
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different alginate microbead formulations were evaluated in vivo and implanted into 
cartilage focal defects made in the xiphoid.   
 
The outcomes of this study were expected to show that ASC microbeads secrete 
factors that can influence cartilage regeneration.  In addition, this study provided a new 
set of criteria to evaluate the therapeutic potential of stem cell therapies.  The research 
was significant because it provided greater insight into cartilage and adult stem cell 
biology while addressing problems with current cartilage repair techniques.  This insight 




BACKGROUND AND LITERATURE REVIEW 
 
CURRENT CARTILAGE REGENERATION METHODS 
There is a large and growing demand to develop effective cartilage regeneration 
methods.  Approximately 1.5 million arthroscopic surgical procedures are performed on 
the knee each year [1], many of which aim to repair histologic and macroscopic lesions in 
articular cartilage [2]. These lesions are generated during the course of many joint 
diseases, most notably osteoarthritis, the largest form of disability in the industrialized 
world [3].  Current treatments for these types of tissue damage involve drug therapy and 
reparative surgeries like microfracture to manage the pain.  However, patients treated 
with these techniques often experience short-term pain relief and develop progressive 
symptoms because of continued tissue deterioration [4-6].  Eventually, patients with 
osteoarthritis receive a total joint replacement.  Although these procedures are relatively 
successful in alleviating pain and restoring partial function, total joint replacements 
typically need implant revision surgeries every 10 to 20 years and have significantly 
higher morbidity and mortality with each subsequent procedure [7, 8].    
 Because of these treatment options’ shortcomings, regenerative medicine is 
viewed by many clinicians as the ultimate goal for treating cartilage damage and disease.  
Autologous chondrocyte implantation (ACI) was the first FDA-approved therapy aimed 
to regenerative cartilage lesions before the need for total joint arthroplasty and has gained 
scientific and clinical support [9, 10].  However, high variability in cartilage quality and 
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functional outcomes, possibly due to low cell retention in the defect site and 
dedifferentiation of chondrocytes during in vitro expansion, have led to limited adoption 
[11, 12].  Therefore, second generation cell implantation therapies for cartilage 
regeneration have implemented scaffolds [13, 14] along with characterized or modified 
chondrocytes [15, 16] in clinical studies. 
 The objective of scaffolds for second generation cell therapies approved in 
Europe is to keep cells localized within the defect site while providing a template for 
extracellular matrix (ECM) deposition.  However, preclinical trials have suggested that 
cell viability on scaffolds is low once implanted [17, 18].  Genetically-modified 
chondrocytes or selected chondrocytes are undergoing pre-clinical and human trials to 
see if these cells can maintain their chondrocytic phenotype and create more functional 
cartilage [19-21].  However, due to donor site morbidity, the supply of reliable 
autologous chondrocytes is limited.  At the same time, the clinical efficacy and 
consistency of any allogeneic graft or cell therapy is questionable due to possible disease 
transmission and immune rejection [22, 23].  Therefore, cell therapies using autologous 
adult stem cells to regenerate cartilage are being investigated.     
 Mesenchymal stem cells derived from bone marrow (MSCs) and adult stem cells 
derived from adipose tissue (ASCs) are the two most commonly used stem cells for pre-
clinical and clinical trials to regenerate cartilage [24, 25].  They have a greater clinical 
potential compared to autologous chondrocytes because they provide a larger and more 
easily accessible pool of cells that can be differentiated into chondrocytes.  However, 
current stem cell therapies have critical shortcomings.  First, once implanted, these cells 
are known to have homing capabilities and migrate through the vasculature to different 
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sites in the body [26-30].  Additionally, it is difficult to control stem cell chondrogenesis.  
Under-differentiated stem cells form fibrous tissue whereas overstimulated cells easily 
undergo hypertrophic differentiation, leading to calcification and osteophyte formation 
[31].  Finally, these cells have yet to form tissue with comparable biological and 
mechanical properties to native cartilage [24].  Therefore, a new paradigm in using stem 
cell therapies to regenerate cartilage needs to be developed. 
Both MSCs and ASCs are known to secrete a wide range of paracrine factors that 
can be used to direct tissue development [32, 33].  Additionally, these cells can be easily 
modified to secrete the appropriate signaling factors to regenerate different types of 
tissues.  Using the paracrine actions of stem cells to stimulate endogenous tissue 
regeneration eliminates the need for these cells to directly differentiate into chondrocytes 
and replace damaged or diseased cartilage.  At the same time, this new paradigm for stem 
cell therapies provides a new set of criteria for scientists and clinicians to investigate the 
therapeutic potential of stem cell therapies.   
In order to use the factors secreted by stem cells to stimulate cartilage 
regeneration, a thorough understanding of the signaling molecules and pathways involved 
in directing cartilage formation is first needed.  Next, different techniques that match the 
secretory profile of stem cells to that seen during cartilage development need to be 
developed.  Finally, delivery methods that localize stem cells within a defect site while 
facilitating paracrine factor secretion need to be optimized.  The remainder of this 
literature review will highlight current developments in these areas of cell biology and 
engineering and discuss the remaining challenges to effectively integrate these distinct 
concepts to use stem cell paracrine factors for regenerate cartilage.     
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SIGNALING MOLECUES REGULATING CHONDROGENESIS 
 It is generally accepted that natural tissue regeneration often recapitulates 
developmental processes [34].  The growth plate is a unique model for understanding 
cartilage development because the different temporal stages of developmental 
chondrogenesis are spatially organized in hierarchical zones within this tissue.  
Proliferation and differentiation between these different zones is tightly orchestrated by 
numerous paracrine and endocrine signaling molecules.  To understand the actions of 
these factors, an overview of the morphological organization of the growth plate is 
needed. 
Morphological Organization of the Growth Plate 
Resting Zone 
 The resting zone consists of cells that are in a relatively quiescent state with a 
large amount of surrounding matrix rich in aggrecan and type II collagen.  This zone is 
also thought to provide ‘stem-like’ cells that supply the reserve of cells for later 
proliferation and subsequent growth plate expansion [35].  However, these stem-like cells 
have a defined proliferative capacity that is gradually exhausted and is thought to lead to 
growth plate fusion [36].  Therefore, epiphyseal fusion is thought to be the result, not the 
cause, of skeletal maturation and the term ‘growth plate senescence’ has been introduced 
[37].  Although endocrine signaling via hormones like estrogen is conventionally thought 
to cause growth plate senescence [38], Stevens et al. showed in transplanted growth plate 
studies that the growth rate of these transplanted tissues were independent of the recipient 
age but dependent on the donor age [39].  This finding by Stevens et al. suggests that 
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‘growth plate senescence’ may actually be regulated by paracrine signaling intrinsic to 
growth plate cells.  It is also thought that chondrocytes in the resting zone secrete growth 
plate-orientating factor (GPOF), a morphogen that directs alignment of proliferative cells 
into their columnar structures along the axial direction of bone [35].  Although the 
underlying mechanism behind this cellular organization is still unknown, it is believed 
that the GPOF concentration gradient within the proliferative zone guides the orientation 
of proliferative chondrocytes [35].   
Proliferative Zone 
As mentioned previously, chondrocytes in the proliferative zone organize as 
columns and undergo mitosis.  These cells are the only ones that divide in the growth 
plate and are also referred to being at the top of the growth zone (which also includes the 
prehypertrophic and upper hypertrophic zones).  The columnar structures are separated 
from each other by ECM with large amounts of type II collagen.  At the same time, this 
zone has relatively high oxygen and glycogen content as well as increased mitochondrial 
ATP production in chondrocytes [40].  At the bottom of this zone, chondrocytes increase 
in volume and begin to undergo hypertrophic differentiation.  
Hypertrophic Zone 
At the top of the hypertrophic zone, chondrocytes are well in the process of 
terminal differentiation and have increased their volumes by 5-10 folds, making a 
significant contribution to bone lengthening (bottom of the growth zone) [36].  This 
differentiation is associated with hypertrophy accompanied by a large increase in matrix 
vesicle associated alkaline phosphatase (ALP) activity and type X collagen secretion [36, 
41].  The chondrocytes in this zone also have large amounts of intracellular calcium, 
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which is essential for the production of the aforementioned matrix vesicles [42].  The 
secretion of these matrix vesicles results in proteolytic remodeling and mineralization of 
the surrounding matrix [43, 44].  At the bottom of this zone, many of the chondrocytes 
undergo apoptosis as the extracellular matrix becomes calcified.  Additionally, this 
calcified matrix becomes vascularized and is invaded with osteoblastic cells, 
chondroclasts, and osteoclasts [36].  All of these actions are orchestrated by an array of 
growth factors and signaling molecules. 
PTHrP, Ihh, and TGF-β Signaling Loop 
Cell proliferation within the growth plate is controlled, in part, by a local negative 
feedback loop involving parathyroid hormone related protein (PTHrP), Indian hedgehog 
(Ihh), and transforming growth factor beta (TGF-β).  Cells in the peri-articular region of 
long bones produce PTHrP, which then delays hypertrophic differentiation by acting on 
cells in the lower proliferative/prehypertrophic zones.  These chondrocytes have high 
levels of PTH/PTHrP receptors and continue to proliferate due to the binding of PTHrP to 
these receptors [45].  When prehypertrophic chondrocytes are too far away from PTHrP-
producing cells near the bone ends, they stop proliferating, begin to undergo hypertrophic 
differentiation, and secrete Ihh.  Ihh can then act on perichondral cells to convert them 
into osteoblasts and is required for sustaining endochondral ossification [46].  Ihh also 
stimulates cells in the perichondrium to release TGF-βTGF-βthen acts upon 
perichondral and peri-articular cells to increase PTHrP synthesis, completing the loop 
[41, 47-50].  TGF-β1, 2, and 3 can also act directly on chondrocytes to directly inhibit 
hypertrophy and promote the synthesis of cartilaginous ECM [6, 11]. 
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BMPs  
Bone morphogenic proteins (BMPs) are a subset of the TGFβ superfamily and are 
well known to stimulate ectopic cartilage and bone formation [51].  They also play 
important roles in both the early and later stages of chondrogenesis and skeletal 
development.  Specifically, BMPs have crucial roles in the aggregation of mesenchymal 
cells during limb bud development, but are also involved in the complex mechanisms in 
bone development [52, 53]. Furthermore, BMPs have distinct spatial expression patterns 
with BMP-2, -3, -4, -5, and -6 being expressed in the perichondrium; BMP-2 and -6 
being expressed in hypertrophic chondrocytes; and BMP-7 being expressed in 
proliferating chondrocytes [36].  BMPs are also integrated into the PTHrP, Ihh, and TGF-
β signaling loop by inducing Ihh expression and subsequent chondrocyte proliferation 
[54].  Additionally, BMP signaling pathways may inhibit FGF signaling by inhibiting 
FGFR1 expression [55] and BMP concentration gradients may play a role in the spatial 
regulation and chondrocyte proliferation and differentiation within the growth plate [37]. 
IGFs 
Insulin-like growth factor-1 (IGF-1) is the main IGF that acts on the growth plate.  
It is an autocrine and paracrine factor that increase proliferation of chondrocytes [56] and 
is involved in bone growth pre- and postnatal [57].  Local IGF-1 synthesis in 
chondrocytes can be stimulated by growth hormone (GH), forming the GF/IGF-1 axis.  
Based on studies investigating IGF-1 null mice, it is widely believed that GH’s actions on 
the growth plate are mainly dependent on IGF-1 [58].  Additionally, IGF-1 produced 
locally by growth plate chondrocytes, and not systemic IGF-1 produced by the liver, is 
the critical source for maintaining normal skeletal growth [59].   IGF-1 may also mediate 
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some of its effects through other growth factors since it has been show to enhance TGF-β 
mediated proliferation [60]. 
FGFs 
Fibroblastic growth factors (FGFs) are important modulators at all stages of 
chondrogenesis and bone formation within the growth plate by binding to at least four 
different types of FGF receptors (FGFRs).  At the earliest stage of chondrogenesis, 
multiple FGFs and FGFR2 are expressed and is thought to stimulate SOX9 gene 
expression [61].  FGFR2 is also expressed on perichondral cells [36].  Additionally, 
FGFR3 is expressed in proliferating chondrocytes while FGFR1 is expressed in 
prehypertrophic and hypertrophic chondrocytes [53].  Meanwhile, signaling through the 
FGFR3 receptor inhibits chondrocyte proliferation and down regulates Ihh expression in 
hypertrophic chondrocytes, therefore shortening the proliferative columns [62].  
Meanwhile FGF-18 binding to FGFR3 is suggested to facilitate hypertrophic 
differentiation and regulate skeletal vascularization [63].  FGF-2 is involved in both the 
early and later stages of growth plate development by stimulating chondroprogenitor 
proliferation and vascular invasion [53]. 
VEGF 
 Vascular endothelial growth factor (VEGF), a potent mitogen for endothelial cells 
and initiator of angiogenesis [64, 65], is expressed in hypertrophic chondrocytes [66].  
The blood vessels formed in this region enables the ingrowth of osteoblasts, which leads 
to ossification.  An absence of VEGF causes disturbances in growth plate architecture 
and longitudinal growth.  Specifically, calcified cartilage remains due to a decrease in 
osteoblast and chondroblast recruitment and differentiation, which leads to a widen 
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hypertrophic region and decreased trabecular bone formation [66].  Angiopoietin-1 and 2 
are also expressed by hypertrophic chondrocytes of the growth plate and may modulate 
the effects of VEGF [67].  VEGF-signaling is also known to enhance catabolic effects on 
chondrocytes and cartilage such as increased MMP expression, osteophyte formation, and 
osteoarthritis progression in articular cartilage [68-71]. 
MMPs and TIMPs 
 Along with VEGF, MMPs are important for the later stages of hypertrophic 
differentiation, matrix remodeling, and vascular invasion, all of which are prerequisites to 
migration and differentiation of osteoclasts and osteoblasts that remove mineralized 
cartilage and replace it with bone.  MMP-13, a downstream target of RUNX2, is 
expressed by terminal hypertrophic chondrocytes [53].  Deficiencies in MMP-13 lead to 
interstitial collagen accumulation and delayed endochondral ossification of the growth 
plate with a hypertrophic zone of increased size [72, 73].  MMP-9 is expressed in 
endothelial cells that migrate into the central region of hypertrophic cartilage.   
Additionally, both MMP-9 and MMP-13 are involved in degrading non-mineralized 
matrix during primary and secondary ossification [44, 74].  Meanwhile, membrane-bound 
MT1-MMP (MMP-14) is essential for chondrocyte proliferation and secondary 
ossification [75].  Although not studied in detail within the growth plate, tissue inhibitors 
of MMPs (TIMPs) also play a role in articular cartilage development, mesenchymal stem 
cell chondrogenesis, and osteoarthritis progression [76-78].  
Other Signaling Molecules 
Cartilage development and endochondral ossification are not limited to the growth 
factors and proteases just discussed.  Wnts are another class of signaling molecules that 
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are involved in chondrogenesis at two distinct stages.  Initially, Wnt/β-catenin acts at low 
levels to promote chondroprogenitor differentiation, while at later stages, high levels of 
Wnt act via the canonical pathway to promote hypertrophic differentiation and 
subsequent endochondral ossification [79, 80]. Meanwhile, hormones like vitamin D 
metabolite 24R,25(OH)2D3 has been shown to increase resting zone chondrocyte 
proliferation while inhibiting the activity of processing enzymes and imparting 
cytoprotective effects [81, 82].  Additionally, this metabolite reduces levels of 
arachidonic acid and ultimately prostaglandins [83].  Prostaglandins are a class of 
autocrine and paracrine lipid compounds that are produced in response to 
proinflammatory cytokines and regulate cartilage formation and bone repair [84-87].  
Meanwhile, 1α,25(OH)2D3 has been shown to increase maturation of growth zone 
chondrocytes and subsequent matrix formation [88-90].  Other hormone metabolites such 
as 17β-Estradiol regulates proliferation and differentiation of female chondrocytes [91] 
while dihydrotestosterone increases proliferation and maturation of male growth zone 































Figure 2.1: Signaling Molecules Regulating Chondrogenesis 
Endocrine factors include hormones that can stimulate the production of paracrine factors 
or can directly influence proliferation and differentiation.  Paracrine factors can act 
within specific zones or can have differential actions in multiple stages of 
chondrogenesis. 
 
PARACRINE ACTIONS OF STEM CELL THERAPIES 
 The signaling molecules that regulate cartilage formation are numerous and have 
differential actions depending on the differentiation state of the recipient cell.  
Specifically, these factors promote and inhibit proliferation, chondrogenesis, 
hypertrophic differentiation, and vascular invasion. In order to use the paracrine actions 
of stem cell therapies to regenerate cartilage, the secretory profile of stem cells and their 
effects on general tissue regeneration first need to be understood.  Methods then need to 
be developed to enhance the secretion of favorable factors while decreasing the secretion 
of unfavorable ones. 
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Stem Cell Secretory Profile and Paracrine Effects 
Inflammation and Immune Modulation 
Adult stem cells like MSCs and ASCs are well known to secrete a wide range of 
cytokines that can reduce inflammation and adaptive immunity responses [93-97].  For 
example, these cells secrete indoleamine 2,3-dioxygenase (IDO), TGF-β, human 
leukocyte antigen-G (HLA-G), and prostaglandin E2 (PGE2) to inhibit natural killer cell 
function [98-101].  Data also suggests that MSCs can modulate dendritic cell maturation 
via interleukin-6 (IL-6), M-colony stimulating factor (M-CSF), and PGE2 secretion [102-
105].  Furthermore, these cells can suppress allogeneic T-cell response [99] via the 
secretion of TGF-β1, hepatocyte growth factor (HGF), nitric oxide, PGE2, and IDO [106-
110].  Both MSCs and ASCs can also regulate hematopoietic cell production by secreting 
various hematopoietic cytokines such as G-CSF, M-CSF, GM-CSF, IL-7, and FMS-like 
tyrosine kinase 3 ligand [111, 112].  Although MSCs have underwent clinical trials for 
treating acute graft-versus-host disease (GvHD) by reducing severe inflammation, the 
results have been conflicting, possibly because the paracrine factors these cells secrete 
may depend on the inflammatory environment in the host [113, 114].  MSCs, ASCs, and 
other adult stem cell sources are also being investigated in treating autoimmune diseases 
such as diabetes, rheumatoid arthritis, Crohn’s disease, inflammatory bowel disease, 
systemic lupus erythematosus, autoimmune encephalomyelitis, systemic sclerosis, and 




Adult stem cells are also known enhance tissue regeneration via their paracrine 
actions.  Specifically, they support cell survival and vascularization by secreting 
angiogenic and cytoprotective factors such as VEGFs, FGFs, IGF-1 and HGF [123-125].  
Stem cells derived from different populations also have different secretory profiles as 
ASCs express IGF-1, VEGF-D, and IL-8 at higher levels than MSCs and other stem cells 
isolate from dermal sheath and dermal papilla [33].  MSCs and ASCs also secrete 
molecules such as FGF-2, VEGF, platelet-derived growth factors (PDGFs), IL-1β, IL-10, 
stem cell-derived factor-1 (SDF-1), HGF, IGF-1, thymosin-β4, and Wnt5a, that reduce 
apoptosis and necrosis in cardiomyocytes in vitro and in vivo [126-131].   These MSC 
and ASC-secreted factors, in addition to angiopoietin-1 and -2 (Ang-1 and -2), have also 
increased vascular density and blood flow in ischemic myocardium, increased cardiac 
function and perfusion [112, 132, 133], enhanced granulation tissue thickness, and 
improved epithelialization and capillary formation in chronic dermal wounds [32, 134, 
135].  MSCs and other adult stem cell populations also secrete glial cell and brain-
derived neurotrophic factors (GDNF and BDNF), and have been shown to increase 
neuron survival, differentiation, and growth in models of amyotrophic lateral sclerosis, 
Parkinson’s Disease, and Huntington’s disease [136-142].  
Genetic Manipulation 
 MSCs and ASCs have been genetically modified to increase secretion of trophic 
factors via a number of different approaches, including viral and non-viral delivery of 
plasmids and switches for conditional gene expression [23, 143].  MSCs, ASCs, and 
muscle-derived stem cells have been modified to overexpress BMP-2, -4, -7, and -9, LIM 
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mineralization protein-1 and IGF-1 to repair critical size bone defects [144-146] while 
VEGF-A has also been overexpressed in ASCs to promote angiogenesis for bone repair 
[147]. Over expression of genes to improve stem cell graft survival has also had non-
specific effects on growth factor production.  MSCs overexpressed with Bcl-2 had 
increased VEGF-A secretion, which lead to increased capillary density and augmented 
functional recovery in ischemic myocardium in vivo [148].  Meanwhile, Akt-modified 
MSCs had increased secretion of VEGF, IGF-1, secreted fizzled-related protein 2, and 
FGF-2, which led to enhanced cardioprotective and inotropic effects on ischemic 
cardiomyocytes [129, 149-151]. 
 Although genetic manipulation of stem cells can increase cell survival when 
delivered in vivo and enhance growth factor secretion, this approach also has several 
shortcomings.  First, the ability to only target one gene at a time limits the therapeutic 
potential of this approach since cartilage formation is orchestrated by numerous growth 
factors and other signaling molecules [32, 53].  Furthermore, the potentially harmful side 
effects of genetic manipulation have hindered the clinical potential of these techniques 
[32, 152].  It is also unknown how long genetically modified stem cells can maintain their 
therapeutic potential in vivo. 
Preconditioning 
 Preconditioning stem cells by intentionally exposing them to a specific stimulus at 
a defined intensity for a controlled amount of time has possible utility in enhancing the 
paracrine actions of these cells.  Unlike genetic manipulation, preconditioning can affect 
production of a more global set of different trophic factors.  For cartilage, this means 
enhancing the secretion of factors that promote chondrocyte and progenitor cell 
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proliferation and chondrogenesis while reducing the secretion of factors that promote 
hypertrophic differentiation and vascular invasion. 
Hypoxic Exposure 
In vitro pretreatment with hypoxic or anoxic exposure relative to normoxic 
atmospheric conditions (<5% O2) provides an efficient method to precondition stem cells.  
These conditions up-regulate hypoxia-inducible factor-1α (HIF-1α), which then binds to 
the hypoxia response elements in a number of target genes, including several angiogenic 
growth factors [153, 154].  Although temporary exposure to hypoxic conditions had no 
effect on cell survival, it did increase expression of VEGF, FGF-2, IGF-1, thymosin-β4, 
and HGF in MSCs [148, 150, 153, 154] and secretion of VEGF-A in ASCs [155].  
Additionally, hypoxic preconditioning increases expression of enzyme endothelial nitric 
oxide synthase (eNOS) [127, 149] and enhances the protective effects of MSCs on 
cardiomyocytes when transplanted into an infarcted myocardium [156].  
Thermal Shock Induction 
 Considering the role heat shock proteins (Hsp) have in immune modulation and 
tissue development, thermal shock induction may be an effective method to enhance the 
paracrine actions of stem cells.  Transient exposure to increased temperatures between 39 
to 45
o
C increases secretion of Hsp molecules, which in turn negatively regulate Fas-
mediated apoptosis and prevent proinflammatory cytokine production [157-159].  
Additionally, Hsps are important in various stages of chondrogenesis.  Hsp47 is a 
collagen-specific molecular chaperon that facilitates intracellular procollagen polypeptide 
synthesis and type II collagen triple helix assembly [160, 161].  Meanwhile, Hsp90 is 
abundant in a subpopulation of chondrocytes that are highly responsive to hormones like 
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GH while Hsp25 is deleterious to cartilage differentiation [161-163].  Although exposing 
dental pulp stem cells to hyperthermic conditions enhanced production of inflammatory 
modulator leukotriene B4 [164], extensive characterization of trophic factor production 
from various stem cell populations when exposed to thermal shock has yet to be 
vigorously tested.   
Physical Environment 
 The ability of stem cells to interact with their environment to direct differentiation 
may also provide another method to direct growth factor production.  MSCs grown on 
rough and hydrophilic titanium surfaces had increased secretion of TGF-β1, osteocalcin, 
and osteoprotegerin compared to smooth tissue culture polystyrene [165].  These same 
microstructured surfaces also increased expression of calcium-dependent Wnt5a and 
decreased expression of canonical Wnt ligands in a time-dependent manner [166].  
Additionally, osteoblasts have a similar response to surface roughness and hydrophilicity, 
which is mediated by α2β1 integrin signaling and Dkk2 paracrine signaling [165-167].  
Nanoscale features added to these microstructured Ti surfaces further increased the 
production of osteocalcin, osteoprotegerin, and VEGF-A from osteoblastic cells [168].   
Biomimetic ligands may also be used to control growth factor production as MSCs 
microencapsulated in alginate microbeads modified with arginine-glycine-aspartic acid 
(RGD) peptides increased expression of FGF-2 compared to unmodified alginate [169].  
Additionally, osteoblasts cultured on surfaces with lysine-arginine-serine-arginine 
(KRSR) had decreased secretion of TGF-β1 and PGE2 compared to unmodified surfaces 
whereas surfaces with lysine-serine-serine-lysine (KSSR) had increased levels of 
osteocalcin and PGE2 [170]. 
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Mechanical and Biophysical Stimulation 
 Given the role mechanical loading and other biophysical stimuli have in stem cell 
differentiation, chondrogenesis, and cartilage homeostasis, mechanical preconditioning 
may serve as another mechanism to tailor the secretory profile of stem cells.  Cyclic 
strain on MSCs increased MMP-2, -3,-13, and TIMP-2 secretion but not their mRNA 
levels, indicating that mechanical stimulation may have a post-translational regulatory 
role in paracrine factor production [171].  Subsequent actions of MMPs include 
modulating TGF-β1, VEGF, and FGFs in MSCs and displacing VEGF and members of 
the TGF-β family from extracellular matrix [53, 171, 172].  Mechanical preconditioning 
may also have direct effects on growth factor production as cyclic stretching of tendon 
fibroblasts increased secretion of TGF-β1, FGF-2, and PDGF-AB [173].  Low intensity 
ultrasound has been shown to increase PDGF-AB production from osteoblasts and 
endothelial cell lines [174] while enhancing transforming growth factor-beta 1 (TGF-1) 
mediate chondrogenesis of MSCs [175], providing another viable method for 
preconditioning stem cells.  Additionally, lasers extensively used by orthopaedic 
surgeons, have been shown to induce expression of Hsp70 in neural cells [176]. 
Pharmacologic Treatment 
 The cellular effects of various pharmacological agents are well characterized and 
may provide a viable and controllable method to tailor stem cell growth factor secretion.  
Dexamethasone, a potent anti-inflammatory and immunosuppressant corticosteroid, has 
been shown to decrease VEGF-A secretion for hemangioma-derived stem cells [177] and 
increase FGF-18 expression in MSCs [178].  Additionally, treating MSCs with β-
mercaptoethanol increased Hsp72 expression and subsequently increased resistance to 
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oxidative stress [179].  MSCs and skeletal myoblasts treated with diazoxide, a potassium 
channel activator, enhance cell survival when implanted into ischemic environments.  
Specifically, diazoxide increased Akt phosphorylation, cyclooxygenase-2 and IL-11 
expression levels, and secretion of Ang-1, VEGF, HGF, and FGF-2 in skeletal myoblasts 
[180, 181].  Verapamil, an L-type calcium channel blocker, has been shown to decrease 
IL-6 and VEGF production in keloid fibroblasts [182], and calcium has been shown to 
increase secretion of PTHrP from a variety of cell types including lung epithelial cells 
and human prostate and cancer cell lines [183, 184].  Other inhibitors such as 6-
bromoindirubin-3'-oxime (BIO), a specific pharmacological inhibitor of glycogen 
synthase kinase-3 (GSK-3), has been shown to activate Wnt signaling in embryonic stem 
cells and help maintain their pluripotent state [185]. 
Biological Treatment 
 With the increasing number of recombinant cytokines, growth factors, hormones, 
and other proteins being approved as clinical therapies, preconditioning stem cells with 
this class of molecules may have promising results.  Treating MSCs with interferon-
gamma (IFN-γ) increased these cells immunosuppressive effects on T-cells and in 
patients with GvHD [113, 114].  Additionally, TNF-α enhanced IFN- γ induced 
immunosuppression activation [107, 113].  Growth factors and hormones are well-known 
to induce proliferation and differentiation of stem cells, but their actions on trophic factor 
production are only starting to become more well-defined.  Injecting VEGF-A 
intramuscularly has been shown to increase circulating and myocardial levels of stromal-
derived factor-1 (SDF-1) [186].  Additionally, both IL-6 and TGF-α have been shown to 
increase VEGF production from MSCs [187].  Though the effect of growth hormone on 
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IGF-1 secretion has been well-characterized, thyroid-stimulating hormone was more 
recently shown to up-regulate noncanonical Wnt components such as frizzled and Wnt5a 
and increase secretion of osteoprotegerin to attenuate bone resorption [188].  Estrogen 
treatments have also been shown to decrease levels of Wnt agonist sclerostin in 
osteoprogenitor cells in postmenopausal women [189].  
 
DELIVERY METHODS FOR STEM CELLS AND SECRETED FACTORS 
 Cell encapsulation technology used to create ‘living cell medicines’ to provide 
long term drug delivery is a relatively old concept pioneered over 50 years ago [190].  
The objective behind this concept was to isolate allogeneic or xenogeneic cells from the 
host’s immune response by embedding them within permeable microcapsules that 
facilitated the outward diffusion of therapeutic molecules and inward diffusion of 
nutrients.  This approach has been used as treatments for diseases of deficient hormone 
production such as insulin in diabetes [191], erythropoietin in anemia [192], and factors 
VIII and IC in hemophilia [193].  Although the optimal surface area-to-volume ratio for 
protein and nutrient diffusion make microcapsules the ideal candidate to deliver the 
paracrine actions of stem cell therapies, several modifications need to be made.  First, 
microcapsules must improve cell protection and localization to the targeted tissue during 
initial delivery in vivo.  Afterwards, microcapsules must control the temporal secretory 
profile of a wide range of different paracrine signaling molecules.  Finally, microcapsules 
must have biomimetic characteristics to control cell release and engraftment and 
subsequent tissue integration.  Possible parameters that can be adjusted to fulfill these 
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requirements include the biomaterials used for microencapsulation, the fabrication 
method, and subsequent biomimetic functionalization.  
Biomaterials 
 Numerous biomaterials have been used for tissue engineering and regenerative 
medicine applications, but few of them are suitable for microencapsulating cells into 
microcapsules.  Not only must they have favorable mass transfer properties, but they also 
must have favorable and repeatable gelation characteristics for forming microcapsules 
consistent in size and shape.  Additionally, these materials should have parameters that 
are tailorable to adapt these microcapsules for different stem cell therapies.   
Alginate  
Alginate is a family of unbranched binary copolymers derived from brown 
seaweed and bacterium that consists of β-D-mannuronic acid (M) and α-L-guluronic acid 
(G) dimers that vary in proportions depending upon the source from which the alginate 
was isolated [194].  Specifically, the G dimers are responsible for crosslinking by 
sequestering divalent ions and affect the mechanical stiffness, diffusivity, 
biodegradability, swelling behavior, stability, and biocompatibility of alginate hydrogels 
[194-196].  Alginate has been the most prominent microencapsulation polymer because it 
has favorable mass transfer properties [197], can be molded into specific shapes [198, 
199], has adjustable degradation kinetics [200-202], supports a range of different cell 
phenotypes [203-205], can be mechanically and biochemically modified [196, 206, 207], 
supports cell differentiation in large animal models [208], and is biocompatible for 
delivery of cells in human trials [6, 209].  Additionally, most studies use alginate in 
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combination with other materials.  Poly-L-lysine as a polycationic shell to enhance the 
immunoisolation properties of microcapsules is the most common addition [204, 210].   
Agarose 
 Agarose, a modified form of the agar material used for bacteria cell culture, is a 
polysaccharide derived from seaweed.  Unlike alginate, agarose has the ability to form 
thermally reversible gels.  Agarose has previously been used for cartilage tissue 
engineering [211, 212] and for submicron encapsulation of proteins [194].  Agarose 
microcapsules can be formed by using a reduction in temperature [213].  One 
disadvantage of using agarose for delivery of autologous stem cells is its unfavorable 
biodegradative properties. 
Chitosan 
 Chitosan is a biodegradable polysaccharide derived from the deacetylation of 
chitin found in crustacean shells, fungi, insects, and molluscs.  Chitosan forms hydrogels 
by ionic or chemical cross-linking with glutaraldehyde and degrades via enzymatic 
hydrolysis.  Chitosan has been used in a number of biomedical applications such as 
wound dressings, drug delivery, and space-filling implants [214-216].  Because of its 
weak meachanical properties and limited bioactivity, it is often combined with other 
materials such as polyglicolic acid, calcium phosphate, and collagen [194].   
Other Materials 
 Collagen, fibrin, and hyaluronic acid are naturally derived polymers with 
favorable mass transfer and gelation characteristics to deliver cells for regenerating 
tissues [194, 217].  Collagen gelation is controlled by changes in pH whereas fibrin is 
formed from the reaction between fibrinogen and thrombin.   Synthetic poly (ethylene 
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glycol) functionalized with vinyl end groups, such as methacrylates and acrylates, 
employs a radical cross-linking approach involving two or more polymerizable moieties 
to encapsulate cells [218].   Self-assembling peptides, characterized by amino acid 
sequences of alternating hydrophobic and hydrophilic side groups, are a promising class 
of biomaterials for cell encapsulation due to the flexibility of manipulating peptide 
sequences to control cell adhesion and differentiation [219], scaffold degradation [220, 
221], and delivery of stimulatory growth factors [222]. 
Fabrication Methods 
Microcapsules can be classified into 3 main categories: matrix core, liquid or 
hollow core/shell, and cell-core shell.  Matrix cores, or microbeads, consist of a porous 
hydrogel or polymer with cells seeded uniformly within and may have an outer shell to 
enhance delivery and biocompatibility.  Liquid or hollow core/shells consists of a 
permeable protective membrane with cells suspended in liquid or adhered to the inner 
membrane.  Cell-core shell or conformal coating consists of a cell mass surrounded by a 
permeable membrane.  Microbeads are by far the most investigate microcapsule in 
preclinical and clinical studies because of their long term stability and various methods to 
fabricate them [217].  
Extrusion 
 Extrusion is the most common method of forming microbeads as a viscous 
polymer-cell suspension – almost always consistent of alginate – is fed through a needle 
to form droplets that fall into a crosslinking solution containing a divalent cation.  To 
counteract the capillary surface interactions between the extruded droplet and needle, 
vibration, mechanical disruption with air flow, and application of an electrostatic 
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potential can be used to form microbeads 25 to 500μm in diameter [194, 217].  
Microencapsulation with an electrostatic potential is favorable because of the consistent 
size, shape, and uniformity [223], but are not effective in forming microbeads under 100 
μm.  To form smaller microbeads with high mechanical stability and controlled size, 
spraying techniques have been developed to encapsulate MSCs and monocytes [224].   
Emulsion 
 Emulsion techniques are also used to encapsulate cells in agarose and alginate.  
These methods involve the aqueous form of the biomaterial to be mixed and dispersed in 
an immiscible organic phase, such as oil, which is often facilitated by a surfactant.  When 
the dispersion reaches equilibrium, microbead formation is initiated by cooling or adding 
a gelling agent.  Although this method has been used to encapsulate pancreatic islets 
[213, 225-227], its feasibility for stem cell delivery is unknown.  Despite its 
advantageous scalability, large microbead size distributions and shear stress applied to 
cells have limited the use of this technique.   
Microfluidics  
 Over the past decade, the manipulation of multiphase flows in microfluidic 
devices has created a new method to generate polymer particles, emulsions, and foams of 
uniform shape and size [228].  This method exploits the fluid dynamics within 
microchannels, such as laminar flow, to better control microbead characteristics.  By 
varying the flow rates of the different liquid phases, various microfluidic devices have 
been able to make alginate microbeads 50 to 200μm in size [229-232].  All of these 
devices extrude alginate or other hydrogels under the laminar flow of an oil phase.  More 
recently, this method has been combined with a bio-electrospraying technique to maintain 
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cell viability of microbeads containing single or multiple cells [233].  However, the use 
of organic solvents and surfactants and the shear forces induced by microchannels, make 
this approach less favorable for stem cell delivery.   
Microlithography and Micromolding 
In addition to forming microfluidic devices for microencapsulation, a lithographic 
approach has also been used directly to form alginate microcapsules with various shapes 
and sizes [234].  Using standard soft lithography techniques, a polydimethylsiloxane 
template with arrays of microwells on its surface is fabricated, filled with alginate 
solution, and crosslinked in CaCl2, resulting into free standing alginate microcapsules.  
Continuous-flow microlithography processes have been proposed to increase microbead 
fabrication output, but none have been successful in microencapsulating cells [235].  In a 
similar approach to microlithography, micromolding has also been used to form 
microbeads.  A layer of hyaluronic acid monomer and photoinitiator are place on a 
methacrylate glass slide and a polydimethylsiloxane stamp with void regions is placed on 
top.  This mold is then exposed to ultraviolet light to cure the hyaluronic acid, which has 
successfully microencapsulated NIH-3T3 cells [236].  Although innovative, these 
processes have had limited use due to their limited scalability [237].  
Biomimetic Functionalization 
  For cell microencapsulation, the biomaterial used has always been considered a 
simple device to entrap the cells.  In order to harness the full regenerative capacity of 
stem cells’ paracrine actions, microbeads must be able to direct stem cell behavior and 
the subsequent secretion profile of multiple growth factors.  Therefore, microbeads must 
have parameters that can adjust cell adhesion to direct cell proliferation and 
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differentiation, growth factor retention to control growth factor localization and secretion, 
and degradation to promote cellular release and tissue regeneration.  
Cell Adhesion 
 Biomimetic peptides modified to the polymer backbone can be used to promote 
cell adhesion and subsequent proliferation and differentiation.  RGD in alginate 
hydrogels is well known to promote cell adhesion, proliferation, and FGF-2 expression 
[169, 205-207], but has also been shown to inhibit chondrogenesis [238].  Other peptide 
moieties such as IKLLI, IKVAV, LRE, PDSGR, and YIGSR have also been used to 
promote cell focal adhesions, which then trigger a cascade of intracellular signaling 
events [239-242], which can also affect trophic factor secretion from stem cells.  In 
addition to biomimetic peptides, incorporating natural ECM components, like hyaluronic 
acid, for cells to adhere on has been shown to increase chondrogenesis of MSCs in 
alginate cultures [243].   
Growth Factor Retention 
 ECM components and binding proteins are well known to bind growth factors, 
store otherwise rapidly degraded proteins, present them in a localized fashion, and release 
them to regulate soluble distribution [244].  A common method for controlling growth 
factor retention and release kinetics in biomaterials involves pre-encapsulating 
therapeutic proteins into PLGA microspheres which gradually releases growth factor via 
degradation [245].  However, this strategy does not directly control the paracrine actions 
of microencapsulate stem cells.  An example of an alternative approach is the peptide 
GGWSHW derived from thrombospondin-1, which mimics its ability to bind TGF-1 
[246, 247].  Additionally, other studies suggest further biomimetic sequences that can 
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bind IL-1α[248, 249].   Methods to reversibly bind growth factors directly to fibrin 
scaffolds have also been investigated [250].  In spite of these potential strategies, none 
have been successfully implemented to control the secretory profile of microencapsulate 
stem cells. 
Biodegradation 
Strategies to promote degradation of large biomaterial and alginate constructs 
have been successful in decreasing mechanical properties and increasing cell proliferation 
and migration.  Several studies by Mooney et al. have shown that oxidizing alginate 
polymers alters the chain conformation and promotes hydrolysis in aqueous solutions, 
which decreases construct compressive modulus and subsequently facilitates the 
deposition of cartilaginous extracellular matrix in chondrocyte seeded constructs [202, 
251].  Alternatively, modifying alginate with matrix metalloproteinase (MMP)-cleavable 
peptides facilitated human mesenchymal stem cells (MSCs) to migrate and form cellular 
networks as constructs visibly decreased in size in vitro [252].  For specific degradation, 
Sarkar et al. discovered a collagen mimetic peptide containing GIAGQ that is exclusively 
cleaved by MMP-9 and not by trypsin or other general enzymes [253].  Additionally, 
poly(lactide-co-glycolide) (PLGA) microspheres loaded with alginate lyase have been 
able to degrade hydrogels, leading to a significant increase in expansion rate of 
encapsulated neural progenitor cells [254].  Despite these efforts, no reported strategy has 




 Methods that direct the paracrine actions of adult stem cells to regenerate cartilage 
will need to integrate the latest discoveries and innovations in both cell biology and 
engineering.  Cartilage formation, maturation, and subsequent endochondral ossification 
are orchestrated, in part, by a network of paracrine factors.  Not only are these growth 
factors’ actions dependent on each other, but their actions are also contingent upon the 
differentiation state of the recipient cell.  Just as numerous and complex are the paracrine 
actions of adult stem cells, which naturally modulate inflammation and adaptive 
immunity while promoting cell survival and angiogenesis.  For cartilage regeneration, 
different forms of genetic manipulation or preconditioning are needed to make stem cells 
secrete factors that cause chondroprogenitor proliferation, chondrogenesis, and matrix 
deposition while preventing hypertrophic differentiation and vascular ingrowth.  Finally, 
to improve localization and viability of stem cells in vivo while maximizing mass transfer 
of their secreted factors, microbeads appear to be a promising candidate.  However, 
modifications to the materials used, the fabrication method, and biomimetic 
functionalization are needed to control the spatial and temporal secretion profiles of 
different factors.  Meanwhile, these modifications are also needed to promote cartilage 




FORMATION OF TETHERS LINKING THE EPIPHYSIS AND 




 Vitamin D deficiency during long bone growth results in development of rickets, 
a condition in which the growth plate becomes extended due to a failure of the 
hypertrophic chondrocytes to calcify their extracellular matrix [255].  Cartilage cells 
within the growth plate continue to enter the zone of hypertrophy, but because there is not 
a concomitant removal of calcified cartilage at the metaphysis, hypertrophic cells pile up 
onto each other, causing the growth plate to thicken and the tissue eventually becomes 
deformed, leading to structural deformities in the bone.  
 Rachitic growth plates are also seen in mouse models that lack functional vitamin 
D receptors (VDR) [256, 257].  The defect can be treated by restoring serum calcium 
concentration [258, 259], supporting the hypothesis that rickets is due to defective 
calcium ion homeostasis [260].  However, vitamin D metabolites also contribute to 
growth plate development via mechanisms that are not directly associated with the rapid 
stimulation of intestinal Ca
++
 transport by the steroid hormone, lα,25-dihydroxy vitamin 
D3 [1α,25(OH)2D3][83, 261]. 
 MicroCT images of rat tibial growth plates show that the natural process of 
growth plate closure is marked by an accumulation of mineralized struts termed “tethers” 
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[262].  The tethers form perpendicular to the plane of the growth plate, connecting the 
epiphyseal and metaphyseal bone surfaces.  Tether formation has been noted on 
histological sections of fusing dog, pig, and human epiphyses and has been described in 
the metatarsus of calves as multiple perforations of the growth plate [263].  Although the 
rat growth plate never fully fuses, it becomes thinner and the number and volume of these 
tethers rapidly increase starting at adolescence, following a sigmoidal manner over the 
average rat life span [262].  Investigators have used three dimensional (3D) magnetic 
resonance imaging (MRI) to examine human growth plates during premature closure, and 
have reported the presence of large bone bridges [264, 265], but it  appears likely that 
these bone bars were due to trauma and may not be comparable to the tethers seen during 
normal growth plate closure.   
 The long bones of active adolescent animals including humans undergo an array 
of different directional and dynamic loading patterns with, at times, large magnitudes.  In 
addition to absorbing these loads, the growth plate must facilitate rapid bone growth.  It 
has been shown in 1 day old chick tibias that external loading can alter growth plate 
shape and gene expression while negatively impacting bone biomechanics and formation 
[266].  Additionally, relative mechanical behavior among the three zones of neonatal and 
5 week old rat growth plates appear to be vastly different [267, 268], suggesting that 
growth plate composition changes significantly between birth and adolescence.  Tethers 
that appear in the growth plate before skeletal maturation may provide the needed 
stability to protect the growth plate from deleterious loading while contributing to its 
changing mechanical behavior.  Before this functional role of tethers can be investigated, 
however, it must first be determined if tether formation is a regulated characteristic of 
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normal growth plate maturation or if it is just a coincidental artifact of extracellular 
matrix calcification.  Figuring out the mechanism controlling tether formation will be 
essential in developing tissue engineering or regenerative medicine strategies for treating 
diseased and damaged growth plates. 
 In order to glean further insight into how tethers originate, it would be 
advantageous to assess growth plates from an animal model where the genotype can be 
modified such as the mouse.  The benefit of using microCT imaging over histology is the 
ability to quantitatively evaluate the growth plate and tether formation via three 
dimensional reconstructions without destroying the actual tissue.  No study, however, has 
yet investigated tether formation in the growth plate in long bones of mice using microCT 
imaging or investigated tether formation in an animal model with an altered genotype that 
would affect bone development.  Therefore, we took advantage of the vitamin D receptor 
knockout mouse model (VDR-/-) in which structural stability of the growth plate is 
compromised due to rickets [269] and abnormal mineral homeostasis is exhibited [256].  
Symptoms of rickets and osteomalacia in VDR-/- mice are well established by 8 weeks of 
age with almost their entire bone surface covered with osteoid by 10 weeks of age [259]. 
When VDR-/- mice are fed a high calcium, phosphorus, lactose, and vitamin D3 rescue 
diet, normal growth plate volume, bone mineralization, and bone mechanical properties 
are restored while eliminating secondary hyperparathyroidism and osteomalacia [258, 
259].   
We imaged the growth plates of 8-week old rachitic VDR-/- mice and their 
normal VDR+/+ littermates by microCT and histomorphometry to determine if microCT 
was an effective method for analyzing tether formation in mice.  To determine if any 
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changes in tether formation or distribution were due to altered calcium ion homeostasis or 
other VDR-dependent signaling we used microCT imaging to quantify tether formation 
in 10-week old VDR+/+ and VDR-/- mice fed a rescue diet high in lactose, calcium, 
phosphate, and vitamin D3.  We hypothesized that microCT imaging would be an 
accurate and effective method to study tether formation in mice with different genotypes 
and that altered growth plate morphology associated with a nonfunctional VDR will have 
decreased tether formation and altered distribution.  We also hypothesized that tether 
formation is strongly influenced by signaling via the VDR and is not an artifact of tissue 
calcification; therefore normal mineral homeostasis alone would not fully restore their 
presence in animals lacking a functional VDR.  
 
METHODS AND MATERIALS 
Animal Maintenance 
 Male and female VDR-/- mice and their VDR+/+ littermates were used as the 
animal model.  The phenotypic characteristics of the VDR-/- mice have been described in 
detail in a series of publications [256, 269, 270].  Although the 1α,25(OH)2D3-dependent 
membrane associated PDIA3 signaling pathway is still functional in growth plate 
chondrocytes from these mice [271], they develop rickets due to reduced serum Ca
++
 
[259].  A heterozygous [VDR+/-] breeding pair was obtained as a gift from Dr. Marie 
Demay (Harvard Medical School, Massachusetts General Hospital, Boston, MA), and a 
mouse colony was established in the Physiology Research Laboratory in the Institute of 
Bioengineering and Bioscience at the Georgia Institute of Technology under an 
Institutional Animal Care and Use Committee approved protocol.  Offspring were 
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genotyped at two weeks after birth.  VDR+/- mice were allowed to breed.  Homozygous 
VDR+/+ and VDR-/- mice were euthanized when 8 weeks old.  This age was chosen to 
ensure that the rachitic pathology was fully developed in VDR-/- mice since osteomalacia 
is not observed in these mice until at least 35 days of age [259].  In addition to 
genotyping, homozygotes were assessed for evidence of rickets by histologic analysis of 
the costochondral cartilages.  VDR-/- mice exhibited phenotypic markers of vitamin D 
deficiency, including rachitic growth plates with expanded hypertrophic cell zones.   
 In a subsequent study, homozygous VDR+/+ and VDR null mice were also fed a 
rescue diet containing 20% lactose, 2% calcium, 1.25% phosphorus, and 2200IU vitamin 
D3/kg (TD96348, Teklad, Madison, WI) from 22 days of age.  These mice were then 
euthanized at 10 weeks of age.  This different age was selected to accurately assess the 
rescue diet’s effect on mineralization since over 85% of the bone surface is covered with 
osteoid in VDR-/- mice fed a regular diet at this time [259].   
Sample Preparation 
 A total of 30 animals (15 mice each for VDR+/+ and VDR-/-) were used in the 
initial study and 24 more (6 mice for each genotype and diet) were used in the subsequent 
study. Following euthanasia by CO2 asphyxiation, the right femurs were disarticulated 
from pelvic bone and tibia and cleaned of soft tissues by sharp dissection.  The bones 
were soaked in phosphate buffered saline and stored at -20ºC until used.  Prior to 
microCT scanning, the femurs were thawed at room temperature.  After scanning, 9 
specimens from the VDR+/+ and VDR-/- groups on a regular diet were randomly chosen 
and fixed in 10% buffered formalin for 24 hours with post fixation in 70% ethanol and 
processed for histology.  One specimen from each group was used for undecalcified bone 
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histology and the remaining eight specimens were decalcified and embedded in paraffin 
ad described below. 
MicroCT Processing 
 The VDR-/- mouse was generated in a C57BL/6 background [269]; accordingly, 
in a preliminary study, C57BL/6 mice were used to verify that mice also possess growth 
plate tethers (data not shown).  Based on these observations, the distal portion of the right 
femurs of VDR-/- mice and their VDR+/+ littermates were scanned by microCT (μCT 
40, Scanco Medical, Switzerland) with a voxel size of 16μm.  The growth plate was 
contoured and isolated from the microCT scan by reconstructing the image at a specific 
value identified to threshold out all soft tissue including the growth plate (Figure 3.1A).  
Scanco software was used to invert the image and contour out the growth plate while 
calculating the average thickness and growth plate volume along with the tether volume 
within the growth plate.  3D color images representing the range of X-ray attenuation 
values were generated to visualize growth plate morphology and distribution of X-ray 
opaque regions signifying calcified tethers.  Projections of these images were then used to 
measure projected growth plate and tether area using Image Pro Plus software 
(MediaCybernetics, Bethesda, MD).  To assess tether distribution, a 3D color image 
derived from the microCT scan of a representative VDR+/+ growth plate was marked 
with ellipses coded from 1 to 12 to form a distribution map based on the distribution of 
tethers (Figure 3.1B).  This map was then overlaid on all 3D color images of both 
VDR+/+ and VDR-/- growth plates to assess the distribution of the tethers within each 
region.  The probability of finding tethers in any one region of the growth plate was 
determined by counting the tethers within each of the 12 ellipses on the growth plate 
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map.  The probability index was defined as the percentage of samples with tethers in each 
area.  
Histological Processing 
 One specimen in each group was fixed and processed for undecalcified 
histomorphometry.  Sagittal sections were stained with silver nitrate to detect the 
presence of tethers in growth plate.  Undecalcified specimens were used to orient 
histological sections in order to compare different measured parameters from histological 
analysis to 3D reconstruction of microCT images (Figure 3.1A). 
 Because of the difficulties associated with doing serial sectioning on 
undecalcified samples, eight femurs in each group were then decalcified and processed 
for histologic analysis.  Paraffin-embedded sagittal sections 4μm in thickness were 
consecutively sliced with a microtome (Micom HM 355s Rotary microtome, Germany), 
and every fourth section was stained with haematoxylin and eosin.  VDR-/- growth plates 
averaged 400 slices, whereas VDR+/+ growth plates averaged 300 slices.  The growth 
plates of microscope images (Leica DMLB, Germany) of each stained section were 
outlined and tethers, defined as sharp changes in texture and color that span the growth 
plate and resembled the bordering bone, were subsequently outlined for 
histomorphometric analysis (Figure 3.1C).  After marking the tethers directly on each 
serial micrograph, a 3D reconstruction of tether dimension was generated so that each 
tether was counted only once in the overall assessment of the growth plate.  Moreover, 
this allowed us to directly compare the histological image with the corresponding three-
dimensional microCT image. 
 39 
Comparing MicroCT Assessment to Histology 
 To determine whether microCT images of tethers based on X-ray refraction 
correlated with histological micrographs of bone-like tissue bridging the growth plate, we 
rotated the 3D microCT image and created secondary ISQ images using Scanco software 
to match the orientation of histological images and aligned the microCT image 
accordingly (Figure 3.1A).  In order to do this, it was necessary to calculate a shrinkage 
percentage for the VDR-/- and VDR+/+ tissues following histological processing using 
morphometric data from the histological and microCT images of the same orientation.  
Shrinkage percentage was determined in part by normalizing the difference between the 
microCT and histological values to the microCT value.  
 After alignment of the microCT image with the histological image, the vertical 
height (GP thickness), horizontal length, and number of tether were determined on 
histology sections using Image Pro Plus.  In histology images, growth plate volume was 
calculated by equation 1:  
 
GP Volume = ΣAi × 16μm (1)  
 
where Ai is the growth plate area of a particular serial section in the sagittal direction, i is 
the total number of serial sections of the growth plate, and 16μm is the interval between 
each serial section.   
 Tether volume within the growth plate was approximated in a similar manner for 
each tether detected in histology sections.  Tether volume percentage for each growth 
plate was then calculated by dividing tether volume by growth plate volume for both 
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histological and microCT analysis.  Projected growth plate area was calculated utilizing 
equation 2:  
 
Projected GP Area = Σ Li × 16μm (2)  
 
where Li is the growth plate length in the horizontal direction, i is the total number of 
serial sections of the growth plate, and 16μm is the interval between each serial section.  
Tether projected area was calculated in a similar fashion.  Additionally, tether area 
percentage for each growth plate was calculated by dividing tether projection area by 
growth plate projection area for both histological and microCT analysis.   
Statistical Analysis 
 There were no statistically significance differences between male and female 
samples for all measured parameters so data for each measurement were expressed as 
overall means ± standard errors.  Student’s t-test comparing VDR+/+ to VDR-/- mice and 
2-way ANOVA comparing VDR+/+ to VDR-/- on regular and rescue diets were 
performed with Statistix (Analytical Software, FL, USA) using a post-hoc Tukey test for 
pairwise comparison (p<0.05) to determine statistical differences.  The correlations 
between histological measurements and microCT measurements were investigated by 
linear regression in Minitab 15 (Minitab Inc., State College, PA, USA).  The correlation 
coefficient for each parameter was compared with a critical value for the number of 
corresponding measurements in the study to determine statistical significance (2-tail 




Figure 3.1: Micro-CT and Histological Evaluations of the Growth Plate  
(A) Schematic of growth plate morphology and tether distribution analysis with both 
micro-computed topography and (B) Outline of how tethers were quantified using 
histomorphometric analysis (C)Tether distribution map overlaid on a typical VDR+/+ 
mouse distal femoral growth plate used to assess the distribution of the tethers within 
each region of all growth plates. 
 
RESULTS 
Micro-Computed Tomography Analysis 
 Analysis of the microCT images showed that the projected growth plate area in 
the VDR-/- mice was more than twice that seen in VDR+/+ growth plates (Figure 3.2A).  
Moreover, microCT analysis revealed that average growth plate thickness was more than 
five times greater in VDR-/- femurs compared to VDR+/+ controls (Figure 3.2B) and 
growth plate volume was more than six times greater in VDR-/- animals than VDR+/+ 
mice (Figure 3.2C).  Serial microCT images showed significant differences between 
VDR+/+ and VDR-/- growth plates (Figure 3.3A-F).  In general, serial images separated 
by 40μm showed that VDR+/+ mice had narrow growth plates, thin distinct tethers 
distributed throughout the length of the growth plate, and frequent changes in both 
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growth plate morphology and tether distribution along the sagittal direction (Figure 3.3A-
C).  Meanwhile, serial sections separated by 70μm showed that VDR-/- femurs had large 
growth plates, a large and weakly visible tether localized to the center of the growth 
plate, and relatively few changes in both growth plate morphology and tether distribution 
along the sagittal axis (Figure 3.3D-F).   
 
Figure 3.2: Parameters of 3-D Morphology of VDR+/+ and VDR-/- Growth Plates 
(A) Projected growth plate area, (B) average growth plate thickness, and (C) growth plate 
volume for VDR+/+ and VDR-/- femurs calculated from 3D micro-CT images;   For each 
measured parameter, n=15±SE.  (*) p<0.05 for VDR-/- compared to VDR+/+.     
 
Distribution of tethers in the VDR -/- growth plates also differed from their 
distribution in VDR+/+ animals as seen in 3D color images of the growth plate (Figure 
3.3G, H) and highlighted by the table of probability indexes for each region (Table 3.1).  
Tethers most frequently occurred throughout peripheral regions of 1 to 7 in VDR+/+ 
growth plates, while most tethers in VDR-/- mice were in the central part in region 10.  
Probability indexes also indicate that whereas tethers were present in all VDR+/+ growth 
plates, not all VDR-/- growth plates had tethers.  The number of tethers in femoral 
growth plates experienced a 20-fold reduction when VDR was knocked out (Figure 
3.4B).  At the same time, projected tether area percentage decreased by 99% (Figure 
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3.4C) and projected tether area per growth plate in VDR-/- mice was one quarter of the 
projected tether area in VDR+/+ mice (Figure 3.4D).  Tether volume percentage had a 
92% reduction when VDR was knocked out (Figure 3.4E); however, the tether volume 
per growth plate remained about the same regardless of VDR genotype (Figure 3.4F).  
 
Figure 3.3 Micro-CT 3-D Evaluation of VDR+/1+ and VDR-/- Growth Plates 
(A-C) Serial micro-CT images of a VDR+/+ growth plate separated by 40μm.  (D-F) 
Serial micro-CT images of a VDR-/- growth plate separated by 70μm.  Orange arrows 
point to tethers crossing the growth plate. (G) Magnified micro-CT image of tethers (H) 
3-D micro-CT color image of a VDR+/+ growth plate and (I) VDR-/- growth plate.  





Table 3.1: Tether Probability Index and Distribution in the Growth Plate 
Region VDR+/+ (%)  VDR-/- (%) 
1  93.3   0 
2  100   6.7 
3  100   6.7 
4  100   6.7 
5  93.3   0 
6  86.7   0 
7  100   0 
8  13.1   0 
9  47.4   6.7 
10  13.3   2 
11  26.7   0 
12  60   0   
 
Histological Analysis 
 Growth plates in the distal femurs of VDR-/- and VDR+/+ mice exhibited 
differences in their shrinkage properties following decalcified histological processing 
(Figure 3.4A).  While no differences in projected growth plate area shrinkage were seen 
in VDR-/- and VDR+/+ specimens following histological processing, there was a greater 
loss of growth plate volume and growth plate thickness in mice lacking a functional 
VDR.  Histological sections indicate that knocking out VDR incurs a 5.5 fold reduction 
in the number of tethers present in the growth plate (Figure 3.4B).  In addition, projection 
tether area percentage was decreased by 63% (Figure 4C) but projected tether area per 
growth plate was 2.7 times larger in VDR-/- femurs (Figure 3.4D).  Tether volume 
percentage decreased by 84% (Figure 3.4E) but tether volume per growth plate was 
statistically the same for both VDR+/+ and VDR -/- growth plates (Figure 3.4F). 
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Figure 3.4: Parameters of Tethers in VDR+/+ and VDR-/- Growth Plates 
(A) Shrinkage percentages for VDR+/+ and VDR-/- growth plates during histological 
processing (n=8±StDev). (B) Number of tethers, (C) projected tether area percentage, (D) 
projected tether area per growth plate, (E) tether volume percentage, (F) tether volume 
per growth plate for VDR+/+ and VDR-/- femurs measured from micro-CT images and 
histology sections.  n=15±SE for micro-CT and n=8±SE for histology. (*) p<0.05 for 
VDR-/- compared to VDR+/+. 
 
 Decalcified histology showed VDR-/- mice exhibited changes in their femoral 
epiphyses characteristic of rickets.  Serial sections of VDR-/- mice had expanded growth 
plates and the epiphyseal bone contained enlarged marrow spaces and thin trabeculae in 
comparison with VDR+/+ mice (Figure 3.5D-F).  Additionally, growth plates in the 
VDR-/- femurs had an expanded hypertrophic cell zone and the tissue was malformed 
and disorganized.  Rather than the well-defined W-shaped morphology seen in the 
VDR+/+ animals, the VDR-/- growth plates were distended, resulting in a wider 
metaphysis.  This was reflected in the need to cut 400 serial sections for the VDR-/- 
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growth plates versus 300 sections for the VDR+/+ specimens.  Tethers in haematoxylin 
and eosin stained sections were defined as regions of darker staining that span the growth 
plate and resembled the surrounding metaphyseal and epiphyseal bone they linked.  
Tethers were evident in the undecalcified histologic images of the VDR+/+ growth plates 
and evolved quickly in the sagital direction (Figure 3.5A-C), but few, if any, were seen in 
the VDR-/- growth plates and were mainly localized to the center of the growth plate 
(Figure 3.5D-F). 
 
Figure 3.5: Serial Histology of VDR+/+ and VDR-/- Growth Plates 
(A-C) Serial decalcified histological micrographs of a VDR+/+ growth plate separated by 
48μm.  (D-F) Serial decalcified histological micrographs of a VDR-/- growth plate 
separated by 48μm.  Black arrows point to tethers crossing the growth plate.  For all 
micrographs, bar represents 100μm.   
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Comparison between Histological and MicroCT Analyses  
 Measurements by histological and microCT analyses exhibited similar trends 
when comparing VDR+/+ femurs to VDR-/- femurs for all tether parameters except for 
projected tether area per growth plate (Figure 3.4B-F).  When analyzed by linear 
regression, histological and microCT measurements of growth plate thickness, projected 
area, and volume were highly correlated (Figure 3.6A-C) with microCT measurements 
being 2-9 times larger due to shrinkage during decalcified histological processing (Figure 
3.4A).  The number of tethers per growth plate measurements were correlated between 
the two analytical techniques (Figure 3.6D), whereas measurements for the tether area 
percentage and tether volume percentage had lower correlation coefficients (Figure 3.6E, 
F).  Measurements from histology sections and microCT imaging were not correlated for 
either tether area per growth plate nor bone volume per growth plate (Data not shown). 
  
Figure 3.6: Comparison of Micro-CT and Histology Parameters 
(A) Micro-CT measurement versus histological measurement for individual samples of 
growth plate thickness, (B) growth plate projected area, (C) growth plate volume, (D) 
number of tethers, (E) tether projected area percentage, and (F) tether volume percentage.  
Each comparison has n=16. 
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Shrinkage percentages due to decalcified histological processing of each sample 
were then compared to corresponding microCT measurements of tether parameters.  
Linear regression analysis showed that tether volume percentage was highly correlated 
with decreased shrinkage in both growth plate thickness and volume and the number of 
tethers also showed strong correlations to decreased shrinkage percentages for both 
thickness and volume (Table 3.2).  Correlations between tether area percentage and 
decreased thickness and volume shrinkage were not as strong.  Meanwhile, none of the 
tether parameters were correlated with projected growth plate area shrinkage. 
Table 3.2: Correlation (R
2
 values) Between Shrinkage Percentages and Tether 
Parameters (n=16) 
    ____________________________________________ 
    Tether Number    Tether Volume %         Tether Area% 
Shrinkage % of thickness 0.816, p<0.01  0.872, p<0.01  0.643, p<0.01 
Shrinkage % of area  0.143, p>0.1  0.089, p>0.1  0.059, p>0.1 
Shrinkage % of volume 0.824, p<0.01  0.862, p<0.01  0.576, p<0.02 
 
Rescue Diet 
The rescue diet was effective in restoring VDR-/- growth plate volume at 10 
weeks of age (Figure 3.7A) as growth plate volume was reduced by 88.6% compared to 
VDR-/- growth plates treated with a regular diet, and there was no statistical difference 
between wild type and knock out samples.  Additionally, rescue diets had no effect on 
VDR+/+ growth plate volume.  For mice fed a regular diet, 10 week old VDR+/+ growth 
plate volumes were 20% smaller than VDR+/+ growth plate volumes at 8 weeks, but 10 
week old VDR-/- growth plates volumes were 11.7% larger than VDR growth plate 
volumes at 8 weeks (Figures 3.7A, 2C).  3D colored images showed extensive tether 
formation throughout the growth plate at 10 weeks compared to 8 week old samples 
(Figure 3.7B, 3.3H).   
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Rescue diet treatment did not restore normal tether formation in VDR-/- growth plates at 
10 weeks of age.  VDR null mice on a rescue diet had a 26 fold increase in tether volume 
percentage compared to VDR-/- mice on a regular diet but only restored 12.4% of the 
total volume percentage compared to VDR+/+ growth plates (Figure 3.7C).  Also, rescue 
diets did not have a statistically significant effect on VDR+/+ tether volume percentage.  
For mice fed a regular diet, 10 week old VDR+/+ growth plates had a 78% larger tether 
volume percentage compared to 8 week old VDR+/+ growth plates but 8 week old VDR-
/- growth plates had a 87% higher tether volume percentage compared to 10 week old 
VDR-/- growth plates (Figure 3.7B, 3.4E).  Tether distribution in VDR-/- growth plates 
treated with a rescue diet also resembled growth plates of VDR-/- mice on a normal diet 
(Figure 3.7D, 3.3I). 
 
Figure 3.7:  Morphology of Growth Plates and Tethers of VDR+/+ and VDR-/- Mice  
(A) Growth plate volume (B) 3-D micro-CT color image of a VDR+/+ growth plate at 10 
wks (C) Tether volume percentage (D) VDR-/- growth plate on a rescue diet.  n=6 ±SE, 




 This study is the first to show that mouse femoral growth plates, like rat tibial 
growth plates [262], contain X-ray opaque bone-like tethers visible by microCT.  
Moreover, it is the first to thoroughly show by direct morphometric analysis that X-ray 
opaque bone-like tethers evident in microCT images correspond to specific 
morphological entities in histological micrographs of the same tissues.  In addition, this 
study shows for the first time that the lack of a functional VDR results in a marked 
reduction in tether formation, as well as alterations in tether morphology and anatomic 
distribution.  This study also demonstrates that normal mouse growth plates at 8 and 10 
weeks are different in both size and tether composition and that knocking out the VDR 
has increasing adverse effects with age.  Finally, this study shows that the presence of 
tethers is not solely dependent on normal mineral homeostasis and that signaling via the 
VDR not associated with extracellular calcium ion content may be involved in tether 
formation.   
 The rachitic pathology in the distal femur of VDR-/- mice seen in this study was 
characterized by a broadening of the epiphysis and metaphysis as a consequence of loss 
of morphologic integrity of the VDR-/- growth plates.  This was consistent with the 
previous reports of VDR-/- murine growth plates [270], including a significant increase 
in thickness due to the expansion of the hypertrophic cell zone, leading to bowing of the 
epiphyses.  In addition to changes in the growth plate, the bones were also affected, 
exhibiting large marrow spaces and thin trabeculae, which previous investigators linked 
to increased mechanical fragility [259].  
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 Our results demonstrated the utility of using microCT to assess growth plate 
structural elements in a volumetric manner.  MicroCT images showed that many tethers 
were distributed throughout the growth plate in VDR+/+ mice but a fewer amount were 
limited to the central region in VDR-/- growth plates.  Tethers in VDR+/+ growth plates 
were thin and appeared highly calcified whereas tethers present in VDR-/- were thicker 
with little calcification.  These microCT observations were validated histologically.  Non-
decalcified sections were used to orient the growth plate to the microCT image and serial 
sections of decalcified paraffin embedded tissue provided a means to assess the 
effectiveness of using 3D reconstructions from microCT imaging to evaluate tether 
formation.  Structures reminiscent of “multiple tide-lines and a sharp change in texture” 
observed during epiphyseal closure in mammals [263] connected the epiphysis and 
metaphysis in decalcified serial sections of the VDR+/+ femurs.  In contrast, tether 
distribution and morphology were affected by the lack of a functional VDR in the VDR-/- 
mice.  
 Although the tether volume percentage and number of tethers in microCT images 
and decalcified histological micrographs of VDR-/- tissues were markedly reduced, tether 
volumes for both VDR+/+ and VDR-/- growth plates remained the same.  This finding 
suggests that although tether formation is significantly decreased when the VDR is 
knocked out, the length of the tether increases significantly with growth plate thickness 
causing the tether volume within the growth plate to remain constant.  The growth plate 
volume, however, is increased by the thickness cubed, which is why tether volume 
percentage is significantly less without a functional VDR.   
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The projected tether area percentage per growth plate decreased significantly for 
both microCT and histological measurements in VDR-/- tissues, but microCT 
measurements of projected tether area per growth plate decreased whereas histological 
measurements increased in VDR-/- femurs.  This result suggests that projected tether area 
is a poor assessment of tether formation since it does not take into account the sinuous 
contours of the growth plate.  The inability of projected tether area to predict tether 
formation is further confirmed as measurements by histology and microCT showed no 
correlation.  The relatively wide range of tether volume per growth plate values measured 
by microCT compared to narrow distribution of values measured by decalcified histology 
may imply that microCT imaging is more sensitive in detecting the presence of tethers.  
Furthermore, strong correlations between microCT and histological measurements of 
growth plate geometry, tether number, and tether volume percentage emphasize that 
microCT imaging is an effective imaging and analytical modality for studying tether 
formation. 
 Thus, even though microCT and histological measurements were generally 
correlated with each other, differences did exist between the actual measurements.  
Several reasons may explain why there were similar trends but absolute differences for 
some of the measured parameters.  First and foremost, tissue shrinkage accounts for most 
of the discrepancies between microCT and histological analyses, and histological 
processing may cause additional damage to the tissue structure.  At the same time, since 
tethers are heterogeneously distributed throughout the growth plate tissue shrinkage may 
not be uniform within the tissue.  In addition, due to the small size of the mouse femurs, 
it is possible that the very thin tethers visible in histological sections may have been 
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below the voxel size resolution of microCT imaging used in this study.  Additionally, 
hematoxylin and eosin staining of decalcified sections may not be as effective in 
detecting the presence of calcified structures in the growth plate compared to microCT 
imaging.  
 It was surprising that thickness and volume shrinkage percentages were 
statistically different between VDR+/+ and VDR-/- growth plates but the projected area 
shrinkage percentage was about the same.  Further analysis showed that decreased 
shrinkage in growth plate thickness and volume were strongly correlated to tether 
formation whereas projected area shrinkage had no dependence on tether formation.  
These results suggested that differences in horizontal and vertical shrinkage of VDR+/+ 
and VDR-/- growth plate might result from differences in mechanical properties; 
specifically, bone-like tethers may provide structural stability in growth plates along the 
axial direction. 
While the mechanical properties of the growth plate have not been extensively 
characterized, the static compressive properties of newborn swine growth plate explants 
are non-uniform along its thickness with the reserve zone being twice as stiff as the 
proliferative and hypertrophic zones in the axial direction [267].  However, the strain 
patterns of loaded rat tibia growth plates reveal that at 5 weeks of age, the proliferative 
zone is the stiffest portion of the growth plate [268] suggesting that growth plates may 
exhibit different mechanical behavior due to changing tissue compositions at different 
stages of development.  In comparing normal mice growth plates at 8 and 10 weeks in 
this study, noticeable differences were seen in tether volume formation.  Whether or not 
tether formation plays a role in the temporal change of growth plate mechanical behavior 
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or provides mechanical stability of growth plates during bone growth and active loading, 
however, cannot be assessed without a more extensive measurement of tether formation 
throughout skeletal development and vigorous comparisons between growth plate 
mechanics and tether composition.  
Normal mineral homeostasis imparted by a diet high in calcium, phosphorous, 
lactose, and vitamin D3, was able to restore growth plate volume in mice lacking a 
functional VDR but was not enough to create normal levels of tether formation, 
suggesting that tether formation maybe dependent on signaling via the VDR not 
associated with extracellular calcium content.  It is well known that cells in the growth 
plate respond to different metabolites of vitamin D3 [83, 261], and although these 
metabolites can interact with a membrane receptor independent of VDR [273, 274], it 
seems reasonable for VDR mediated signaling to be partially responsible for tether 
formation.  In mice with pseudo vitamin D deficiency rickets caused by mutations in the 
25-hydroxyvitamin D-1α-hydroxylase gene, a high calcium diet was able to restore bone 
morphology and biomechanical properties but, unlike 1α,25(OH)2D3 replacement 
therapy, was unable to restore bone growth [275].  The fact that both tether formation and 
bone growth are disrupted in the absence of 1α,25(OH)2D3 signaling via the VDR, 
despite having normal bone structure and mechanics, should be further investigated and 
may provide beneficial insight into skeletal development.  Additionally, it will be 
important to determine what other biological factors are required for tether development 
in order to truly understand their function.  Knocking out extracellular matrix proteins 
like collagen type II has been linked to abnormal endochondral ossification [276] and 
may play a role in the beginning stages of tether development.  
 55 
CONCLUSION  
 In summary, our results show that tethers are present in vitamin D replete 
C57BL/6 mouse growth plates with functional VDRs and that they occur in specific 
regions that can be mapped.  MicroCT images indicate that the number of mineralized 
tethers and tether volume percentage is reduced significantly in the rachitic growth plates 
of VDR-/- mice in comparison with their VDR+/+ littermates, and those that occur 
appear to be less calcified and are localized to the central region.  Additionally, a rescue 
diet that restores normal mineral homeostasis is able to restore growth plate size but not 
tether formation in VDR-/- growth plates, suggesting that VDR mediated signaling 
independent of calcium ion homeostasis plays a critical role in tether formation.  Serial 
decalcified histological sections confirm the findings from microCT analysis as number 
and volume percentage measurements are strongly correlated between the two imaging 
and analytical techniques, suggesting that microCT imaging is an effective 
nondestructive tool for analyzing tether formation.  Shrinkage in the axial direction was 
correlated with tether formation, suggesting that bone-like tethers may provide 
mechanical stability.  Growth plate size and the extent of tether formation were also 
different between animals of different ages.  Although extensive studies are still needed 
to determine the role of tethers in growth plate mechanics and bone development, it is 
now known that tether formation is regulated in part by the VDR, which may prove to be 
beneficial in developing treatments for diseased or damaged growth plates.   
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CHAPTER 4 
CORDINATED TEHTER FORMATION IN ANATOMICALLY 
DISTINCT GROWTH CENTERS IS DEPENDENT ON A 
FUNCTIONAL VITAMIN D RECEPTOR AND IS TIGHTLY 
LINKED TO THREE-DIMENSIONAL TISSUE MORPHOLOGY 
 
INTRODUCTION  
 In order for coordinated and proportional skeletal growth to occur, endochondral 
ossification at growth centers throughout the body, such as growth plates of the long 
bones and synchondroses of the cranial base, need to be tightly regulated.  Disruptions to 
normal growth in these tissues can lead to limb, body, and craniofacial deformities.  
Although the mechanisms regulating endochondral bone growth of long bones have been 
characterized extensively, less is known about differential modulation of endochondral 
ossification and growth center fusion in other cartilaginous tissues throughout the body.  
Growth plates and synchondroses can be divided into a series of anatomic zones with 
distinct morphological and biochemical properties that are tightly controlled by growth 
factor signaling pathways [48, 50, 277, 278].  In addition, cells in the growth plate are 
modulated by systemic hormones, including estrogen and vitamin D.  Specifically, the 
vitamin D metabolites l,25-dihydroxy vitamin D3 [1,25(OH)2D3] and 24R,25-
dihydroxy vitamin D3 [24R,25(OH)2D3] act on different cells in growth centers to 
regulate chondrocyte differentiation and bone lengthening [83, 88, 279]. 
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Deficiency in 1,25(OH)2D3 during long bone growth results in rickets, a 
condition where the growth plate enlarges because hypertrophic chondrocytes are unable 
to calcify their extracellular matrix [255], partially due to abnormal mineral homeostasis.  
As hypertrophic chondrocytes continue to pile onto each other, structural deformities in 
the bone ensue.  Abnormal mineral homeostasis and resulting rachitic growth plates are 
also seen in mouse models with an ablated vitamin-D receptor (VDR-/-) [256, 269].  The 
gross morphology of the growth plate can be restored by returning serum calcium 
concentration to normal levels [258, 259, 280], either via systemic injection or by feeding 
the mice a high lactose, high calcium “rescue” diet, supporting the hypothesis that rickets 
is due to defective Ca
2+
 ion homeostasis [260].  The 1,25(OH)2D3-dependent membrane 
associated protein disulfide isomerase family A, member 3 (PDIA3) signaling pathway is 
still functional in growth plate chondrocytes from these mice [271], suggesting that it 
may provide sufficient response to 1,25(OH)2D3 to support matrix calcification with 
adequate restoration of extracellular Ca
2+
.  However, it is clear that simply raising Ca
2+
 is 
not the only function of 1,25(OH)2D3 in regulating the biology of growth centers.  
Studies using growth plate chondrocyte cultures show that 1,25(OH)2D3 mediates a 
broad range of responses including synthesis and maturation of extracellular matrix [261, 
281].  Recently, we observed that the failure of VDR-/- mice to form growth plate tethers 
could not be rescued using the rescue diet, indicating that their development may be 
VDR-dependent [280]. 
Tethers are mineralized struts present in the growth plates of long bones of mice, 
rats, dogs, pigs, and human [262, 263, 280, 282].  They form perpendicular to the plane 
of the growth plate and eventually connect the epiphyseal and metaphyseal bone surfaces. 
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Although rat and murine growth plates never fully fuse, they become thinner as tether 
formation increases with time [262].  We have previously shown that CT is an accurate 
modality for studying tethers by correlating computed measurements with histological 
observations [280].  In VDR-/- mice, tether formation is markedly reduced and those 
tethers that are present are localized to the center of the growth plate.  Although VDR-/- 
mice that were raised on the high lactose, high calcium rescue diet had growth plates with 
normal volumes, tether formation was only partially restored. 
Little is known about the functional role tethers play in bone growth and 
maintenance.  They have been linked to changing growth plate morphology and fusion 
[262] and to providing tissue stability [280], suggesting that they play a mechanical role – 
potentially limiting fractures through the growth plate during post fetal development.  
Whether tethers are present in other growth centers is not known, nor is it known if 
growth centers that experience different kinds of loads will have tethers that are regulated 
in a similar fashion. 
 Synchondroses in the skull are believed to be regulated similarly to the growth 
plates of long bones [283], but because of their anatomic location, they serve other 
functions in addition to longitudinal growth.  The cranial base has been considered as a 
guide for maxillary-mandibular complex, midface, and lower facial development, linking 
the development of the cranial vault with that of the facial skeleton [283-285].  The 
spheno-occipital synchondrosis (SOS) is the main remnant of a cartilaginous basicranium 
from embryonic development and has a cellular organization resembling two adjacent 
growth plates with the reserve zones back to back [283].  After birth, a mineralized 
bipolar column eventually develops within the reserve zones, separating the 
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synchondrosis into two regions.  Endochondral ossification of the SOS has a direct 
contribution to basicranial growth and subsequent craniofacial development [286, 287] 
and disruptions to SOS  growth can lead to cranial malformations that are characteristic 
of achondroplasia [288], Apert’s syndrome [289, 290], anterior transverse crossbite 
[291], and cleidocranial dysplasia [292, 293].  The SOS is still visible on lateral 
radiographs through adolescence and has been shown to widen in response to  maxillary 
and midpalatal suture expansion [294].  Additionally, clinical and laboratory 
investigations have suggested that premature closure of the cranial vault sutures in 
nonsyndromic craniosynostosis is associated with characteristic alterations in SOS 
morphology [31].   
The purpose of this study was to determine if tether formation is a conserved 
feature of growth centers other than the growth plates and if so, whether tethers are 
regulated in a similar manner and have similar phenotype and function at different 
anatomic locations.    To do this, we used CT to compare the growth plate in the distal 
femoral condyle to the SOS in normal C57Bl/6 mice of various ages.  We took advantage 
of our VDR-/- mouse model to assess the regulation of tether formation in these two 
anatomical sites.  VDR+/+ and VDR-/- mice were fed a regular diet or a rescue diet with 
and without vitamin D3.  Finally, to gain insight into what role tethers may have in 
affecting tissue morphology or stability, correlations were analyzed among animal 
weight, growth center thickness, and tether phenotype.  We hypothesized that the three-
dimensional morphology of both the femoral growth plate and SOS would be similar 
with respect to temporal development.  We also hypothesized that lack of a functional 
VDR would increase the size of both the growth plate and SOS while greatly reducing 
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the presence of tethers.  Additionally, we hypothesized that restoring normal mineral 
homeostasis would restore the morphology of the growth centers but not the presence of 
tethers.  Finally, we hypothesized that tether phenotype would be correlated to animal 
weight and growth center morphology. 
 
MATERIALS AND METHODS 
Animal Maintenance  
All animal procedures were conducted under an Institutional Animal Care and 
Use Committee approved protocol in the vivarium in the Institute for Bioengineering and 
Bioscience at the Georgia Institute of Technology.  To investigate tether formation with 
age in normal murine growth plates and synchondroses, male C57Bl/6 murine pups were 
obtained from Jackson Laboratory (Bar Harbor, ME).  Animals were weaned, then fed 
Purina rodent chow (5010, Ralston Purina Co., St. Louis, MO) containing 1% calcium, 
0.67% phosphorus, 0% lactose, and 4.4 IU vitamin D/g (regular diet) with water, and 
euthanized at ages 2, 4, 6, 7, 8, 10, and 15 weeks.  This age range was chosen since the 
epiphysis was not visible in microCT scans at 10 days and animals exhibited no statistical 
change in weight between 12 and 15 weeks. 
To investigate the role VDR-mediated signaling may have in tether formation, 
VDR-/- mice were used, in which structural stability of the growth plate is compromised 
due to rickets [269] and abnormal mineral homeostasis is exhibited [256].  A 
heterozygous (VDR+/-) breeding pair, which was generated in a C57Bl/6 background 
[269], was obtained as a gift from Dr. Marie Demay (Harvard Medical School, 
Massachusetts General Hospital, Boston, MA), and a mouse colony was established.  
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Offspring were genotyped two weeks after birth and VDR+/- mice were allowed to breed.  
To normalize blood mineral ion levels [258], male and female homozygous VDR+/+ and 
VDR-/- mice were fed a rescue diet containing 20% lactose, 2% calcium, 1.25% 
phosphorus, and 2200IU vitamin D3/kg (TD96348, Teklad, Madison, WI) from day 22.  
This diet has previously been shown to restore serum ionized calcium levels, phosphorus 
levels, and immunoreactive PTH levels in the VDR null mice compared to wild type 
mice at 70 days of age  [258].  To gain better insight into the role metabolites of vitamin 
D3 may have in tether formation, mice were also fed a rescue diet without the added 
vitamin D3 (TD87095, Teklad).  Therefore, six groups of animals were investigated: 
VDR+/+ mice on regular diet, rescue diet, and rescue diet with vitamin D3 and VDR-/- 
mice on regular diet, rescue diet, and rescue diet with vitamin D3.  All mice were 
euthanized when 10 weeks old.  This age was chosen to accurately assess the rescue 
diet’s effect on mineralization since over 85% of the bone surface is covered with osteoid 
in VDR-/- mice fed a regular diet at this time [259].  In addition to genotyping, 
homozygotes were assessed for evidence of rickets by histologic analysis of the 
costochondral cartilages.  VDR-/- mice exhibited phenotypic markers of vitamin D 
deficiency, including rachitic growth plates with expanded hypertrophic cell zones.  
Sample Preparation and MicroCT Processing 
 Once animals were euthanized, both the right femur and cranial base were excised 
from all mice (n=6 for each age and n=6 for each genotype and diet) and cleaned of soft 
tissues by sharp dissection.  Bone samples were then fixed in 10% buffered formalin for 
24 hours and post fixed in 70% ethanol.  The distal portion of the right femur was 
scanned by CT (μCT 40, Scanco Medical, Switzerland) with a voxel size of 12μm [280] 
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while the cranial base was scanned at a voxel size of 8m because of the smaller growth 
center size.  Both the distal femoral growth plate (GP) and the anterior region of the SOS 
were isolated with user-guided contours and evaluated at a threshold corresponding to 
250mg hydroxyapatite/cm
3
.  This threshold was previously confirmed to be accurate for 
tether evaluation by comparing histomorphometric results to CT [280].  To qualitatively 
assess tissue morphology and tether distribution, 3D reconstructions of the GP (Figure 
4.1A) and the SOS (Figure 4.1B) were used to create 3D color images to visualize growth 
plate morphology and 3D tether maps to visualize formation within the growth center and 
along the surface.  For quantitative measurements, Scanco software using a direct 
distance transformation method was implemented to determine microarchitecture 
morphology of both the GP and SOS and the tethers within each as previously discussed 
[295, 296].  Specifically, this method results in global volumetric measurements that 
represent averages along all relevant axes.  Parameters derived in both the growth plate 
and SOS include tissue volume (mm
3
), tether volume/growth center (GC) volume, tether 
number (#/mm), tether thickness (mm), and tether spacing (mm).  Additionally, average 
tissue thickness (mm) along the axial direction between the epiphysis and metaphysis was 
also measured.  
Statistical Analysis 
One way ANOVA comparing VDR+/+ mice from 2 to 15 weeks of age and two-
way ANOVA comparing VDR+/+ to VDR-/- on regular and rescue diets were performed 
with Statistix (Analytical Software, FL, USA) using a post-hoc Bonferroni correction test 
for pairwise comparison (p<0.05) to determine statistical differences.  A power analysis 
on a preliminary study determined that a sample size of 6 (n=6) was sufficient to detect 
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significant statistical differences between groups.  Additionally, the preliminary study 
showed no statistically significant difference between male and female VDR+/+ mice and 
between male and female VDR-/- mice in terms of growth center thickness and tether 
volume.  Because it was unfeasible to get only 10 week old males for all six groups 
(VDR+/+ and VDR-/- mice on regular diet, rescue diet, and rescue diet with vitamin D3) 
measurements were expressed as overall means ± standard errors of both male and 
female mice.  The correlations between tether parameters and other measurements were 
investigated in Minitab 15 (Minitab Inc., State College, PA, USA).  The correlation 
coefficient for each parameter was compared with a critical value for the number of 
corresponding measurements in the study to determine statistical significance (2-tail 
analysis, p<0.05) [272].  
 
RESULTS 
Normal Morphological Development of the GP and SOS 
Both the murine GP and SOS decreased rapidly in size over the course of 15 
weeks after birth (Figure 4.1C, D).  Specifically, X-ray cross-sections showed the GP 
becoming thinner in the axial direction with increasing curvature while the bipolar 
column of the SOS started to develop and thicken.  3D color maps of growth center 
morphologies (Figure 4.1E, F) confirmed the decrease in tissue thickness.  The overall 
GP and SOS morphologies experienced the most change between weeks 2 and 7, with 
little to no change in shape between weeks 7 and 15.  At week 15, an accumulation of X-
ray opaque regions seen in the 3D color maps signified tethers that traversed the entire 
length of the growth plate.  Quantitative analysis revealed that both the GP and SOS 
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decreased in thickness by approximately 85% between weeks 2 and 8 (Figure 4.1G, I) 
with little to no decrease afterwards.  GP and SOS volumes experienced a similar trend 
with an approximately 50% decrease in size between weeks 4 and 8 (Figure 4.1H, J).  
Although growth center thickness experienced a rapid decrease between weeks 2 and 4, 
GP and SOS volumes did not decrease because of corresponding tissue expansions in the 
sagital and axial directions respectively. 
 
Figure 4.1:  Normal Morphological Development of the GP and SOS  
CT imaging and 3D evaluation of the (A) growth plate (GP) and (B) spheno-occipital 
synchondrosis (SOS).  X-ray cross-sections from 2 to 15 weeks show a decrease in (C) 
GP and (D) SOS size.  3D color maps of the (E) growth plate and (F) synchondrosis show 
changing morphology with age (bar represents 1mm for all images).  Quantified (G) 
average GP thickness, (H) GP volume, (I) SOS thickness, and (J) SOS volume decrease 
with age from 2 to 15 weeks (n=6, mean±SE for each time and tissue). 
 
The Role of Mineral Homeostasis and VDR in Growth Center Morphology  
 The size of the GP was greatly expanded in VDR-/- mice, leading to a 
disorganized morphology (Figure 4.2A).  The SOS also expanded in VDR-/- mice, 
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resulting in a distorted morphology with minimal calcification of the bipolar column 
(Figure 4.2B).  Rescue diets with and without vitamin D3 had similar effects on the GP 
and SOS as tissue size was almost restored, but morphology was visibly different from 
VDR+/+ mice in both x-ray cross-sections and 3D color images of each tissue (Figure 
4.2C-D).  Specifically, VDR-null GPs with normal mineral homeostasis had rougher 
surfaces and less curvature compared to VDR+/+ GPs.  Meanwhile, VDR-/- SOSs with 
normal mineral homeostasis had more curvature than VDR+/+ SOSs with slight bowing 
of the tissue. 
  Average GP and SOS thicknesses increased by 7.8-10 fold in the VDR-/- mice 
(Figure 4.2E, G).  Rescue diets with and without vitamin D3 were able to decrease tissue 
thicknesses by 75% but did not restore GP or SOS thicknesses as seen in VDR+/+ mice.  
GP and SOS volumes experienced a similar trend by increasing 5-10 fold in the absence 
of VDR and rescue diets significantly reducing tissue volume (Figure 4.2F, H).  Rescue 
diets with vitamin D3 were effective in restoring VDR-/- GPs and SOSs to wild-type 
volumes. 
Normal Tether Development in the GP and SOS  
Tethers that traversed the entire GP and SOS were apparent in x-ray cross-
sections of both 7 and 15 week old tissues (Figure 4.3A, B).  For both the GP and SOS at 
week 15, there appeared to be a higher density of thicker tethers present.  3D tether maps 
further confirmed these findings as a large accumulation of underlying tethers budding 
along the surface and within the growth centers were observed at both weeks 7 and 15 
(Figure 4.3C, D).  Tether volume/GC volume increased rapidly from week 8 to 15 in both 
the GP and SOS with nearly identical trends over 15 weeks (Figure 4.3E).  Tether 
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number/mm for both the GP and SOS increased by 4-5 fold from week 6 to 15 (Figure 
4.3F) as tether width increased by 3-3.5 fold over the first 8 to 10 weeks of age with little 
increase afterwards (Figure 4.3G).  Tether spacing decreased rapidly over the first 8 
weeks in both the GP and SOS (Figure 4.3H).  At all ages, tether number/mm was greater 
in the SOS, but tether width and spacing were greater in the GP. 
 
Figure 4.2: Effect of Mineral Homeostasis and VDR on GP and SOS Morphology   
X-ray cross sections of (A) GPs and (B) SOSs of 10 week old VDR+/+ and VDR-/- mice 
on regular and rescue diets with and without vitamin D3 show that growth center 
morphology is largely influenced by normal mineral homeostasis.   3D color maps of (C) 
GPs and (D) SOSs show restored size but altered morphologies of 10 week old VDR-/- 
mice on regular and rescue diets with and without vitamin D3 (bar represents 1mm for all 
images).   (E) GP thickness is partially restored by rescues diets whereas (F) GP volume 
is statistically restored with rescue diet and vitamin D3.   (G) SOS thickness is partially 
restored by rescue diets whereas (H) SOS volume is restored with rescue diets (n=6, 
mean±SE for each tissue and treatment, *p<0.05 vs. corresponding VDR+/+, **p<0.001 
vs. corresponding VDR+/+, #p<0.05 vs. VDR-/- on regular diet, ##p<0.001 vs. VDR-/- 




Figure 4.3: Normal Tether Development in the GP and SOS  
X-ray cross sections in the (A) GP and (B) SOS show increased tether width and 
accumulation between weeks 7 and 15.  3D tether maps of the (C) GP and (D) SOS show 
tether accumulation between weeks 7 and 15 within each tissue (bar represents 1mm for 
all images).  (E) Tether volume/growth center volumes in each growth center have 
similar increases with age.  (F) Tether number/mm and (G) tether width in both tissues 
increase as (H) tether spacing decreases with age (n=6, mean±SE). 
 
The Role of VDR-mediated Signaling in Tether Formation 
Tether formation was nearly abolished in VDR-/- mice and although rescue diets 
were effective in restoring growth center volume, few to no tethers that traversed the 
entire tissue were present in either the GP (Figure 4.4A) or SOS (Figure 4.4B).  3D tether 
maps confirmed these results as little tether formation was observed in VDR-/- tissues 
with normal mineral homeostasis (Figure 4.4C, D).  A more thorough quantitative 
assessment showed tether volume/GP volume and tether volume/SOS volume in VDR-/- 
mice on a regular diet was 0.2-0.4% of those in VDR+/+ mice (Figure 4.4 E, I).  Rescue 
diets were partially effective in restoring the tether phenotype, increasing tether 
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volume/tissue volume by 35 and 150 fold in the GP and SOS, respectively, but only 
restored 20-25% of the tether formation found in their wild-type littermates.  Tether 
number/mm in both tissues was similar to tether volume/tissue volume, as rescue diets 
were only able to partially restore tether accumulation (Figure 4.4F, J).  The effect of 
knocking out VDR on tether width was not as pronounced as a statistically insignificant 
decrease was observed in the GP and a 33% decrease was seen in the SOS (Figure 4.4G, 
K).  Rescue diets had no influence on tether width.  Tether spacing in the GP and SOS 
was significantly higher in VDR-/- mice as rescue diets partially reduced tether spacing 
in the GP but not the SOS (Figure 4.4H, L). 
Relationships among Animal Weight, Growth Center Morphologies, and Tethers   
In VDR+/+ mice 2 to 15 weeks of age, normalized GP and SOS average 
thicknesses with respect to the thickness at 2 weeks of age were inversely correlated with 
animal weight (Fig. 5A) as the two correlations were nearly indistinguishable from each 














).  Tether volume/growth center volume was exponentially related 
to animal weight as GP and SOS correlations were nearly identical (Fig. 5B).  Tether 
number/mm versus animal weight was also exponentially related for both the SOS and 
GP (Fig. 5C).  Tether width was linearly correlated with animal weight in both the GP 
and SOS (Fig. 5D) as tether spacing was inversely correlated with weight in both tissues 
(Fig. 5E).  These tether parameters for the GP and SOS had similar relationships to femur 
length and basicranial length respectively.   
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Tether number/mm had an inverse exponential relationship with normalized tissue 
thickness in the GPs and SOSs of VDR+/+ mice 2 to 15 weeks of age (Fig. 5F).  In 10 
week old VDR+/+ and VDR-/- mice on regular and rescue diets, tether number/mm also 
had a similar inverse exponential relationship with normalized growth center thickness 
for both the GP and SOS (Fig. 5G).  GP and SOS tether spacing in VDR+/+ mice 2 to 15 
weeks in age were linearly correlated with corresponding tissue thicknesses (Fig. 5H), 
and these correlations between tether spacing and GP and SOS thicknesses were nearly 
identical in 10 week old VDR+/+ and VDR-/- mice on regular and rescue diets. 
 
Figure 4.4:  The Role of VDR-mediate Signaling in Tether Formation 
X-ray cross sections of 10 week old VDR+/+ and VDR-/- (A) GP and (B) SOS treated 
with rescue diets.  3D tether maps of (C) GPs and (D) SOSs (bar represents 1mm for all 
images).  (E) Tether volume/GP volume, (F) GP tether number/mm, (G) GP tether width 
and (H) GP tether spacing.   (I) Tether volume/SOS volume, (J) SOS tether number/mm, 
(K) SOS tether width, and (L) SOS tether spacing (n=6, mean±SE,*p<0.05 vs. 
corresponding VDR+/+, **p<0.001 vs. corresponding VDR+/+, #p<0.05 vs. VDR-/- on 
regular diet, ##p<0.001 vs. VDR-/- on regular diet). 
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Figure 4.5: Relationships among Animal Weight, Growth Center Morphologies, and 
Tethers 
(A) Normalized growth center thickness with respect to the thickness at 2 weeks of age is 
inversely correlated to animal weight.  (B) Tether volume/growth center volume and (C) 
tether number/mm are exponentially related to animal weight. Growth center (D) tether 
width is correlated to animal weight whereas (E) tether spacing is inversely correlated.  
Growth center tether number/mm in (F) 2 to 15 week old VDR+/+ mice and (G) 10 week 
old VDR+/+ and VDR-/- mice on regular and rescue diets have an inverse exponential 
relationship with corresponding normalized tissue thickness.  Tether spacing in (H) 2 to 
15 week old VDR+/+ mice and (I) 10 week old VDR+/+ and VDR-/- mice on regular and 
rescue diets are correlated to their respective normalized growth center thickness (GP [
___        
], SOS [___        ]). 
 
DISCUSSION 
Tether formation in the tibia and femur occurs naturally [280, 297], but little is 
known about its functional role, its presence in other growth centers during endochondral 
ossification, or the mechanism that regulates its formation.  This study is the first to 
demonstrate that in addition to growth plates found in long bones, tethers are also present 
in the spheno-occipital synchondrosis, a growth center locatedat the base of the skull that 
serves other functions in addition to longitudinal growth.  Specifically, this study 
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demonstrated that tether morphology in both the growth plate and synchondrosis have 
strikingly similar patterns of post-fetal development; the VDR and mineral homeostasis 
have analogous effects on growth center tissue and tether formation in long bones and the 
cranial base; tether formation in both the growth plate and synchondrosis is significantly 
associated with animal weight and respective bone length; and tether phenotype appears 
strongly linked to growth center thicknesses in normal development and diseased animals 
with rescued phenotypes.  
In both the growth plate and synchondrosis, there appears to be two stages of 
tether development: an initial phase of tether thickening that is followed with rapid 
accumulation in number.  Tether thickening appears to be most dominant in post-fetal 
development between weeks 2 and 8 while tether density and overall accumulation has 
their most rapid increase starting at week 6.  These trends in tether phenotype appear to 
have an inverse relationship with growth center morphology in normal post-fetal 
development, which steadily decreases in thickness and size after week 2.  Additionally, 
these trends between tether phenotype and growth center morphology are seen in rachitic 
growth centers as tethers are less dense and thinner while growth center volumes and 
thicknesses of these diseased tissues are larger.    
To thoroughly investigate the relationship between growth center morphology and 
tether formation, correlations between tether phenotype and tissue thickness were 
investigated in the growth plates and synchondroses of both normal mice at different ages 
and of 10 week old VDR ablated mice with and without normal mineral homeostasis.  
Tether density – which appears most dominant in later stages of tether formation – had an 
overall inverse exponential relationship with tissue thickness, but was linearly correlated 
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once the growth centers reached a quarter of their original size.  Meanwhile, tether 
spacing – a parameter that takes into account both initial tether thickening and later tether 
accumulation – appeared to be directly correlated with tissue thickness throughout 
growth center development in all groups.  These findings suggest that tether formation 
and tissue morphology are somehow linked in normal and diseased tissues.  Specifically, 
it appears that overall tether spacing is connected to tissue thickness throughout 
development whereas tether density has a role once the growth center tissue starts to 
decrease in size. 
  Despite this very strong link between tether formation and thinning growth 
centers in different anatomical locations, it is unclear if there is a definitive mechanism 
that links the two.  Although it is possible that tether formation can be partially attributed 
to endochondral ossification, it is not the main mechanism for tether development.  
Specifically, this study showed that restoring mineral homeostasis in VDR-/- mice with 
rescue diets containing vitamin D3 was able to restore growth plate and synchondrosis 
volume but unable to restore their respective tether phenotype – specifically tether 
density and spacing.  This finding suggests that 1,25-dihydroxy vitamin-D3 acting 
through its receptor regulates tether accumulation in growth centers throughout the body, 
not endochondral ossification.  It may also be hypothesized that tethers facilitate the 
changing morphology of growth centers during the pubertal growth spurt and their 
eventual closure during sexual maturity, which has been reported to be between five to 
six weeks of age [298].  Although the largest changes in growth center volumes and 
tether numbers occur immediately after this time frame, it may be difficult to prove that 
tethers lead to growth center closure during sexual maturity since the wide array of 
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variables that influence growth plate closure is not completely understood.  Specifically, 
weight loading [266], injuries [264, 299], abnormal hormone levels [300, 301], and 
genetic mutations [302, 303] all have an influence on growth plate morphology and 
subsequent closure, but how they influence tethers is unknown.  Finally, it is not clear 
how to decouple tether formation from temporal changes in growth plate morphology. 
We have previously suggested that tethers may contribute to overall tissue 
stability in the axial direction [280], and to gain insight into this possible role for tethers, 
the relationship between tether phenotype and animal weight was investigated.   Tether 
density, width, and spacing appeared to be linked with animal weight.  Tether width was 
linearly correlated and tether spacing was inversely correlated with weight up to 30 
grams.  Although the differences in mechanical properties and experienced mechanical 
loads of long bone growth plates and the spheno-occipital synchondrosis in mice are 
unknown, it is interesting to note the differences in tether phenotype at these distinctly 
different anatomical locations.  Specifically, at all ages, tethers in the growth plate are 
thicker and spaced farther apart whereas thinner tethers in the synchondrosis occur at a 
higher density.  Investigating tether formation in heavier mouse strains and in bipedal 
species in which body weight is distributed differently would provide further insight into 
the role of tethers in tissue stability.  However, it is also possible that the increase in 
tether size and number and decrease in tether spacing can be the result of animal growth 
and not a response to tissue stability due to increased weight; specifically, tether size, 
number, and spacing had the same correlations to length as weight.  Additionally, the 
correlations between weight and tether formation will most likely be different for males 
and females.  Regardless, more extensive comparisons between growth plate mechanics 
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and tether composition need to be performed to arrive at a definitive conclusion about 
tethers’ role in tissue stability.  
Disruptive skeletal growth and corresponding growth center organization may 
provide insight into the role of tethers.  In a rat defect model of growth plate injury, 
length reduction was correlated with percentage difference in growth plate thickness 
[297], suggesting that growth plate morphology may play a role in bone growth.  
Although the change in bone tether volume was not correlated to length reduction, tethers 
in these animals were associated with bone bridges that form during trauma [264, 265] 
and may not be comparable to tethers seen in healthy tissue.  In homozygous 
brachymorphic (bm/bm) mice, which are characterized by a disproportionately short 
stature, the SOS was significantly larger than wild-type, lacked a calcified biopolar 
column or tethers, and had a disturbed morphology that resembled that seen in VDR-/- 
mice with no rescue diet [291].  Additionally, the anteroposterior length of the posterior 
cranial base in the bm/bm mice was significantly shorter, suggesting that synchondrosis 
morphology is important for normal bone growth.  In mice with pseudo vitamin D 
deficiency rickets caused by mutations in the 25-hydroxyvitamin D-1-hydroxylase 
gene, a high calcium diet was able to restore bone morphology and biomechanical 
properties but, unlike 125(OH)2D3 replacement therapy, was unable to restore bone 
growth [275].  The elimination of bone growth and tether accumulation in the absence of 
1,25(OH)2D3 signaling via its receptor – along with the previously reported 
relationships between tethers, growth center morphology, and subsequent bone growth – 
suggests that tethers may play a role in bone lengthening.  Although our study showed 
that tether accumulation in two different growth centers was strongly linked to animal 
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weight and respective bone length during normal post-fetal development, the relationship 
between tether formation and bone growth rates should be further investigated. 
 
CONCLUSION 
 In summary, tethers are present in both the growth plates of long bones and 
synchondroses of the cranial base.  Tethers in both growth centers thicken and 
accumulate in number with age as the tissue decreases in size.  When the VDR is ablated, 
tether formation is nearly eliminated in both rachitic growth plates and synchondroses.  
Restoring mineral homeostasis with rescue diets restored the overall size of both growth 
centers but only partially restored growth center morphology and tether formation, 
suggesting that tether formation in both growth centers is partially regulated by VDR 
signaling via 1,25-dihydroxy vitamin-D3.  During post-fetal development from 2 to 15 
weeks of age, tether phenotype had significant relationships to animal weight.  
Synchondrosis and growth plate thicknesses were inversely correlated to weight in wild-
type mice, whereas in both 2-15 week old normal mice and 10 week old VDR-/- mice 
with normal and abnormal mineral homeostasis, tether phenotype was tightly linked to 
growth center thickness.  The strong association between tether formation and growth 
center morphology may have implications on normal skeletal development and 






TAILORING ADIPOSE STEM CELL TROPHIC FACTOR 
PRODUCTION WITH DIFFERENTIATION MEDIUM 
COMPONENTS TO REGENREATE CARTILAGE 
 
INTRODUCTION  
Adipose stem cells (ASCs) have been considered a promising candidate for 
cartilage repair because of their easy accessibility and chondrogenic potential [304, 305].  
More recently, ASCs have demonstrated the ability to secrete trophic factors that can 
potentially stimulate endogenous cartilage regeneration [306], eliminating the need for 
ASCs to directly replace damaged chondrocytes or synthesize new cartilaginous tissue.  
However, ASCs secrete other factors that can delay or even inhibit cartilage repair.  
Specifically, VEGF-A, an angiogenic growth factor that is secreted in large quantities by 
ASCs [155, 307], has been shown to increase matrix metalloproteinase expression in 
chondrocytes [68] and is highly expressed in osteoarthritic cartilage [71].  Additionally, 
prolonged exposure to hypertrophic growth factors like FGF-18 and BMP-2 and can lead 
to hypertrophic differentiation, calcification, skeletal vascularization, and subsequent 
bone formation [53, 63, 308].  Growth factors such as FGF-2, IGF-I, and PTHrP can 
increase chondrocyte proliferation and regulate hypertrophy [309-312], while growth 
factors such as TGF-β1 and TGF-β2, can stimulate proteoglycan synthesis [313, 314].  
Furthermore, BMP inhibitors like noggin have an important role in regulating cartilage 
differentiation and endochondral ossification [315].  Therefore, well defined methods that 
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increase ASC secretion of factors that promote chondrocyte proliferation and 
cartilaginous tissue synthesis, decrease secretion of angiogenic factors, and limit 
secretion of hypertrophic factors from ASCs are needed to treat chondral defects 
effectively. 
Although viral and non-viral genetic manipulations of ASCs can be used to 
increase or decrease secretion of specific trophic factors, their ability to target only one 
gene at a time limits their therapeutic potential since cartilage formation is orchestrated 
by numerous growth factors and other signaling molecules [32, 53].  Furthermore, the 
potentially harmful side effects of genetic manipulations have hindered the clinical 
potential of these techniques [32, 316].  Therefore, preconditioning stem cells in vitro to 
obtain a desired secretory profile has also been suggested.  While hypoxic exposure, heat 
induction, and biophysical stimulation have previously been used to augment the 
paracrine actions of stem cells [32, 159, 317], pharmacological treatments (chemical 
compounds) and biological treatments (growth factors and hormones) may provide the 
most precision in controlling the intensity and time of preconditioning.  Additionally, 
providing different structural microenvironments (3-D scaffolds, cell-cell interactions) 
such as microencapsulation may further control the secretome of stem cell therapies in 
vitro and in vivo.  Microencapsulation of ASCs may also provide a delivery method to 
localize these therapies.   
The effects of differentiation media, such as chondrogenic medium, on multiple 
stem cell sources under varying structural environments are well defined [243, 304, 318].  
However, the effects that short-term exposure to these media has on trophic factor 
production from ASCs are unknown.  To decide if chondrogenic medium and its 
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individual components could be used to effectively precondition ASCs to secrete factors 
for regenerating cartilage, the objectives of this study were to determine the effect 
chondrogenic medium has on ASC growth factor secretion in different structural 
environments and to determine the effect different chondrogenic medium components 
have on ASC growth factor production. 
 
MATERIALS AND METHODS 
Cell Isolation 
ASCs were isolated from the inguinal fat pads of 125 g male Sprague-Dawley rats 
(Harlan Laboratories, Indianapolis, IN, USA) as previously described in detail  [319, 320] 
and cultured in Lonza Mesenchymal Stem Cell Growth Medium (MSCGM, Lonza, 
Walkersville, MD, USA).  After one passage, these cells were negative for CD 45 and 
positive for CD73 and CD271 [320].  Costochondral chondrocytes from the ribs of 125 g 
male Sprague Dawley rats were isolate as described  previously [82, 321].  Primary cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal 
bovine serum (FBS) and 50 μg/ml ascorbic acid (Invitrogen, Carlsbad, CA, USA) until 
fourth passage prior to experimental analysis. These cells continue to express type II 
collagen, aggrecan, and cartilage oligomeric matrix protein [321]. 
Microencapsulation 
When primary ASCs reached 90% confluence, they were harvested by 
trypsinization and microencapsulated in low molecular weight (~150 kDa) alginate with a 
high mannuronate to guluronate ratio (40% guluronate, FMC BioPolymer, Sandvika, 
Norway) as previously described [322].  The alginate (20 mg/mL) was dissolved in 
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sterile-filtered saline (Ricca Chemical, Arlington, TX, USA).  Cells were suspended in 
the alginate solution at a concentration of 25×10
6
 cells/mL.  Microbeads were formed 
using a Nisco Encapsulator VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, 
Switzerland) and a crosslinking solution of 50 mM CaCl2, 150 mM glucose, and 15 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer, pH=7.3, Sigma, St. 
Louis, MO, USA).  Microbeads were washed three times in GM prior to cell culture 
studies.  First passage ASCs were also plated in 6-well plates. 
Cell Culture  
Once first passage ASCs reached 90% confluence, ASC monolayers and 
microbeads were then treated for 5 days with either GM or chondrogenic medium (CM) 
consisting of DMEM containing 4.5g/L glucose with 1 mM sodium pyruvate (Mediatech, 
Manassas, VA, USA), 40 μg/ml proline (Sigma), 50 μg/ml ascorbic acid 2-phosphate 
(AA2P, Sigma), 1% ITS+ (Sigma), 100 nM dexamethasone (Dex, Sigma), 10 ng/ml 
recombinant human transforming growth factor beta-1 (TGF-1, R&D Systems, 
Minneapolis, MN, USA) and 100 ng/ml recombinant human bone morphogenic protein 6 
(BMP-6, PeproTech, Rocky Hill, NJ, USA).  In subsequent studies, ASC monolayers 
were treated for five days with either GM that was supplemented with different 
combinations of 50μg/mL AA2P, 100nM Dex, 10ng/mL TGF-1, and 100ng/mL BMP-6 
or with CM that lacked different combinations of 50μg/mL AA2P, 100nM Dex, 10ng/mL 
TGF- β1, and 100ng/mL BMP-6.  Once media were changed on the fifth day, RNA was 
collected after 8 hours as described below.  Conditioned media and ASCs were collected 
after 24 hours, and ASCs were lysed in 0.05% Triton X-100.  Monolayer fourth passage 
chondrocytes cultured in DMEM, 10% FBS, and 50μg/mL ascorbic acid and Sprague 
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Dawley-derived clone 9 liver cells (ATCC, Manassas, VA, USA) cultured in F12K 
medium and 10% FBS served as a reference.  All media contained 1% penicillin and 
streptomycin. 
RNA Isolation and Reverse Transcription 
Alginate microbeads were uncrosslinked in 82.5 mM sodium citrate (Sigma), 
pelleted at 500×g for 10 minutes and washed two more times in sodium citrate to remove 
any residual alginate.  TRIzol reagent (Invitrogen) was added to the resulting cell pellet, 
homogenized using a QIAshredder (QIAGEN, Valencia, CA, USA), and RNA was 
isolated using chloroform and an RNeasy Kit (QIAGEN) as previously described [323].  
1 μg RNA was then reverse transcribed to cDNA using a High Capacity Reverse 
Transcription cDNA kit (Applied Biosystems, Carlsbad, CA, USA).   
Microarray Analysis 
 cDNA was converted into cRNA using a RNA transcript labeling kit (Enzo 
Diagnostics, Farmingdale, NY, USA).  Biotin labeled cRNA was cleaned up using a 
GeneChip Sample Cleanup Module (Affymetrix Inc., Santa Clara, CA, USA) and 
fragmented at 94°C in Fragmentation Buffer for 35 minutes.  Following fragmentation, 
15 μg biotinylated cRNA was hybridized to an Affymetrix Rat  Genome GeneChip (Rat 
230_2.0) at 45°C for 16 hours, washed, stained with streptavidin phycoerythrin (Fluidics 
Station 400, Affymetrix), and scanned according to manufacturer’s guidelines.   The 
GeneChips were then assessed for data quality using Affymetrix-developed quality 
controls.  Data analysis was performed using GeneSifter (Geospiza, Seattle, WA) with 
significant differences in expression of a single gene being defined as a 3-fold change in 
mRNA levels.  Significant differences in mRNAs of Kyoto Encyclopedia of Genes and 
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Genomes (KEGG) pathways were defined as z-scores greater than 2.0.  RNA isolated 
from rat liver tissue served as a reference control. 
Growth Factor mRNA Levels and Production 
Because chondrogenesis is a complex process orchestrated by a wide array of 
growth factors, mRNA levels and production of paracrine factors involved in 
chondrocyte proliferation, proteoglycan synthesis, hypertrophic differentiation, and 
vascular invasion were quantified.  Along with these paracrine factors, mRNAs for 
chondrocytic markers were also quantified as previously described using real-time PCR 
with gene-specific primers using the Step One Plus Real-time PCR System and Power 
Sybr® Green Master Mix (Applied Biosystems) [166].  All primers were designed using 
Beacon Designer software (Premier Biosoft, Palo Alto, CA, USA) and synthesized by 
Eurofins MWG Operon (Huntsville, AL, USA), unless otherwise noted (Table 1).  
Growth factor production over the last 24 hours of culture was quantified using ELISA 
(R&D Systems) and normalized to DNA content measured with a Quant-iT PicoGreen kit 
(Invitrogen).  To measure growth factor retention within the microbeads, cultures were 
uncrosslinked in 82.5mM sodium citrate and both supernatants and cells were frozen at -
80
o
C.  Samples were then lyophilized for 24 hours and the resulting dried constructs were 
digested in 1 unit/mL alginate lyase (Sigma) for 1 hour and measured with ELISA.  TGF- 
β1 production and secretion was not measured because of the large concentration of 
recombinant human TGF-β1 in chondrogenic medium.  Quantified mRNA levels were 
referred to by the name of the gene whereas quantified protein levels were referred to by 
the name of the growth factor. 
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Table 5.1: Primer Sequences for Rat ASCs 
Gene Direction Sequence 
Acan Sense GCTTCGCTGTCCTCAATGC 
 
Antisense AGGTGTCACTTCCCAACTATCC 
Bmp2 Sense TGTGAGGATTAGCAGGTCTTTG 
 Antisense CTTCCGCTGTTTGTGTTTGG 
Bmp6 Sense CCGCAGCAGCAACAATCG 
 Antisense ATCCTCTTCGTCGTCCTTGG 
Col2 Sense CGAGTATGGAAGCGAAGG 
 
Antisense GCTTCTTCTCCTTGCTCTTGC 




Global Gene Sequence (Qiagen) 
 
Antisense 
Fgf18 Sense CTTCCAGGTTCAGGTGTTG 
 Antisense GCTTCCGACTCACATCATC 
Igf1 Sense GGTTCCTTATCTCCATTTCTTCC 
 Antisense CCCAGTTGCTATTGCTTTCG 
Nog Sense TAAGCCATCCAAGTCTGTG 
 Antisense AGCAGGAACACTTACACTC 
Pdgfa Sense GAGGAGACGGATGTGAGG 
 
Antisense ACGGAGGAGAACAAAGACC 
Pthlh Sense TGGTCGCAGGCTAAAACG 
 Antisense TGTGGATCTCCGCAATCAG 
Rps18 Sense TCGCTATCACTGCCATTAAGG 
 
Antisense TGTATTGTCGTGGGTTCTGC 
Sox9 Sense GTGGGAGCGACAACTTTACC 
 
Antisense ATCGGAGCGGAGGAG GAG  
Tgfb1 Sense AGCCTGCTTCTTGAGTCC 
 Antisense AAGTGGGGTGTTCTTAAATAGG 
Tgfb2 Sense AGCCTGCTTCTTGAGTCC 
 Antisense CTCAGAGGAAGGGATGGG 
Tgfb3 Sense AAGGAGTGGACAACGAAG 
 Antisense CGGTGTGGAGGAATCATC 
Vegfa Sense GGACATCTTCCAGGAGTACC 
  Antisense CGTCTTGCTGAGGTAACC 
 
Statistical Analysis 
Statistical differences among all experimental groups were determined via 
ANOVA with a post hoc Tukey test (GraphPad Prism, La Jolla, CA, USA).  Statistical 
differences between control and experimental groups were determined via Student’s t-
test.  Differences in means were considered to be statistically significant if the p-value 
was less than 0.05.  All in vitro experiments had six independent cultures per treatment 
group to ensure sufficient power to detect statistically significant differences and were 
conducted multiple times to validate the observations.  However, only data from a single 
representative experiment are shown and are expressed as means ± standard errors.   
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RESULTS  
Growth Factor Signaling Pathways with High and Low Expressions in ASC Cultures 
 mRNAs for 21 out of 52 proteins associated with the TGF-β signaling pathway 
were higher in ASC monolayers compared to liver RNA (Table 5.2).  These higher 
mRNAs included paracrine factor genes bmp2, nog, tgfb1, tgfb2, and tgfb3; receptor 
genes tgfbr2, tgfbr3, and bmpr2; and secondary messengers genes smad2, smad3, smad4, 
and p300 (data not shown).  mRNAs for proteins associated with the mitogen activated 
protein kinase (MAPK) signaling pathway were also higher in ASC monolayers and 
microbeads compared to liver RNA with z-scores of 3.27 and 2.26 respectively (Table 
5.2).  Higher mRNAs included numerous fgfs and pdgfa, pdgfra, pdgfrb, fgfr, mapk3, 
rras, prkcc, and rac1 (data not shown).  mRNAs for proteins associated with the Wnt 
signaling pathway were higher in both ASC monolayers and microbeads (Table 2) 
compared to liver.  However, higher mRNA levels were mainly due to secondary 
messengers of the Wnt canonical pathway; Wnt2 and 4 were the only Wnt proteins with 
higher mRNA levels.  mRNAs for proteins associated with PPAR signaling pathway 
were significantly lower in both ASC monolayers and microbeads with z-scores of 3.22 
and 4.63 respectively.  Based on these results, paracrine factors associated with TGF-β 







Table 5.2: Gene Array of Signaling Pathways 
Signaling Pathways 
















monolayer 27/52 21 6 3.5 -2.08 
microbeads 18/52 14 4 1.65 -1.99 
       
MAPK signaling 
pathway 
monolayer 90/185 56 34 3.27 -1.75 
microbeads 71/185 45 26 2.26 -1.53 
       
Wnt signaling pathway 
monolayer 40/87 30 10 3.18 -2.71 
microbeads 32/87 23 9 2.04 -1.94 
       
PPAR signaling 
pathway 
monolayer 31/58 7 24 -1.67 3.22 
microbeads 32/58 8 24 -0.88 4.63 
       
Jak-STAT signaling 
pathway 
monolayer 38/84 14 24 -0.97 1.08 
microbeads 26/84 18 8 0.79 -2.1 
 
Effect of Chondrogenic Medium on ASC Cultures 
 CM increased igf1, pthlh, tgfb2, and bmp2 by 1.8 to 46 fold (Figure 5.1A) and 
nog by 110 fold (Table 5.3) in ASC monolayers.  ASC microbeads experienced a similar 
increase in igf1 and tgfb2 when treated with CM (Figure 5.1A).  CM decreased fgf2 and 
vegfa in both ASC monolayers and microbeads by 3 to 4 fold while microencapsulation 
alone increased igf1, pthlh, tgfb2, and bmp2 (Figure 5.1A).  CM also increased acan, 
sox9, and comp in both ASC monolayers and microbeads (Table 5.3).  Compared to 
chondrocytes, ASC cultures treated with CM had similar amounts of tgfb2 and vegfa and 
higher amounts of igf1, pthlh, and tgfb2 when compared to liver cells.  
   CM had similar effects on protein secretion as it increased ASC monolayer IGF-I, 
TGF-β2, and TGF-β3 secretion by 6.3 to 30 fold (Figure 5.1B, Table 5.3).  CM also 
increased secretion of IGF-I, TGF-β2, and TGF-β3 from ASC microbeads by 2 to 37 
fold.  Microencapsulation alone increased IGF-I, TGF-β2, VEGF-A, and FGF-2 
secretions by 3 to 40 fold (Figure 5.1B, Table 5.3).  CM decreased VEGF-A secretion 
from ASC monolayers and microbeads by 15 to 20 fold and decreased FGF-2 secretion 
from ASC microbeads by 2.4 fold.  ASC monolayers treated with CM had higher 
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secretion levels of TGF-2 and TGF-β3, similar secretion levels of VEGF-A and FGF-2, 
and lower secretion levels of IGF-I compared to chondrocytes (Figure 5.1, Table 5.3).  
Detectable amounts of FGF-2, IGF-I, TGF-2, and VEGF-A were maintained within the 
microbeads as CM decreased the amounts of FGF-2, IGF-I, and VEGF-A and increased 
the amount of TGF-2 inside the microbeads.     
Table 5.3: Effect of Chondrogenic Medium on ASC Monolayers and Microbeads 
*p<0.05 vs. Chond, n = 6, mean±SE
 
1
Value less than 0.05. 
2 
Units of ng/μg. 
n.m. Not Measured 
 





Bmp6/Rps18 11.8 ± 4.0 14.9 ± 2.0 9.5 ± 1.7 *26.7 ± 5.1 *1.6 ± 0.4 *35.7 ± 5.0 
Fgf18/Rps18 21.8 ± 6.7 *49.0 ± 8.1 19.8 ± 4.6 *125.3 ± 21.8 8.7 ± 0.7 *366.6 ± 70.9 
Nog/Rps18 55.8 ± 19.6 17.5 ± 2.3 *1995.3 ± 442.4 100.3 ± 16.0 *589.3 ± 156.0 69.7 ± 6.1 
Pdgfa/Rps18 1.7 ± 0.1 1.2 ± 0.2 1.5 ± 0.2 0.7 ± 0.1 *0.5 ± 0.1 1.2 ± 0.2 
Tgfb1/Rps18 6.0 ± 1.8 3.5 ± 0.5 7.7 ± 0.8 4.7 ± 0.8 11.0 ± 2.9 3.1 ± 0.3 
Tgfb3/Rps18 207.9 ± 57.5 *17.4 ± 1.8 265.3 ± 29.4 *9.5 ± 1.3 106.1 ± 21.9 17.2 ± 1.6 
Acan/Rps18 7.5 ± 2.2 *
1
0.0 ± 0.0 *46.0 ± 6.3 *0.4 ± 0.1 *54.7 ± 8.9 *1.4 ± 0.3 
Col2/Rps18 13.5 ± 1.6 *0.2 ± 0.0 *0.2 ± 0.0 *
1
0.0 ± 0.0 *0.1 ± 0.0 *
1
0.0 ± 0.0 
Comp/Rps18 14.0 ± 4.4 *0.2 ± 0.0 *31.5 ± 5.3 *0.8 ± 0.2 *164.2 ± 70.4 *0.3 ± 0.1 
Sox9/Rps18 8.4 ± 2.4 14.0 ± 1.4 *35.4 ± 7.1 9.6 ± 1.7 *44.1 ± 6.8 *4.7 ± 0.6 
Growth Factor Production 
FGF-2/DNA
2
 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 *1.2 ± 0.1 0.5 ± 0.0         n.m. 
TGF-β3/DNA
2
 8.3 ± 4.6 11.9 ± 6.5 *75.4 ± 18.2 13.3 ± 6.9 *23.8 ± 6.4         n.m. 
FGF-2/DNA
2
    
(in microbeads) 
   n.m. n.m. n.m. 2.1 ± 0.4 0.9 ± 0.1         n.m. 
IGF-I/DNA
2
      
(in microbeads) 
   n.m. n.m. n.m. 1.3 ± 0.2 0.3 ± 0.1         n.m. 
TGF-β2/DNA
2
    
(in microbeads) 
   n.m. n.m. n.m. 
1
0.0 ± 0.0 
1
0.0 ± 0.0         n.m. 
TGF-β3/DNA
2
    
(in microbeads) 
   n.m. n.m. n.m. 34.2 ± 2.6 63.4 ± 7.9         n.m. 
VEGF-A/DNA
2
   
(in microbeads) 
   n.m. n.m. n.m. 12.0 ± 0.7 4.0 ± 0.7         n.m. 
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Figure 5.1:  Effect of Chondrogenic Medium on ASC Monolayers and Microbeads  
 (A) Trophic factor mRNA levels of ASCs in chondrogenic medium (CM) or microbeads 
(μB) with chondrocytes (Chond) and liver cells (Liv) serving as controls.  (B) Growth 
factor secretion from ASCs in chondrogenic medium (CM) or microbeads (μB) with 
chondrocytes (Chond) serving as controls (n = 6, mean±SE, *p<0.05 vs. Chond, #p<0.05 









Effect of Ascorbic Acid-2-Phodphate, Dexamethasone, and Growth Factors in MSC 
Growth Medium 
 Adding AA2P to GM decreased bmp6, fgf18, nog, and pdgfa by 2.9 to 10.9 fold 
(Table 5.4) while adding Dex to GM increased igf1, tgfb2, bmp2, fgf18, nog, pdgfa, and 
tgfb3  by 1.5 to 10.2 fold (Figure 5.2A, Table 5.4).  AA2P also increased IGF-I, FGF-2, 
and TGF-β3 secretion by 2.7 to 8.9 fold (Figure 5.2B, Table 5.4).  Adding Dex decreased 
pthlh, fgf2, and vegfa by 1.3 to 5.2 and VEGF-A secretion by 87 fold (Figure 5.2A, B).  
Adding both AA2P and Dex to GM was not as effective in increasing igf1, bmp2, fgf18, 
and nog as adding only Dex to GM.  The combination of adding both AA2P and Dex in 
GM effectively increased acan but not col2 or comp.   
 Adding TGF-β1 and BMP-6 to GM had the opposite effect of AA2P and Dex on 
igf1, fgf2, and vegfa (Figure 5.2A).  Exogenous TGF-β1 decreased igf1 by 48 fold and 
increased fgf2 and vegfa by 11 and 3.8 fold respectively (Figure 5.3A).  TGF-β1 also 
decreased pthlh by 4 fold and increased tgfb2, bmp2, fgf18, and pdgfa by 1.6 to 6.3 fold 
(Figure 5.3A, Table 5.4).  BMP-6 decreased pthlh and increased tgfb2, fgf2, fgf18, and 
nog.  Growth factor secretion by ASCs in GM was also influenced as exogenous TGF-β1 
increased TGF-β2, VEGF-A, and FGF-2 secretion by 2.5 to13.6 fold (Figure 5.3B, Table 







Table 5.4: Effect of Components in MSC Growth Medium 
*p<0.05, vs. MSCGM, n = 6, mean±SE 
1
Value less than 0.05. 
2 










The Effect of Ascorbic Acid 2-Phosphate, Dexamethasone, and Growth Factors on ASC Monolayers 
 






Bmp6/Rps18 97.9 ± 12.0 *33.3  ± 18.1 *51.7 ± 3.9 *49.6 ± 11.9 *37.4 ± 9.7 
Fgf18/Rps18 487.5  ± 61.4 *44.9 ± 6.1 *1974.8 ± 499.9 895.3 ± 186.2 *2385.3 ± 422.9 
Nog/Rps18 32.3 ± 7.0 *8.8 ± 2.0 *52.9 ± 7.1 29.7 ± 5.3 *414.6 ± 29.0 
Pdgfa/Rps18 10.9 ± 1.2 *4.4  ± 1.3 *16.8 ± 2.0 *25.7 ± 3.6 *44.8 ± 3.8 
Tgfb1/Rps18 28.2  ± 4.7 *13.2  ± 3.2 *5.2 ± 0.4 *5.2 ± 1.0 *60.7 ± 16.0 
Tgfb3/Rps18 51.6  ± 8.0 58.4  ± 8.8 *158.2 ± 10.9 *237.2 ± 53.2 47.3 ± 9.6 
Acan/Rps18 0.2  ± 0.0 0.2  ± 0.1 0.2 ± 0.0 *0.5 ± 0.1 *2.8 ± 0.3 
Col2/Rps18 
1
0.0   ± 0.0 
1
0.0 ± 0.0 
1
0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.2 
Comp/Rps18 0.1  ± 0.0 0.0 ± 0.0 
1
0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 
Sox9/Rps18  0.3 ± 0.1 *0.1  ± 0.0 *0.1 ± 0.0 0.1 ± 0.0 *0.3 ± 0.1 
Growth Factor Production 
FGF-2/DNA
2
 4.8 ± 1.3 *42.7 ± 7.6 3.5 ± 0.7 3.0 ± 0.7 *11.6 ± 1.1 
TGF-β3/DNA
2
 9.4 ± 1.0 *26.8 ± 4.3 5.5 ± 1.5 30.3 ± 1.5 *14.7 ± 1.4 
The Effect of TGF-β1 and BMP-6 on ASC Monolayers 
 
MSCGM +TGF-β1 +BMP-6 
+TGF-β1 
+BMP-6 
   
mRNA Levels   
Bmp6/Rps18 43.7 ± 5.0 30.9 ± 6.9 45.8 ± 4.3 27.7 ± 9.2   
Fgf18/Rps18 385.8 ± 115.8 *619.2 ± 109.0 *1141.1 ± 246.0 *1203.3 ± 212.4   
Nog/Rps18 2.6 ± 0.8 3.5 ± 0.9 *30.3 ± 6.8 *13.8 ± 4.8   
Pdgfa/Rps18 6.9 ± 1.4 *43.5 ± 7.0 7.8 ± 0.9 *51.2 ± 1.6   
Tgfb1/Rps18 4.7 ± 0.8 9.9 ± 2.2 5.9 ± 0.8 *9.7 ± 1.6   
Tgfb3/Rps18 0.1 ± 0.0 0.3 ± 0.1 *0.3 ± 0.0 0.6 ± 0.2   
Acan/Rps18 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0   
Col2/Rps18 
1
0.0 ± 0.0 
1
0.0 ± 0.0 
1
0.0 ± 0.0 0.0 ± 0.0   
Comp/Rps18 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0   
Sox9/Rps18 0.2 ± 0.0 0.1 ± 0.0 *1.2 ± 0.6 0.1 ± 0.0   
Growth Fctor Production 
FGF-2/DNA
2
 14.7 ± 1.0 *201.8 ± 21.2 18.1 ± 3.8 *175.5 ± 7.2   
TGF-β3/DNA
2
 8.0 ± 0.6 9.5 ± 0.7 6.8 ± 0.5 12.6 ± 2.2   
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Figure 5.2:  Effect of AA2P, Dex, and Growth Factors in Growth Medium   
(A) Trophic factor mRNA levels of ASCs in growth medium with ascorbic acid 2-
phosphate (AA2P), dexamethasone (Dex), or TGF-β1 and BMP-6 (GFs).  (B)  Growth 
factor secretion from ASCs in growth medium with ascorbic acid 2-phosphate (AA2P), 
dexamethasone (Dex), or TGF-β1 and BMP-6 (GFs) (n = 6, mean±SE, *p<0.05 vs. 
growth medium, #p<0.05 vs. +AA2P, ^p<0.05 vs. +Dex, %p<0.05 vs. +AA2P + Dex).        
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Figure 5.3:  The Effect of TGF-β1 and BMP-6 in Growth Medium 
(A) Trophic factor mRNA levels of ASCs in growth medium with TGF-β1 and BMP-6.  
(B)  Growth factor secretion from ASCs in growth medium with TGF-β1 and BMP-6.  (n 














Effect of Effect of Ascorbic Acid-2-Phodphate, Dexamethasone, and Growth Factors in 
Chondrogenic Medium 
 Removing AA2P from CM decreased igf1, tgfb2, and fgf2 mRNAs by 1.2 to 6.3 
fold (Figure 5.4A).  The absence of AA2P also increased vegfa and fgf18 2.5 to 2.8 fold 
(Figure 5.4A, Table 5.5).  Taking out Dex from CM decreased igf1, pthlh, bmp2, bmp6, 
fgf18, and nog 2.1 to 9.2 fold (Figure 5.4A, Table 5.5).  The lack of Dex from CM also 
increased tgfb2, fgf2, vegfa, pdgfa, and tgfb1 1.2 to 3 fold.  Removing both AA2P and 
Dex further decreased igf1 mRNA while increasing vegfa and pdgfa (Figure 5.4A, Table 
5.5).  Individually removing AA2P and Dex from CM decreased IGF-I secretion 10.5 to 
22 fold and increased VEGF-A secretion 5.3 to 58 fold (Figure 5.4B).  Removing AA2P 
also decreased TGF-β2 secretion 2.5 fold while removing Dex increased TGF-β2 
secretion 2.4 fold.  Removing AA2P decreased acan, comp, and sox9 1.8 to 3.1 fold 
while leaving out Dex increased mRNAs for these same genes 1.5 to 23 fold (Table 5.5).  
 Removing both exogenous TGF-β1 and BMP-6 from CM significantly decreased 
igf1, pthlh, and vegfa by 1.4 to 10.1 fold (Figure 4A); nog 1000 fold; and tgfb3 16 fold 
(Table 5.5).  Specifically, the lack of TGF-β1 reduced igf1, pthlh, tgfb2, fgf18, tgfb1, and 
tgfb3 2.7 to 25 fold while the lack of BMP-6 reduced pthlh, tgfb2, bmp2, vegfa, fgf18, 
and nog 2.2 to 220 fold (Figure 5.5A, Table 5.5). Taking out TGF-β1 also increased 
bmp2, fgf2, bmp6, and nog 1.8 to 4.3 fold while the lack of BMP-6 increased bmp6 8.6 
fold.  Individually removing exogenous TGF-β1 and BMP-6 from CM decreased IGF-I 
secretion 1.7 to 2.4, TGF-β2 secretion 8.3 to 25 fold, and VEGF-A secretion 1.3 to 1.6 
fold.  The absence of TGF-β1 and BMP-6 had similar effect on acan and comp, reducing 
their mRNA levels 1.7 to 31 fold. 
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Table 5.5: Effect of Components in Chondrogenic Medium 
*p<0.05 vs. CM, n = 6, mean±SE
 
1
Value less than 0.05. 
2 






The Effect of Ascorbic Acid 2-Phosphate, Dexamethasone, and Growth Factors on ASC Monolayers 
 






Bmp6/Rps18 67.0 ± 6.6 114.9 ± 24.9 27.3 ± 3.2 53.6 ± 5.1 62.2 ± 9.8 
Fgf18/Rps18 887.6 ± 73.3 *2497.2 ± 634.0 *96.9 ± 13.3 *570.7 ± 45.1 *132.1 ± 29.7 
Nog/Rps18 1746.1 ± 171.4 1382.8 ± 205.8 *310.3 ± 33.7 *826.7 ± 70.7 *1.7 ± 0.4 
Pdgfa/Rps18 12.2 ± 1.2 12.3 ± 2.6 *22.2 ± 2.9 *27.7 ± 2.5 *2.1 ± 0.7 
Tgfb1/Rps18 15.8 ± 2.6 15.6 ± 1.9 *47.9 ± 11.5 *47.3 ± 2.8 *1.7 ± 0.3 
Tgfb3/Rps18 748.9 ± 50.2 656.0 ± 85.4 656.4 ± 82.4 *604.2 ± 30.0 *47.4 ± 8.5 
Acan/Rps18 6.7 ± 0.4 *3.6 ± 0.3 *153.8 ± 19.7 *95.0 ± 5.3 *0.7 ± 0.2 
Col2/Rps18 0.4 ± 0.2 0.1 ± 0.0 0.6 ± 0.1 
1
0.1 ± 0.0 0.2 ± 0.1 
Comp/Rps18 17.5 ± 2.2 *5.7 ± 0.7 *95.1 ± 26.5 *146.6 ± 45.7 *0.2 ± 0.1 
Sox9/Rps18 5.2 ± 0.2 *3.0 ± 0.4 *7.8 ± 0.7 *3.6 ± 0.2 *
1
0.0 ± 0.0 
Growth Factor Production 
FGF-2/DNA
2
 7.2 ± 2.2 2.4 ± 0.6 3.2 ± 1.1 6.1 ± 2.7 4.6 ± 1.4 
TGF-β3/DNA
2
 46.5 ± 3.2 61.7 ± 7.3 *183.1 ± 30.0 *97.6 ± 10.7 *19.2 ± 1.7 
The Effect of TGF-β1 and BMP-6 on ASC Monolayers 
 
CM -TGF-β1 -BMP-6 
-TGF-β1 
-BMP-6 
   
mRNA Levels   
Bmp6/Rps18 12.2 ± 1.4 *21.5 ± 3.4 *103.9 ± 22.6 *37.8 ± 5.7   
Fgf18/Rps18 59.6 ± 17.0 13.9 ± 2.9 *13.0 ± 4.7 36.6 ± 7.1   
Nog/Rps18 18.5 ± 3.4 *80.4 ± 17.7 0.1 ± 0.0 *0.3 ± 0.1   
Pdgfa/Rps18 18.9 ± 3.9 13.7 ± 2.1 26.1 ± 7.6 6.9 ± 0.8   
Tgfb1/Rps18 4.8 ± 1.0 *1.7 ± 0.3 4.0 ± 0.8 *1.6 ± 0.4   
Tgfb3/Rps18 7.0 ± 1.1 *2.6 ± 0.6 4.5 ± 1.3 *0.6 ± 0.1   
Acan/Rps18 3.0 ± 0.8 *0.6 ± 0.2 *0.1 ± 0.1 0.1 ± 0.0   
Col2/Rps18 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0   
Comp/Rps18 0.4 ± 0.1 *0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0   
Sox9/Rps18 0.8 ± 0.2 1.0 ± 0.2 0.5 ± 0.1 0.0 ± 0.0   
Growth Factor Production 
FGF-2/DNA
2
 22.4 ± 1.0 *15.5 ± 2.1 22.7 ± 0.8 16.7 ± 2.3   
TGF-β3/DNA
2
 33.7 ± 2.3 *19.5 ± 0.9 42.7 ± 4.4 *17.6 ± 0.6   
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Figure 5.4:  Effect of AA2P, Dex, and Growth Factors in Chondrogenic Medium   
(A) Trophic factor mRNA levels of ASCs in chondrogenic medium without ascorbic acid 
2-phosphate (AA2P), dexamethasone (Dex), or TGF-β1 and BMP-6 (GFs).  (B)  Growth 
factor secretion from ASCs in chondrogenic medium without ascorbic acid 2-phosphate 
(AA2P), dexamethasone (Dex), or TGF-β1 and BMP-6 (GFs) (n = 6, mean±SE, *p<0.05 
vs. chondrogenic medium, #p<0.05 vs. +AA2P, ^p<0.05 vs. +Dex, %p<0.05 vs. +AA2P 




Figure 5.5:  The Effect of TGF-β1 and BMP-6 in Chondrogenic Medium.   
(A) Trophic factor mRNA levels of ASCs in chondrogenic medium without TGF-β1 and 
BMP-6.  (B)  Growth factor secretion from ASCs in chondrogenic medium without TGF-
β1 and BMP-6.  (n = 6, mean±SE, *p<0.05 vs. growth medium, #p<0.05 vs. + TGF-β1, 











 This is the first comprehensive study to show that microencapsulation and 
different components in chondrogenic medium have distinct effects on growth factor 
production from ASCs and that ASC microbeads can promote cartilage regeneration in a 
focal cartilage defect.   
In this study, ascorbic acid 2-phosphate regulated secretion of IGF-I and FGF-2, both 
potent stimulators of chondrocyte proliferation [309], and decreased mRNA for FGF-18, 
a growth factor associated with hypertrophic differentiation [63].  These results are 
consistent with previous findings where ascorbic acid 2-phosphate and other vitamin C 
derivatives stimulated cell proliferation in a variety of different cell types [324-326] and 
stimulated IGF-I production from dermal papilla cells [327].  Meanwhile, 
dexamethasone, an anti-inflammatory and immunosuppressant corticosteroid, decreased 
mRNA for FGF-2 and secretion of VEGF-A and increased mRNAs for BMP-2 and FGF-
18 in ASCs.  These results are supported by the observation that dexamethasone 
decreased VEGF-A production from hemangioma-derived stem cells, inhibiting tumor 
vasculogenesis in a murine model [177], and upregulated FGF-18 during osteogenesis in 
MSCs [178].  Also in this study, TGF-β1 and BMP-6 increased mRNA levels and 
secretion of factors associated with chondrogenesis and hypertrophic differentiation 
while TGF-β1 also increased secretion of factors associated with angiogenesis.  Others 
have shown that TGF-β1 stimulated production of cartilaginous tissue from chondrocytes 
and progenitor cells [308, 314, 328] but also controlled endothelial cell proliferation, 
invasion, and extracellular matrix turnover [329, 330].  Likewise, BMP-6 has previously 
been shown to stimulate chondrocyte maturation [331] and bone nodule formation [332]. 
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Interestingly, microencapsulation alone increased mRNA levels for PTHrP and 
production of IGF-I and TGF-β2 after 5 days in growth medium but not in chondrogenic 
medium.  This observation may be due to the high density and round morphology that 
ASCs have in alginate microbeads, both of which have been shown to support 
chondrogenesis [333, 334], and may explain why ASC microbeads just preconditioned in 
growth medium promoted tissue ingrowth in focal cartilage defects.  However, high cell 
density and round cell morphology may have less of an effect in chondrogenic medium 
because of the overwhelmingly high concentrations of TGF-β1, BMP-6, and 
dexamethasone.  Microencapsulation also increased VEGF-A production, possibly due to 
hypoxia caused by the high cell density.  Although hypoxic conditions inside the 
microbead were not assayed, increasing cell densities in hydrogel cultures has been 
shown to increase oxygen tension and gradients [335] and, hypoxic conditions can 
increase VEGF-A and FGF-2 secretion from ASCs [336].  The microenvironment can 
also influence the response of ASCs to dexamethasone and TGF-β1 since they exert 
different chondrogenic effects on synovial MSC aggregates and synovial explants [337].     
Along with the structural environment imparted by microencapsulation, exposure 
time to chondrogenic medium and its individual components may have significant effects 
on growth factor production from ASCs.  Chondrogenic medium treatment lengths 
needed to induce optimal chondrogenesis of MSCs and ASCs in 3-D cultures have varied 
between 3 and 12 weeks [243, 304, 338], significantly longer than the treatment times 
used in this study.  This difference in treatment times may explain the minimal effect 
chondrogenic medium components had on type II collagen expression and may suggest 
that longer treatment times are needed to optimize the effects different medium 
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components have on growth factor production.  However the differences in treatment 
times and subsequent effects on cell behavior between previous studies and this current 
work do not take into account the mass-transfer properties of larger 3-D hydrogels. 
The specific concentration of different components may also have a significant 
effect on growth factor production from ASCs.  It is well known that TGF-β1 has a 
biphasic effect: at concentrations ranging from 100 pg/mL to 1 ng/mL, TGF-β1 increases 
endothelial cell proliferation [329] and the effect of FGF-2 and VEGF-induced invasion 
[330] whereas at concentrations ranging from 5 to 10 ng/mL, TGF-β1 inhibits endothelial 
cell invasion and capillary formation [330] and induced ASC chondrogenesis [304, 339].  
Although ascorbic acid 2-phosphate and dexamethasone are also at their optimal 
concentrations for inducing chondrogenesis [243, 304], the concentration of BMP-6 was 
only at 20% of its optimal chondrogenic dose for ASCs [339].  It is possible that higher 
BMP-6 concentrations would significantly affect its actions on ASC growth factor 
production.   
The effects of ascorbic acid 2-phosphate, dexamethasone, TGF-β1, and BMP-6 on 
certain growth factor production in this study were dependent on the presence and 
concentration of each other and other chondrogenic medium components.  For instance, 
TGF-β1 decreased mRNAs for IGF-I and PTHrP in growth medium but increased these 
mRNAs in chondrogenic medium.  Additionally, TGF-β1 was responsible for the 
increased VEGF-A secretion in growth medium, but BMP-6 was also responsible for 
increased VEGF-A secretion in chondrogenic medium.  These different responses in 
these distinct media may be due to the differences in glucose concentrations and the 
presence or absence of ascorbic acid 2-phosphate, dexamethasone, proline, ITS+ culture 
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supplement, and serum.  Although the effects of glucose, proline, ITS+ culture 
supplement, and serum were not directly investigated in this study, these components 
may also have significant effects on ASC growth factor production. 
 It is important to note that this study only disclosed methods to use chondrogenic 
medium components to affect the production of factors associated with angiogenesis, 
chondrogenesis, and hypertrophic differentiation.  Determining the ideal ASC secretory 
profile for cartilage regeneration is a more complex problem due to the differential 
effects individual growth factors have.  For instance, although VEGF-A is an angiogenic 
growth factor that is detrimental to chondrocytes and cartilage [68, 71], FGF-2, another 
important facilitator for blood vessel formation [340], is known to improve cartilage 
regeneration [341].   Additionally, factors associated with hypertrophic differentiation, 
like BMP-2 are important for progenitor cell proliferation and differentiation during early 
stage cartilage development [53] and may be needed to initiate cartilage regeneration.  
Meanwhile, factors like IGF-I and TGF-β1 are essential for chondrogenesis, cartilage 
formation, and homeostasis, but it is unknown whether long-term secretion of these 
factors from ASCs will lead to hypertrophic differentiation or other unforeseen side 
effects.  In this study, it is unknown which factors will be most involved in tissue repair, 
whether different preconditioning treatments will accelerated cell infiltration and 
extracellular matrix deposition, or how long ASC microbeads will be needed more to 




ASC cultures had high mRNA levels of proteins associated with the TGF-β and 
MAPK signaling pathways, and preconditioning ASC cultures with chondrogenic 
medium and its individual components had distinct effects on trophic factor production.  
For ASC cultures in 2-D monolayer and 3-D alginate microbeads, chondrogenic medium 
increased the mRNA levels and secretion of IGF-I, TGF-β2, and TGF-β3 and decreased 
the mRNA levels and secretion of VEGF-A and FGF-2.  Microencapsulation alone 
increased mRNA levels for PTHrP and secretion of IGF-I, TGF-β2, and VEGF-A in 
growth medium, but not necessarily in chondrogenic medium.  In subsequent studies with 
ASC monolayers cultured in growth and chondrogenic media, ascorbic acid 2-phosphate 
decreased mRNA levels for FGF-18 and secretion of VEGF-A but increased IGF-I and 
TGF-β2 secretion.  Meanwhile, dexamethasone increased mRNA levels for BMP-2 and 
FGF-18, decreased mRNA levels for FGF-2, and decreased secretion of VEGF-A in 
growth and chondrogenic media.  TGF-β1 and BMP-6 increased secretion of TGF-β2 and 
mRNA levels for FGF-18 while TGF-β1 also increased secretion of FGF-2 and VEGF-A. 
This study demonstrated that different components of differentiation media can be used 





HUMAN ADIPOSE STEM CELL MICROBEADS AS GROWTH 




Adult stem cell therapies such as adipose stem cells (ASCs) are an attractive 
option for various clinical applications because of their accessibility and ability to 
differentiate into multiple cell types [305].  However, challenges related to their delivery, 
such as high injection pressures [223], low retention in the desired site [342, 343], and 
low viability in vivo when injected or delivered on scaffolds [17, 18], may limit their 
effectiveness in clinical studies [344].  To address these problems, we have recently 
developed a microencapsulation technology where ASC microbeads under 200 microns 
can be injected under low injection pressures without any changes in shape, can maintain 
greater than 80% cell viability for at least 3 weeks post-injection, and can be localized in 
the desired site in vivo for at least 3 months [223].  
Although ASCs can be used for a variety of clinical applications, repairing 
cartilage focal lesions is an attractive option because of the tissue’s limited regenerative 
capacity and the lack of an effective treatment [6, 345].  Current cell therapies, such as 
autologous chondrocyte implantation aim to directly regenerate cartilage by providing a 
source of cells that can then synthesize new tissue.  However, this strategy has had 
limited clinical adoption mainly due to high variability in cartilage quality and functional 
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outcomes [11, 12].  Therefore, a new paradigm has emerged in using stem cells as growth 
factor production sources to stimulate diseased or damaged musculoskeletal tissues like 
cartilage to regenerate themselves [32, 306].  ASC microbeads are highly favorable for 
this new strategy, not only because of their distinct advantages in delivery, but also 
because of the microbeads’ potential ability to control the production and secretion of 
different growth factors.  
Before ASC microbeads consisting of alginate can be used as growth factor 
production sources for regenerating cartilage and other tissues, a few unanswered issues 
need to be addressed.  First, even though the mass transfer properties of soluble 
compounds and growth factors in alginate have been characterized [152, 195, 346], it is 
unknown how microencapsulation affects growth factor production and secretion from 
ASCs.  Additionally, although chondrogenic medium can be used to differentiate ASCs 
in alginate hydrogels into chondrocytes [211], it is unknown if chondrogenic medium can 
also affect growth factor production and secretion from ASC microbeads.  Furthermore, it 
is unknown if chondrogenic treatment and microencapsulation have consistent effects on 
ASCs derived from different donors in terms of growth factor expression and secretion.  
Finally, although the mass transfer properties of alginate hydrogels are dependent on the 
divalent crosslink [347, 348] and the type of alginate polymer used [195], the effects 
these parameters have on growth factor expression and production from ASCs is 
unknown.  Therefore, the objectives of this study were to determine the time course of 
growth factor production and secretion from microencapsulated commercially human 
ASC microbeads cultured in growth and chondrogenic media, to determine if 
microencapsulation and chondrogenic medium treatments have consistent effects on 
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human ASCs from different donors, and to determine the effect microbead composition 
has on growth factor expression and production.  
 
MATERIALS AND METHODS 
Cell Isolation and Passaging 
To determine the extent of growth factor production and secretion from ASC 
microbeads over time, first passage human ASCs from a 28 year old male donor were 
commercially obtained (Lonza, Basel, Switzerland) and cultured up to third passage in 
Lonza Mesenchymal Stem Cell Growth Medium (GM, Lonza) prior to 
microencapsulation.  To test whether chondrogenic medium and microencapsulation had 
consistent effects on ASCs from different donors, adipose tissue was collected from 6 
female patients ranging from 18 to 49 years of age (mean age ± standard error = 
32.7±4.1) under an approved IRB protocol at Georgia Institute of Technology, Northside 
Hospital, and Children’s Healthcare of Atlanta.  Fat was obtained by breast reduction 
from 5 donors and abdominoplasty from 1 donor.  All patients gave written consent to 
both the procedure and handling of fat thereafter.  ASCs were isolated using a 
collagenase and dispase digestion cocktail as previously described [320].  Cells were then 
seeded at 5,000 cells/cm
2
 and cultured in GM.  When primary ASCs from 3 of the donors 
were at 90% confluence (P1 ASCs), they were trypsinized and were microencapsulated 
immediately.  Cells from the other 3 donors were pelleted at 500 g for 10 minutes, 
resuspended in GM with 5% DMSO at 3×10
6





C/min, stored at -80
o
C overnight, and transferred to liquid nitrogen for later 
use.  After 2 to 8 months, these cryopreserved cells were then cultured up to third passage 
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and microencapsulated (P3 ASCs).  To determine the effects microbead composition had 
on growth factor production, cryopreserved ASCs from a 33 year old donor’s breast 
tissue were cultured up to third passage and microencapsulated.  Prior to 
microencapsulation, all ASCs were positive for CD73 and CD271 and negative for 
CD45.   
Microencapsulation 
For all studies, alginate powders (FMC BioPolymer, Sandvika, Norway ) were 
UV light sterilized overnight and dissolved in 0.22μm sterile filtered (Thermos Fisher 
Scientific, Rochester, NY, USA) saline (Ricca Chemical, Arlington, TX, USA) at 20 
mg/mL.  ASCs were then suspended in the alginate solution at 10
7
 cells/mL.  Microbeads 
containing the commercial ASCs were created using a Nisco Encapsulator VAR V1 LIN-
0043 (Nisco Engineering AG, Zurich, Switzerland) at a 10 mL/hr flow rate, 0.12 mm 
inner diameter nozzle, and 6kV/cm electrostatic potential [223, 322]. Microbeads were 
imaged with an inverted microscope (Motic, Richmond, British Columbia, Canada) and 
had a mean diameter ± standard deviation of 122±15 microns (Motic Images Plus 2.0).  
In studies determining growth factor production and secretion from ASC 
microbeads over time and in studies determining the effect of chondrogenic medium and 
microencapsulation on ASCs from multiple donors, microbeads with 130 kDa, 44% 
guluronate alginate (LVM, low viscosity high mannuronate) were crosslinked in a 
solution of 50 mM CaCl2 (Sigma, St. Louis, MO, USA), 150 mM glucose (Sigma), and 15 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma) at pH 7.3 for 
at least 15 minutes.  To determine the effect Ca
++
 crosslinks had on growth factor 
production and secretion, ASC microbeads consisting of LVM were also crosslinked in a 
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solution of 20 mM BaCl2 (Sigma, St. Louis, MO, USA), 150 mM glucose, and 15 mM 
HEPES at pH 7.3.  To determine the effect alginate molecular weight and chemistry had 
on growth factor production and secretion, ASC microbeads were also made with the 
following alginates: 170 kDa, 66% guluronate (LVG, low viscosity high guluronate); <50 
kDa, 44% guluronate (VLVM, very low viscosity high mannuronate); and 220kDa, 43% 
guluronate (MVM, medium viscosity high mannuronate).  These ASC microbeads were 
crosslinked in the CaCl2 solution as described above.  For all studies, microbeads were 
washed three times in GM to remove any excess crosslinking solution.  ASCs were also 
plated in 6-well tissue culture polystyrene (TCPS) plates (BD Biosciences, San Jose, CA, 
USA) for comparison.   
Chondrogenic Treatment 
 Once ASCs in the 6-well plates reached 90% confluence, TCPS and microbead 
cultures were treated with either GM or chondrogenic medium (CM) consisting of 
Dulbecco’s modified Eagle medium (DMEM) with 4.5g/L glucose and 1 mM sodium 
pyruvate (Mediatech, Manassas, VA, USA), 40 μg/ml proline (Sigma), 50 μg/ml 
ascorbate-2-phosphate (Sigma), 1% ITS+ (Sigma), 100 nM dexamethasone (Sigma), 10 
ng/ml recombinant human transforming growth factor beta-1 (TGF-1, R&D Systems, 
Minneapolis, MN, USA) and 100 ng/ml recombinant human bone morphogenic protein 6 
(BMP-6, PeproTech, Rocky Hill, NJ, USA).  For studies determining cumulative growth 
factor production and secretion from ASC microbeads over time, media were collected 
with each media change at 3, 5, 7, 10, 12, 14, and 15 days.  For all subsequent studies, 
treatments lasted 7 and 14 days, RNA was collected 6 hours after the last media change 
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as described below, and media and ASC and lysates in 0.05% Triton X-100 (Sigma) were 
collected 24 hours after the last media change. 
RNA Isolation 
 Alginate microbeads crosslinked in CaCl2 (Ca microbeads) were uncrosslinked in 
82.5 mM sodium citrate (Sigma) whereas alginate microbeads crosslinked in BaCl2 (Ba 
microbeads) were uncrosslinked in 30 mM ethylenediaminetetraacetic acid (EDTA, 
Sigma) and 135 mM NaCl (Sigma).  Released cells were then pelleted and washed two 
more times in their respective uncrosslinking solution to remove any residual alginate.  
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was added to the cell pellet, which was 
fed through a QIAshredder (QIAGEN, Valencia, CA, USA), and RNA was isolated using 
chloroform and an RNeasy Kit (QIAGEN) as previously described [323].  A high 
capacity reverse transcription cDNA kit (Applied Biosystems, Carlsbad, CA, USA) was 
used to reverse transcribe 1 μg RNA to cDNA.   
Quantifying mRNA Levels and Growth Factor Production 
Chondrogenesis is a multi-step process that is regulated by numerous paracrine 
factors.  Therefore, mRNA levels and secretion of multiple signaling molecules were 
measured to assess the therapeutic potential of ASC microbeads.  FGF-2, IGF-I, and 
PTHrP were investigated because of their ability to increase chondrocyte proliferation 
and regulate hypertrophy [309-312].  TGF-β3 secretion was investigated since TGFs are 
potent stimulators of proteoglycan synthesis [313, 314].  However, TGF-β1 secretion was 
not investigated due to its large concentration in chondrogenic medium.  Noggin was 
investigated because of its role in cartilage differentiation [315].  VEGF-A was 
investigated because of its detrimental effects on cartilage regeneration: this growth 
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factor has been shown to increase matrix metalloproteinase expression in chondrocytes 
[68] and may have a potential role in osteoarthritis progression [71].   
Messenger RNA levels for the genes listed in Table 6.1 were quantified using 
real-time PCR with gene-specific primers using the Step One Plus Real-time PCR System 
and Power Sybr® Green Master Mix (Applied Biosystems) as previously described 
[166]. All primers were designed with Beacon Designer software (Premier Biosoft, Palo 
Alto, CA, USA) and synthesized by Eurofins MWG Operon (Huntsville, AL, USA) 
unless otherwise noted (Table 1).  Growth factor production was quantified using ELISA 
(R&D Systems) and normalized to DNA content measured by a Quant-iT PicoGreen kit 
(Invitrogen).  To measure growth factor retention within the microbead, microbeads were 
uncrosslinked in 82.5 mM sodium citrate and frozen at -80
o
C overnight.  Samples were 
then lyophilized at -50
o
C and 10 Pa for 24 hours.  The resulting dried constructs were 
then digested in 1 unit/mL alginate lyase (Sigma) for at least 1 hour at 37
o
C and growth 
factors measured with ELISA.  Quantified mRNA levels were referred to by the name of 










Table 6.1: Primer Sequences for Human ASCs 
Gene Direction Sequence 
Acan Sense TCAGCGGTTCCTTCTCCA G 
 Antisense GCAGTTGTCTCCTCTTCTACG 
Col2 Sense CTGCTCGTCGCCGCTGTCCTT 
 Antisense AAGGGTCCCAGGTTCTCCATC 
Col10 Sense TTACGCTGAACGATACCAAATG 
 Antisense GCTCTCCTCTTACTGCTATACC 
Comp Sense CCTGCGTTCTTCTGCTCAC 
 Antisense GCGTCACACTCCATCACC 
Fgf2 Sense GCGACCCTCACATCAAGC 
 Antisense AGCCAGTAATCTTCCATCTTCC 
Igf1 Sense GGAGGCTGGAGATGTATTG 
 Antisense GACTTCGTGTTCTTGTTGG 
Nog Sense 
Global Gene Sequence (Qiagen) 
 Antisense 
Pthlh Sense CTCGCTCTGCCTGGTTAG 
 Antisense CAATGCCTCCGTGAATCG 
Rps18 Sense CGTCTGCCCTATCAACTTTCG 
 Antisense CTTGGATGTGGTAGCCGTTTC 
Sox9 Sense GAGCAGCGAAATCAACGAGAAAC 
 Antisense ACAAAGTCCAAACAGGCAGAGAG 
Tgfb1 Sense CAACAATTCCTGGCGATACCTC 
 Antisense CCACGGCTCAACCACTGC 
Tgfb2 Sense CGAGAGGAGCGACGAAGAG 
 Antisense TAGAAAGTGGGCGGGATGG 
Tgfb3 Sense CAACGAACTGGCTGTCTG 
 Antisense CTCTGCTCATTCCGCTTAG 
Vegfa Sense CTTGCCTTGCTGCTCTACC 





All experiments had six independent cultures per treatment group and were 
conducted multiple times to confirm the findings.  For studies involving six donors, all 
data are presented in the form of treatment (i.e. CM or microencapsulation [μB]) over 
control (i.e. GM or TCPS).  For these studies, the sample sizes were the mean of six 
samples from each of the six donors and statistical differences between the treatment and 
control groups and among the different groups at 1 and 2 weeks were determined via a 
Mann-Whitney-Wilcoxon test (GraphPad Prism, La Jolla, CA, USA).  The significance 
of medium, microencapsulation, culture time, passage number, and their interactions on 
ASC growth factor mRNA levels and production were determined via a 4-way ANOVA 
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(MATLAB, MathWorks, Natick, MA, USA).  For studies that did not investigate ASCs 
from six donors, only data from a single representative experiment are shown and are 
expressed as means ± standard errors.  Statistical differences among these experimental 
groups were determined via ANOVA with a post hoc Tukey test (GraphPad Prism).  
Linear regression was used to assess cumulative growth factor secretion profiles from 
ASC microbeads and monolayers (GraphPad Prism).  All differences and effects were 
considered to be statistically significant if the p-value was less than 0.05.   
 
RESULTS  
Effect of Chondrogenic Medium and Microencapsulation on Multiple Donors 
 For 6 different donors, CM decreased fgf2 in TCPS cultures by 8.8 to 9.6 fold and 
microbeads by 3.7 to 4.2 fold at day 7 and 14 (Figure 6.1A).  CM treatment for 7 and 14 
days also decreased vegfa in the TCPS cultures and microbeads by 4.3 to 6.5 fold.  7 and 
14 days of CM treatment increased nog in TCPS cultures by 66 and 146 fold respectively, 
but nog in microbeads only increased by 7.2 and 12.8 fold.   
 CM did not decrease FGF-2 secretion on day 7 or 14 (Figure 6.1B) as FGF-2 
production from TCPS cultures in CM was 2 fold higher than TCPS cultures in GM on 
day 7.  VEGF-A secretion from microbeads in CM was 4.9 fold lower than microbeads in 
GM on day 14.  CM also increased acan, col2, col10, comp, igf1, sox9, and tgfb3 and 




Figure 6.1:  Effect of Chondrogenic Medium on Growth Factor mRNA Levels and 
Secretion from ASCs Isolated from Different Donors 
 (A) mRNA levels and (B) growth factor secretion/DNA content on day 7 and day 14 
from ASCs cultured in chondrogenic medium (CM) on tissue culture polystyrene (TCPS) 
and within alginate microbeads (μB) normalized to matching 2-D and 3-D cultures in 
growth medium (GM) (n = 6 donors, mean±SE, *p<0.05 CM vs. GM, #p<0.05 vs. wk1 
TCPS, $p<0.05 vs. wk1 μB, ^p<0.05 vs. wk2 TCPS). 
 
Microencapsulation had differential effects on chondrocyte phenotypic mRNA 
levels of ASCs.  After 7 days in CM, microencapsulation decreased acan and comp by 
3.3 and 5.3 fold respectively but increased col2 by 6.2 fold (Figure 6.2).  After 14 days in 
CM, microencapsulation increased col10 by 8.6 fold.  Meanwhile, microencapsulation 
had no effect on sox9 in either GM or CM.  For growth factor mRNA levels, 
microencapsulation consistently decreased igf1 for 6 different donors with a 4.2 fold 
decrease in CM after 7 days (Figure 6.3A).  The effects of microencapsulation on pthlh 
and tgfb3 were media dependent.  Microencapsulation only increased pthlh in GM by 5.3 
and 3.7 fold after 7 and 14 days respectively.  Microencapsulation increased tgfb3 in GM 
by 8.2 and 4.8 fold after 7 and 14 days respectively but decreased tgfb3 in CM by 2.3 
fold at day 7. 
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 Microencapsulation increased IGF-I secretion at day 7 in GM and CM by 11.9 
and 7.6 fold respectively (Figure 6.3B).  Microencapsulation also increased TGF-β3 
secretion by 2.3 fold at day 7 in CM and by 4.6 fold on day 14 in GM.  VEGF-A 
secretion from ASCs was not affected by microencapsulation, but microencapsulation did 
increase FGF-2 secretion at day 14 in GM and decreased nog expression after 7 and 14 
days in CM (Table 6.2).  
 
 
Figure 6.2:  Effect of Microencapsulation on Phenotypic mRNA Levels of ASCs 
Isolated from Different Donors 
(A) mRNA levels on day 7 and day 14 of ASC microbeads cultured in growth medium or 
chondrogenic medium (CM) normalized to ASCs on tissue culture polystyrene (TCPS) 
cultured in matching media.  (n = 6 donors, mean±SE, *p<0.05 μB vs. TCPS, #p<0.05 vs. 
wk1 GM, $p<0.05 vs. wk1 CM, ^p<0.05 vs. wk2 GM). 
 111 
 
Figure 6.3:  Effect of Microencapsulation on Growth Factor mRNA Levels and 
Secretion from ASCs Isolated from Different Donors  
(A) mRNA levels and (B) growth factor secretion/ DNA content on day 7 and day 14 
from ASC microbeads cultured in growth medium or chondrogenic medium (CM) 
normalized to ASCs on tissue culture polystyrene (TCPS) cultured in matching media (n 
= 6 donors, mean±SE, *p<0.05 μB vs. TCPS, #p<0.05 vs. wk1 GM, $p<0.05 vs. wk1 














Table 6.2:  Effect of Chondrogenic Medium and Microencapsulation on ASCs from 
Multiple Donors 
 CM/GM 
 wk1 TCPS wk1 μB wk2 TCPS wk2 μB 
mRNA Levels  
Acan/Rps18 *94.5±41.3 0*9.9±4.0 *184.7±95.6 *18.3±05.6 
Col2/Rps18 *03.6±01.4 *02.4±1.5 0*02.5±00.8 *10.0±04.5 
Col10/Rps18 *48.8±33.8 *14.9±4.2 0*11.7±07.9 *23.4±11.2 
Comp/Rps18 0*8.7±02.1 0*4.1±1.0 00*8.0±01.9 0*8.2±02.4 
Igf1/Rps18 0*2.8±00.8 *01.6±0.6 *004.6±01.3 0*3.3±00.6 
Pthlh/Rps18 0*0.6±00.2 0*0.1±0.0 *000.5±00.1 0*0.1±00.0 
Sox9/Rps18 *01.8±00.3 0*1.9±0.3 00*2.2±00.6 0*2.4±00.2 
Tgfb1/Rps18 0*2.0±00.2 *01.5±0.4 00*1.6±00.2 *01.0±00.2 
Tgfb2/Rps18 *01.4±00.3 *01.0±0.5 *001.5±00.3 *01.1±00.3 
Tgfb3/Rps18 0*8.4±01.8 *00.6±0.2 00*5.0±01.2 *00.6±00.2 
Growth Factor Secretion 
IGF-I/DNA 0*4.7±02.4 *01.9±0.3 *006.0±02.9 *02.0±00.7 
TGF-β3/DNA *01.2±00.1 *01.0±0.1 *001.1±00.2 *01.0±00.3 
 μB/TCPS 
 wk1 GM wk1 CM wk2 GM wk2 CM 
mRNA Levels    
Fgf2/Rps18 *0.3±0.1 *0.5±0.1 *0.6±0.3 *0.7±0.3 
Nog/Rps18 *1.1±0.6 *0.1±0.0 *1.4±0.7 *0.2±0.1 
Tgfb1/Rps18 *1.9±0.3 *1.5±0.4 *1.8±0.3 *1.0±0.2 
Tgfb2/Rps18 *6.1±1.7 *2.0±0.5 *2.4±0.6 *1.6±0.3 
Vegfa/Rps18 *2.2±0.7 *0.9±0.3 *2.0±0.7 *1.3±0.5 
Growth Factor Secretion    
FGF-2/DNA *0.8±0.4 *1.6±1.4 *6.1±2.3 *5.0±2.4 
VEGF-A/DNA *0.5±0.2 *1.1±0.7 *1.3±0.5 *2.1±1.1 












4-way ANOVA showed that media treatment significantly influenced acan, col10, 
comp, fgf2, igf1, nog pthlh, and sox9 as well as IGF-I and VEGF-A secretion (Table 6.3).  
Microencapsulation significantly affected col2, col10, comp, fgf2, igf1, nog, and tgfb2 as 
well as IGF-I and TGF-β3 secretion.  7 days versus 14 days in culture did not influence 
baseline gene expression but did influence FGF-2 and TGF-β3 secretion.  The interaction 
between medium and microencapsulation had significant effects on nog, pthlh, and tgfb3 
but not on growth factor secretion.  Although there were significant differences in 
baseline growth factor expression and secretion between freshly isolated P1 ASCs and 
cryopreserved P3 ASCs, the interaction between microencapsulation and cell passage did 
not affect mRNA levels but did affect FGF-2 and IGF-I  secretion.   
Table 6.3:  P-values of 4-Way ANOVA of Media, Microencapsulation (μB), Culture 
Time (Time), and Passage Number (Passage) 
 Media μB Time Passage Media × μB μB × Time μB × Passage 
mRNA Levels       
Acan/Rps18 *<0.001 0.822 0.328 0.128 0.058 0.453 0.217 
Col2/Rps18 0.180 *0.001 0.853 *0.006 0.638 0.962 0.101 
Col10/Rps18 *<0.001 *<0.001 0.172 *0.003 0.524 0.546 0.673 
Comp/Rps18 *<0.001 *0.001 0.339 0.198 0.580 0.720 0.299 
Fgf2/Rps18 *<0.001 *<0.001 0.931 *0.070 0.074 0.544 0.831 
Igf1/Rps18 *0.022 *<0.001 0.546 0.612 0.537 0.893 0.978 
Nog/Rps18 *<0.001 *<0.001 0.795 *0.003 *0.019 0.588 0.232 
Pthlh/Rps18 *<0.001 0.428 0.335 *<0.001 *<0.001 0.972 0.386 
Sox9/Rps18 *0.002 0.352 0.818 0.654 0.707 0.787 0.151 
Tgfb1/Rps18 0.465 0.456 0.590 *0.001 0.596 0.827 0.991 
Tgfb2/Rps18 0.968 *0.001 0.328 *<0.001 0.496 0.130 0.703 
Tgfb3/Rps18 0.141 0.393 0.814 *0.045 *<0.001 0.452 0.943 
Vegfa/Rps18 *0.001 0.895 0.881 *0.017 0.626 0.931 0.463 
Protein Secretion       
FGF-2/DNA 0.799 0.132 *0.007 0.250 0.730 0.931 *0.031 
IGF-I/DNA *0.026 *<0.001 0.184 *<0.001 0.379 *0.028 *0.023 
TGF-3/DNA 0.965 *<0.001 *0.001 *0.001 0.825 0.108 0.181 
VEGF-A/DNA *<0.001 *0.029 0.512 0.947 0.981 0.556 0.229 




Igf1 in Ba microbeads was less than that of Ca microbeads (Figure 6.4A).  Ba 
microbeads also secreted less IGF-I than Ca microbeads on day 7 (Figure 6.4B) and Ba 
microbeads maintained 10 fold less IGF-I within than Ca microbeads over 7 days (Figure 
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6.4C).  However, both Ca microbeads and Ba microbeads secreted 10.9 and 4.4 fold 
greater IGF-I than TCPS cultures on day 7 (Figure 6.4B).  Pthlh and tgfb3 in Ba 
microbeads were not statistically different from Ca microbeads and was 28 to 29 fold 
greater than TCPS cultures (Figure 6.4A).  Ca and Ba microbeads secreted similar 
amounts of TGF-β3 on day 7 (Figure 6.4B), and although Ca microbeads maintained 
more TGF-β3 than Ba microbeads (Figure 6.4C), this difference was not significant. 
      
Figure 6.4:  Effect of Divalent Crosslinks in ASC Microbead on Growth Factor 
mRNA Levels and Production 
(A) mRNA levels and (B) growth factor secretion/DNA content on day 7 from ASC 
microbeads crosslinked in CaCl2 (Ca
++
) or BaCl2 (Ba
++
), cultured in growth medium, and 
normalized to ASCs on tissue culture polystyrene (TCPS).  (C) Growth factor retained 
within microbeads normalized to DNA content (n = 6 samples, mean±SE, *p<0.05 μB vs. 




MVM microbeads had 2.3 fold lower pthlh than LVM microbeads, but all 
microbeads had at least 24 fold higher pthlh than TCPS cultures (Figure 6.5A).  LVG 
microbeads had 2.9 fold higher tgfb3 than LVM, but all microbeads still had at least 22 
fold higher tgfb3 than TCPS cultures.  Although the different alginate polymers did not 
have a significant effect on igf1 (Figure 6.5A), VLVM microbeads secreted 2.8 fold less 
IGF-I than LVM microbeads on day 7 (Figure 6.5B).  Additionally, LVM, LVG, and 
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MVM microbeads secreted 2.9 to 4.3 fold more IGF-I than TCPS cultures, but VLVM 
microbeads secreted similar levels of IGF-I to TCPS cultures on day 7.  LVG microbeads 
retained 2.4 fold more IGF-I than LVM microbeads over 7 days (Figure 6.5C).  The 
molecular weight and guluronate content of the alginate polymer had no effect on TGF-
β3 secreted or retained in the microbeads (Figure 6.5B, C). 
 
Figure 6.5: Effect of Alginate Molecular Weight and Chemistry in ASC Microbead 
on Growth Factor mRNA Levels and Production   
(A) mRNA levels and (B) growth factor secretion/DNA content on day 7 from ASC 
microbeads consistent of  LVM, LVG, VLVM, and MVM alginates; cultured in growth 
medium; and normalized to ASCs on tissue culture polystyrene (TCPS).  (C) Growth 
factor retained in microbeads normalized to DNA content (n = 6 samples, mean±SE, 
*p<0.05 μB vs. TCPS, #p<0.05 vs. LVM, $p<0.05 vs. LVG). 
 
DISCUSSION 
This study demonstrated that ASC microbeads have the potential to be growth 
factor production sources for regenerating cartilage.  Specifically, ASC microbeads can 
secrete growth factors at a consistent rate over a two week period, microencapsulation 
and chondrogenic medium have consistent effects on growth factor expression and 
secretion from ASCs derived from multiple donors, and microbead composition can 
influence the production and secretion of certain growth factors.  These findings are 
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consistent with previous studies delivering progenitor cells within alginate.  These studies 
showed that alginate microcapsules could maintain growth factor gene expression and 
sustain growth factor release for at least 22 days while promoting bone and myocardial 
muscle regeneration [169, 349].    Additionally, barium crosslinks have previously been 
shown to reduce secretion of protein from alginate beads [348] and that low guluronate 
content alginate hydrogels with a more flexible polymer backbone have greater solute 
diffusivity [195].   
It is important to note that other parameters, such as alginate degradation and 
electrostatic interaction between the alginate and growth factor, can influence growth 
factor diffusive properties and subsequent secretion from alginate microbeads [152, 350].  
Additionally, including biomimetic peptides within the microbeads, such as RGD, can 
manipulate the expression of certain growth factors [169].  In this study, the alginate 
backbone of the microbeads was not chemically modified and microbead degradation 
was not apparent, but growth factor retention within the microbead was observed.  
Although manipulating the ASCs with chondrogenic medium and alginate chemistry 
were the main drivers for controlling growth factor secretion from microbeads, methods 
for controlling alginate degradation may release growth factors stuck within the alginate 
hydrogel, providing another mechanism to tailor the secretory profile from ASC 
microbeads.       
Interestingly, microencapsulation increased mRNA levels for both PTHrP and 
TGF-β3 in ASCs in growth medium but decreased mRNA and the secretion profile of 
TGF-β3 in chondrogenic medium.  Calcium has been shown to increase secretion of 
PTHrP from human cells [183], but this current study showed that increases in PTHrP 
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and TGF-β3 mRNA levels were independent of the calcium crosslinks.  Previous studies 
have shown that soluble components of serum can hinder chondrogenesis [351] whereas 
TGF-β1 and BMP-6  in chondrogenic medium can increase chondrocytic phenotype in 
ASCs [211, 305, 352].  Although the effects of individual serum components on growth 
factor production were not directly measured in this study, microencapsulation may have 
hindered the mass transport of these inhibitory soluble factors in growth medium and 
stimulatory soluble factors in chondrogenic medium.   
Encapsulation in alginate is well known to restore the chondrocytic phenotype of 
dedifferentiated chondrocytes and to enhance the differentiation of mesenchymal stem 
cells [243, 353].  These chondrogenic effects have been attributed to the round cell 
morphology and cell-cell interactions imparted by high density encapsulation [333, 354].  
This study also showed that alginate microbeads can retain endogenously produced IGF-I 
and TGF-β3.  The retention of these chondrogenic factors may have also been responsible 
for the increased PTHrP and TGF-β3 mRNA levels in ASC microbeads cultured in 
growth medium.  These attributes suggest that the microenvironment within ASC 
microbeads may mimic that of native cartilage, making them ideal candidates as trophic 
factor production sources for cartilage regeneration.   
Several studies have investigated whether donor age or body mass index affect 
ASC density in tissue and their chondrogenic potential, but the results have been 
conflicting [355-357]. These discrepancies may be due to differences in tissue harvesting 
techniques, anatomical location, and donor sex, all of which have been shown to affect 
ASC yield and differentiation potential [355, 358, 359].  Furthermore, extended 
passaging has been shown to increase the chondrogenic potential of these cells [354].  
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The variability in these parameters in this current study may have caused the 
inconsistencies among the different cell culture experiments, specifically in the effect of 
microencapsulation on growth factor secretion between different studies.  Additionally, 
the effects of microencapsulation on growth factor mRNA levels were often not 
consistent with the effects of microencapsulation on growth factor secretion.  These 
discrepencies may be due to post-transcriptional regulation, post-translational 
modifications, or parameters that affect growth factor diffusion and secretion but not 
production as already discussed.   
 
CONCLUSION 
Microencapsulation consistently increased the gene expression of PTHrP and 
secretion of IGF-I and TGF-β3 from ASCs from multiple donors.  Meanwhile, 
chondrogenic medium consistently decreased the expression of FGF-2 and secretion of 
VEGF-A from ASC microbeads derived from the same donor population.  Crosslinking 
microbeads in BaCl2 instead of CaCl2 did not eliminate the beneficial effects of 
microencapsulation, but did decrease IGF-I gene expression and production.  Increasing 
the guluronate content of the alginate microbead increased TGF-β3 expression and IGF-I 
maintained within.  Decreasing the molecular weight of the alginate used eliminated the 
beneficial effects microencapsulation had on IGF-I secretion while increasing the 
molecular weight of alginate used decrease PTHrP gene expression.  This study 
demonstrated that ASC microbeads may be a reliable source for delivering multiple 




ADIPOSE STEM CELLS CAN SECRETE ANGIOGENIC FACTORS 
THAT CAN INHIBIT HYALINE CARTILAGE REGENERATION 
 
INTRODUCTION 
Adult stem cells, such as adipose stem cells (ASCs) are an emerging clinical 
option for treating tissue damage and diseases because of their accessibility and ability to 
differentiate into multiple cell lineages [305, 360].  More recently, ASCs and other adult 
stem cells have been shown to secrete a wide range of trophic factors that can stimulate 
regeneration of tissues from multiple lineages [32].  As these cell therapies become more 
prevalent in different clinical procedures, their secretory profiles need to be more 
thoroughly investigated in terms of the role stem cell-secreted factors have in tissue 
regeneration and in possible side effects.  
Hyaline cartilage is the most prevalent cartilaginous tissue found in the body, with 
adult stem cell therapies used to regenerate hyaline cartilage in the knee and trachea of 
humans [361, 362] and to repair cartilage in the larynx, bronchial stump, and growth 
plate of animals in preclinical studies [363-365].  Unlike most other tissues, hyaline 
cartilage is an avascular and aneural tissue that has complex spatial variation in its 
mechanical properties and composition despite a relatively homogeneous cell population.  
Therefore, adult stem cell therapies used for chondral defect repair must secrete factors 
that stimulate synthesis of specific proteoglycans and collagens without facilitating the 
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infiltration of other tissues – especially blood vessel formation – or enabling hypertrophic 
differentiation of chondrocytes typical of endochondral ossification. 
 Although the secretory profile of ASCs for cartilage regeneration have been 
investigated [306], an in-depth study determining the role ASC-secreted factors have on 
chondrocyte proliferation, phenotype, and cartilage regeneration has yet to be conducted.  
Additionally, techniques such as microencapsulation and differentiation medium 
treatments have been used to improve the regenerative capacity for mesenchymal stem 
cells [223, 349, 366], but no study has investigated the effects these two parameters have 
on the secretion of trophic factors from ASCs.  Therefore, the overall objective of this 
study was to determine the role ASC-secreted trophic factors have in cartilage 
regeneration.  The effect of microencapsulation and chondrogenic medium treatment on 
angiogenic factor production was determined.  Then co-culture and conditioned media 
studies were conducted to determine how ASC-paracrine signaling and ASC-secreted 
factors affect chondrocytes.  Finally, ASCs were implanted into a chondral defect in the 




 ASCs were isolated from inguinal fat pads of 125 g male Sprague Dawley rats 
(Harlan Laboratories, Indianapolis, IN, USA) as described in detail previously [320] and 
cultured in Lonza Mesenchymal Stem Cell Growth Medium (GM, Lonza, Walkersville, 
MD, USA).  After one passage, these cells were positive for CD73 and CD271 and 
negative for CD45 [320].  Costochondral chondrocytes from the ribs of 125 g male 
 121 
Sprague Dawley rats were isolate as described previously [321].  Primary cells were 
cultured in DMEM containing 10% fetal bovine serum (FBS) and 50 μg/ml ascorbic acid 
(Invitrogen) until fourth passage prior to experimental analysis.  These cells continue to 
express type II collagen, aggrecan, and cartilage oligomeric matrix protein [321]. 
Microencapsulation 
 Once primary ASCs reached 90% confluence, cells were trypsinized and 
microencapsulated in 20 mg/mL low molecular weight (~150 kDa) alginate (FMC 
BioPolymer, Sandvika, Norway) with a high mannuronate to guluronate ratio (40% 
guluronate) at a concentration of 25×10
6
 cells/mL using a Nisco Encapsulator VAR V1 
LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) as previously described [322].  
The microbeads were washed three times in GM prior to cell culture studies.  First 
passage ASCs were also plated in 6-well plates (Figure 7.1A).  
ASC Cell Culture  
 Once first passage ASCs reached 90% confluence (Figure 1A), ASC monolayers 
and microbeads were then treated for 5 days with either GM or chondrogenic medium 
(CM) consistent of high glucose DMEM with 1 mM sodium pyruvate (Mediatech, 
Manassas, VA, USA), 40 g/ml proline (Sigma), 50 g/ml ascorbate-2-phosphate 
(Sigma), 1% ITS+ (Sigma), 100 nM dexamethasone (Sigma), 10 ng/ml recombinant 
human transforming growth factor beta-1 (TGF-1, R&D Systems, Minneapolis, MN, 
USA) and 100 ng/ml recombinant human bone morphogenic protein 6 (BMP-6, 
PeproTech, Rocky Hill, NJ, USA).  Once media were changed on the fifth day, RNA was 
collected after 8 hours as described below while media and ASCs lysed in 0.05% Triton 
X-100 were collected after 24 hours.  Fourth passage chondrocytes cultured in DMEM, 
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10% FBS, and 50g/mL ascorbic acid and Sprague Dawley-derived clone 9 liver cells 
(ATCC, Manassas, VA, USA) cultured in F12K medium and 10% FBS served as 
controls.  All media contained 1% penicillin and streptomycin. 
Growth Factor Expression and Production 
 Microbeads were uncross-linked in 82.5 mM sodium citrate (Sigma), pelleted at 
500 g for 10 minutes and washed two more times in sodium citrate to remove any 
residual alginate.  TRIzol reagent (Invitrogen) was added to the resulting cell pellet, 
homogenized using a QIAshredder (QIAGEN, Valencia, CA, USA), and RNA was 
isolated using chloroform and an RNeasy Kit (Qiagen) as previously described [323].  1 
g RNA was then reverse transcribed to cDNA using a High Capacity Reverse 
Transcription cDNA kit (Applied Biosystems, Carlsbad, CA, USA).  Gene expressions 
were quantified as previously described [166].  Primers were designed using Beacon 
Designer software (Premier Biosoft, Palo Alto, CA, USA) and synthesized by Eurofins 
MWG Operon (Huntsville, AL, USA) unless otherwise noted (Table 7.1).  VEGF-A and 
FGF-2 production over the last 24 hours of culture was quantified using ELISA (R&D 
Systems) and normalized to DNA content measured with a Quant-iT PicoGreen kit 
(Invitrogen).   
Paracrine Signaling 
ASC-Chondrocyte Co-culture 
 To assess the effects paracrine signaling between ASCs and chondrocytes have on 
chondrocyte phenotype, the two cell types were co-cultured in a trans-well system 
(Figure 7.2A).  Initial studies determined the number of microbeads per insert needed to 
have the same cell number as ASC confluent trans-well inserts.  ASC monolayers and 
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microbeads were treated with GM or with CM for 5 days in 0.2m high density cell 
culture inserts (BD Biosciences, Franklin Lakes, NJ, USA).  ASC cultures and inserts 
were then washed in DMEM three times and added to wells with confluent chondrocytes.  
The two cell groups were then cultured in 4.5 mL DMEM + 10% FBS.  After 7 days, 
RNA was isolated from the chondrocytes to quantify chondrogenic gene expression.  
Microencapsulated clone 9 liver cells served as a control. 
Chondrocyte Cultures Treated with ASC-Conditioned Media 
 To assess the effects ASC-secreted factors have on chondrocytes, chondrocytes 
were cultured in different ASC-conditioned media (Figure 7.2C) obtained from T-75 
flasks.  Initial studies determined the number of microbeads per T-75 needed to have the 
same cell number as ASC confluent T-75 flasks.  To obtain ASC-conditioned media, 
ASC monolayers and microbeads were treated with GM or CM for 5 days in T-75s.  
After the fifth day of treatment, ASC monolayers and microbeads were washed in 
DMEM three times and 10 mL DMEM +10% FBS was added to each culture.  After 24 
hours, media containing the ASC-secreted factors were collected then immediately added 
to confluent chondrocyte cultures.  After 12 hours in ASC-conditioned medium, RNA 
was isolated from chondrocytes to quantify chondrogenic gene expression.  To assess 
chondrocyte phenotype, apoptosis, and angiogenic response, the following assays were 
performed after 24 hours of ASC-conditioned medium treatments.  Conditioned medium 






 DNA synthesis was assayed by measuring [
3
H]-thymidine incorporation as 
described previously [90].  40% confluent chondrocytes were treated with DMEM + 1% 
FBS to induce quiescence.  Four hours before harvest, [
3
H]-thymidine was added to a 
final concentration of 0.25Ci/mL.  Radioactivity in trichloroacetic acid-insoluble cell 




 Proteoglycan synthesis was assayed by measuring [
35
S]-sulfate incorporation as 
previously described [328].  [
35
S]-sulfate was added to a final concentration of 18Ci/mL 
for the final 4 hours of culture.  Only [
35
S]-sulfate incorporation in the monolayer was 
measured since less than 15% of total radiolabeled proteoglycan production is secreted 
into the medium [367].  [
35
S]-sulfate incorporation was normalized to protein content 
measured with a Pierce Macro BCA protein kit (ThermoScientific, Rockford, IL, USA). 
Alkaline Phosphatase Activity 
 Alkaline phosphatase specific activity in chondrocyte lysates was measured as a 
function of release of p-nitrophenol from p-nitrophenylphosphate as previously described 
[89] and normalized to protein content measured with a Pierce Macro BCA protein kit 
(ThermoScientific). 
Effects of ASCs on Chondrocyte Apoptosis 
DNA Fragmentation 
 To assess effects of ASC-secreted factors on DNA fragmentation, confluent 
chondrocytes were pulsed with [
3
H]-thymidine for 4 hours prior to ASC-conditioned 
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medium treatment.  Chondrocytes were lysed and centrifuged at 13,000 g for 15 minutes 
to separate intact DNA from fragmented DNA as previously described [82].  The amount 
of incorporated [
3
H]-thymidine was determined in each fraction to establish the total 
amount of fragmented DNA. 
Caspase-3 Activity 
 Caspase-3 activity was determined using a colorimetric CaspACE™ Assay 
System from Promega (Madison, WI, USA) following the manufacturer’s protocol 24 
hours after ASC conditioned media were added to confluent chondrocytes.  Caspase-3 
activity was normalized to total protein content measured with a Pierce 660nm protein 
assay (ThermoScientific). 
Effect of Secreted Factors on Angiogenic Response 
 Angiogenic responses to different ASC-conditioned media were assessed with 
endothelial cells cultured in a fibrin gel assay as previously described [368].  Human 
aortic endothelial cells (HAECs, Lonza) were plated in endothelial cell basal medium 
(EGM-2, Lonza) at 5 × 10
3
 cells/well  on fibrin gel and cultured at 37°C for 24 hours.  At 
24 hours, medium was removed, a second layer of fibrin was added on top, and ASC 
conditioned media were added.  After 12 hours, images were taken for morphometric 
analysis and total endothelial tube length was determined using Image Pro Plus. 
Role of VEGF-A and FGF-2 
 To determine the effect exogenous vascular endothelial growth factor A (VEGF-
A) and fibroblastic growth factor 2 (FGF-2) have on chondrocytes, 1 ng/mL and 20 
ng/mL of recombinant human VEGF-A165 and recombinant human FGF-2 (R&D 
Systems) were added to monolayer cultures of fourth passage chondrocytes.  To 
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determine the effect VEGF-A and FGF-2 secreted by ASCs have on chondrocytes, 
conditioned medium from GM-treated ASC monolayers was supplemented with 1 g/mL 
goat anti rat IgG, 1 g/mL goat anti-rat VEGF-A neutralizing antibody, or 1 g/mL goat 
anti-rat FGF-2 neutralizing antibody (R&D Systems) and added to fourth passage 
chondrocyte monolayers as determined by the manufacturer’s protocol.  After 24 hours, 
[
35
S]-sulfate incorporation, caspase-3 activity, and [
3
H]-thymidine incorporation were 
measured as described above.  DMEM + 10% FBS and conditioned medium from ASC 
monolayers treated with CM served as controls. 
Xiphoid Defect in Vivo 
 To assess if ASCs would inhibit cartilage regeneration, non-critically sized 
chondral defects were made in the xiphoids of 125g male Sprague-Dawley rats as 
previously described [369].  The protocol was approved by the Institutional Animal Care 
and Use Committee of the Georgia Institute of Technology and each group was tested in 
seven rats.  A full-thickness 1 mm cylindrical defect was made in the center of the 
xiphoid using a dermal biopsy punch (Mitex, Plainsboro, NJ, USA).  This defect size was 
chosen because cartilage regeneration was previously observed after 35 days and the 
defect is large enough to contain cell pellets 1×10
6 
ASCs in size [369].  ASC monolayers 
cultured in GM or CM were pelleted at 1×10
6 
ASCs/pellet and implanted into the defect.  
Empty defects and autografts (excised cartilage is re-implanted) served as controls.  To 
maintain groups in the defect and to serve as an adhesion barrier, SepraFilm® (Genzyme, 
Cambridge, MA, USA) was then placed on the dorsal and ventral sides of the defect.   
Xiphoids were excised 35-days post-surgery and examined as described below.  
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 Radiographic imaging (Faxitron Bioptics, Lincolnshire, IL, USA) was performed 
in the coronal plane at a voltage of 22 mV and exposure time of 16 s to visualize soft 
tissue penetration as previous described [369].  A blind observer then scored the presence 
of soft tissue penetration with a score of 0 representing no healing, a score of 0.5 
representing partial healing, and a score of 1 representing full healing. 
 Equilibrium partitioning of an ionic contrast agent via micro-computed 
tomography (EPIC-CT) was used to visualize the distribution of proteoglycans within 
the xiphoid defects as previously described [369, 370].  Xiphoids were incubated in 40% 
Hexabrix (Mallinckrodt, St. Louis, MO, USA) in phosphate buffered saline (PBS) 
containing 1% proteinase inhibitor cocktail (CalBiochem, Darmstadt, Germany) 
overnight and scanned using pre-determined settings [369].  Low X-ray attenuation 
(green/yellow) of three-dimensional color images corresponded to regions of high 
proteoglycan concentration and no or high X-ray attenuation (black and red/orange) 
indicated regions of low proteoglycan concentration.  To determine cartilage volume, the 
1 mm defect was isolated with user-guided contours and evaluated at a 100 – 250 
threshold range.    
 After scanning, samples were washed in PBS for four hours, fixed in 10% 
phosphate-buffered formalin for 48 hours, and embedded in paraffin.  Seven-micrometer 
thick serial sections were stained with haematoxylin and eosin stain (H&E) to highlight 




 All in vitro experiments had six independent cultures per treatment group to 
ensure sufficient power to detect statistically significant differences.  All in vitro 
experiments were conducted multiple times to validate the observations, but only data 
from a single representative experiment are shown and are expressed as means ± standard 
errors.  A power analysis determined that seven samples per group were needed for the in 
vivo study based on results from a previous study [369].  Statistical analysis was 
conducted using ANOVA analysis with a post hoc Tukey test (GraphPad Prism, La Jolla, 
CA, USA).  Differences in means were considered to be statistically significant if the p-
value was less than 0.05. 
 
Table 7.1: Phenotypic and GF Primer Sequences for Rat ASCs 
Gene Direction Sequence 
Acan Sense GCT TCG CTG TCC TCA ATG C 
 
Antisense AGG TGT CAC TTC CCA ACT ATC C 
Col2 Sense CGAGTATGGAAGCGAAGG 
 
Antisense GCTTCTTCTCCTTGCTCTTGC 
Comp Sense AGT GAC AGC GAT GGT GAT GG 
 
Antisense TCC CCG TCC TGG TCT TGG 
Fgf2 Sense 
Global Gene Sequence (Qiagen) 
 
Antisense 
Pdgfa Sense GAGGAGACGGATGTGAGG 
 
Antisense ACGGAGGAGAACAAAGACC 
Runx2 Sense TTGGACACCTTGGACGCTAATT 
 
Antisense AGA GGC AGA AGT CAG AGG 
Sox9 Sense GTG GGA GCG ACA ACT TTA CC 
 
Antisense ATC GGA GCG GAG GAG GAG  
Vegfa Sense GGACATCTTCCAGGAGTACC 







Angiogenic Growth Factor Production from ASCs 
 ASC monolayers and microbeads cultured in GM had 1.5-3 times higher levels of 
mRNAs for fgf2 and vegfa compared to chondrocytes while CM reduced mRNAs for 
both vegfa and fgf2 to levels similar to that of chondrocytes (Figure 7.1B).  CM did not 
influence pdgfa expression in ASCs, which was half the expression seen in chondrocytes.  
ASC monolayers and microbeads secreted 10-30 times more VEGF-A than chondrocytes 
while CM reduced secretion by 3-3.5 fold (Figure 7.1C).  FGF-2 secretion from ASC 
cultures and chondrocytes was very low compared to VEGF-A production. 
 
 Figure 7.1: Effects of Microencapsulation and CM on Angiogenic Factors 
 (A) Diagram of ASC monolayer and microbead (B) treatments with CM.  (B) Gene 
expression and (C) growth factor production of ASCs, chondrocytes (chond), and liver 
cells (liv) (n=6±SE. *p<0.05 vs. chond, #p<0.05 vs. ASCs, ^p<0.05 vs. ASC microbeads 
(ASC + B)).   
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Effect of ASC Paracrine Signaling and Secreted Factors on Chondrocyte Gene 
Expression 
 Chondrocytes co-cultured with ASC monolayers cultured in GM experienced 3.5-
4 fold reductions in col2, comp, and runx2 mRNAs compared to chondrocytes with no 
co-culture (Figure 7.2B).  However, CM-treated ASC monolayers increased acan 
expression in chondrocytes and had no effect on col2, comp, and runx2 expression in 
chondrocytes compared to control.  GM-cultured ASC microbeads reduced col2 
expression in chondrocytes but CM-treated ASC microbeads reduced col2, comp, and 
runx2 expression in chondrocytes compared to control.  ASC co-cultures did not affect 
sox-9 expression and co-culture with clone 9 liver cell microbeads did not influence 
chondrocyte gene expression compared to control. 
Conditioned medium from GM-cultured ASC monolayers decreased chondrocyte 
mRNAs for sox9 by 50%, acan by 78%, and col2 by 35% compared to chondrocytes 
treated with control medium (Figure 7.2D).  However, conditioned medium from CM-
treated ASC monolayers had no effect on chondrogenic gene expression compared to 
control medium.  Conditioned medium from GM-cultured ASC microbeads decreased 
acan expression, but conditioned medium from CM-treated ASC microbeads had no 
effect on chondrocyte gene expression.  Clone 9 liver cell microbeads decreased mRNAs 
for acan in chondrocytes but had no effect on sox9, col2, comp, or runx2. 
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Figure 7.2: Effects of ASC co-culture and ASC-conditioned media on Chondrocyte 
Phenotypic Expression   
(A) Diagram of ASC co-culture and (B) gene expression of chondrocytes after 7 days.  
(C) Diagram of ASC-conditioned media treatment and (D) gene expression of 
chondrocytes after 12 hours (n=6±SE. *p<0.05 vs. control, #p<0.05 vs. ASCs, ^p<0.05 











Effect of ASC-secreted Factors on Proliferation, Phenotype, and Apoptosis  
 Conditioned media from GM-cultured ASC monolayer and microbeads decreased 
[
35
S]-sulfate incorporation by 75% and 60% respectively (Figure 7.3B), had no effect on 
alkaline phosphatase activity (Figure 7.3C), and decreased [
3
H]-thymidine incorporation 
by approximately 76% (Figure 7.3D) compared to chondrocytes treated with control 
medium.  Treating ASC monolayers and microbeads with CM prior to conditioned media 
collection eliminated the deleterious effects ASC-secreted factors had on chondrocytes 





S]-sulfate incorporation, or alkaline phosphatase activity (Figure 7.3B-
D). 
 Conditioned medium from GM-cultured ASC monolayers increased caspase-3 
activity 120%, bax/bcl expression 79%, and DNA fragmentation 114% compared to 
control medium (Figure 7.3E-G).  Treating ASC monolayers with CM prior to collecting 
conditioned medium eliminated the apoptotic effects ASC-secreted factors had on 
chondrocytes.  Conditioned medium from ASC microbeads cultured in GM did not 
increase apoptosis compared to control medium. Conditioned medium from liver 
microbeads had no effect on caspase-3 activity and bax/bcl, but did increase DNA 
fragmentation compared to control (Figure 7.3E-G). 
 ASC monolayer and microbead conditioned media increased endothelial tube 
length by 2.6 fold and 2 fold respectively (Figure 7.3G).  Treating ASC monolayers and 
microbeads with CM prior to conditioned media collection eliminated this angiogenic 




Figure 7.3: Effects of ASC-conditioned Medium on Chondrocyte Phenotype, 
Proliferation, Apoptosis, and Angiogensis 
 (A) Diagram of ASC-conditioned media experiments, (B) [
35
S]-sulfate incorporation, (C) 
alkaline phosphatase activity, (D) [
3
H]-thymidine incorporation, (E) caspase-3 activity, 
(F) bax/bcl2 expression, (G) DNA fragmentation, and (H) endothelial tube length 
(n=6±SE. *p<0.05 vs. control, #p<0.05 vs. ASCs, ^p<0.05 vs. ASC microbeads (ASC + 
B)).   
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Effect of Exogenous VEGF-A and FGF-2 on Chondrocytes 
 1 ng/mL and 20 ng/mL of VEGF-A reduced [
35
S]-sulfate incorporation by 
approximately 30% and 50% respectively (Figure 7.4A).  Adding FGF-2 at both 1 and 20 
ng/mL alone had no effect on [
35
S]-sulfate incorporation but did eliminated the inhibitory 
effect rhVEGF-A had on [
35
S]-sulfate incorporation at both concentrations.  Meanwhile 
both 1 ng/mL and 20 ng/mL VEGF-A significantly increased caspase-3 activity by 32% 
and 84% respectively (Figure 7.4B).  Adding 1 ng/mL of FGF-2 had no effect on 
caspase-3 activity and did not reduce the apoptotic effect of VEGF-A compared to 
control.  However, 20 ng/mL FGF-2 eliminated the apoptotic effect of VEGF-A. VEGF-
A and FGF-2 had a more limited effect on chondrocyte proliferation, as only the 20 
ng/mL FGF-2 dosage increased [
3
H]-thymidine incorporation (Figure 7.4C). 
 
 
Figure 7.4: Effects of Exogenous VEGF-A and FGF-2 on Chondrocytes 
(A) [
35
S]-sulfate incorporation of chondrocytes treated with recombinant human VEGF-A 
and FGF-2, (B) caspase-3 activity of chondrocytes treated with recombinant human 
VEGF-A and FGF-2, and  (C) [
3
H]-thymidine incorporation of chondrocytes treated with 
recombinant human VEGF-A and FGF-2 (n=6±SE. *p<0.05 vs. control, #p<0.05 vs. 




Effect of ASC-secreted VEGF-A and FGF-2 on Chondrocytes 
 ASC-conditioned medium with a goat-anti-rat IgG and FGF-2 neutralizing 
antibody decreased [
35
S]-sulfate incorporation by approximately 50% (Figure 7.5B) and 
increased caspase-3 activity by approximately 94% (Figure 7.5C) compared to control 
medium.   Adding VEGF-A neutralizing antibody to ASC-conditioned medium 
eliminated both its deleterious effect on chondrocyte phenotype and apoptotic effect.  
ASC conditioned media with or without VEGF-A or FGF-2 neutralizing antibodies all 
decreased [
3
H]-thymidine incorporation compared to control medium (Figure 7.5D).  As 
previously observed, conditioned medium from ASC monolayers treated with CM had no 





compared to control medium (data not shown).  
 
Figure 7.5: Effects of ASC-secreted VEGF-A and FGF-2 on Chondrocytes 
(A) Schematic outlining chondrocytes treated with ASC-conditioned medium with 
VEGF-A and FGF-2 neutralizing antibodies and assayed for (B) [
35
S]-sulfate 
incorporation, (C) caspase-3 activity, and (D) [
3
H]-thymidine incorporation (n=6±SE. 
*p<0.05 vs. control, #p<0.05 vs. ASCs).   
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Effect of ASCs in Cartilage Defect 
 Radiograph images showed that 7 of 7 defects with autografts had partial or full 
healing and empty defects had 3 of 7 defects with partial or full healing; however, only 1 
of 7 defects with ASC pellets had partial healing whereas 4 of 7 defects with pellets of 
ASCs treated with chondrogenic media had partial or full healing (Figure 7.6A).  
Proteoglycan was visible in EPIC-CT images of empty defects and defects with pellets 
of CM-treated ASCs but absent from defects with pellets of GM-cultured ASCs (Figure 
7.6B).  EPIC-CT calculated cartilage volume for defects with ASC pellets was 
significantly smaller than cartilage volume in both autografts and empty defects.  Defects 
with CM-treated ASCs had more cartilage than defects with GM-cultured ASCs, but 
were not different from empty defects (Figure 7.6B).  
 In histological sections of defects with autografts, early-stage cartilage and 
infiltrating cells were starting to integrate the graft with the surrounding xiphoid (Figure 
7.6C).  Similar tissue deposition and cell infiltration was observed for empty defects and 
defects with ASCs treated with chondrogenic media.  However, defects with ASCs were 
infiltrated with surrounding epithelial tissue instead and lacked the connective tissue that 







Figure 7.6: Effects of ASCs on Cartilage Regeneration  
(A) Radiographic scoring.  (B) 3-D EPIC-CT images of xiphoids and calculated 
cartilage volume within defects (n=7±SE. *p<0.05 vs. empty defect, #p<0.05 vs. ASCs).  
(C) Representative H&E staining.  Bar represents 100 m at 20x magnification (D = 
defect, X = xiphoid, AG = autograft). 
 
DISCUSSION 
 This study is the first to definitively show that adipose stem cells secrete 
angiogenic factors that are detrimental for chondrocytes and can prevent cartilage 
regeneration.  Specifically, ASCs secrete a relatively large amount of VEGF-A, which 
can inhibit chondrocyte phenotype and lead to chondrocyte apoptosis.  Additionally, 
ASCs secrete factors that negatively influence chondrocyte proliferation.  Finally, ASCs 
prevent cartilage regeneration in a non-critical, hyaline cartilage defect in vivo.  Despite 
these deleterious effects, treating ASCs with chondrogenic medium can reduce the 
expression and production of VEGF-A, eliminate the damaging effects ASC-secreted 
factors have on chondrocytes, and prevent the adverse effects ASCs have on regenerating 
cartilage in vivo. 
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 Previous studies have extensively studied the secretory profiles of bone marrow-
derived mesenchymal stem cells (MSCs) and ASCs, showing that they not only secrete 
several factors that can facilitate cartilage regeneration [52, 306], but that they also 
secrete a large amount of angiogenic factors [155, 307].  VEGF-A, an important initiator 
and mediator of angiogenesis [64, 65], was secreted in large quantities by ASC 
monolayers and microbeads, decreased chondrocyte proteoglycan production, and 
induced chondrocyte apoptosis in the current study.   Although VEGF-A typically elicits 
anabolic responses from most cell types, this growth factor has catabolic effects on 
chondrocytes and has been shown to induce matrix metalloproteinase expression in these 
cells [68].  Although VEGF-A was not responsible for reduced chondrocyte proliferation 
due to ASC-secreted factors, ASCs also express pro-inflammatory factors [111], which 
may have inhibited chondrocyte proliferation.   
 Although VEGF-A alone did not prevent chondrocyte proliferation, it mitigated 
the ability of FGF-2 to stimulate chondrocyte proliferation at a high concentration.  
Additionally, FGF-2 restored proteoglycan production in chondrocytes treated with 
VEGF-A, and high concentrations of FGF-2 eliminated the apoptotic effect VEGF-A had 
on chondrocytes.  Although both FGF-2 and VEGF-A are important mitogens and 
facilitators for angiogenesis [340, 371], had similar gene expression responses to 
chondrogenic medium treatment in this current study, and appear to be linked in terms of 
production in MG63 cells [368], ASCs secreted an order of magnitude lower amount of 
FGF-2 than VEGF-A.  And unlike VEGF-A, FGF-2 has previously been shown to 
enhance the chondrogenic potential of different stem cell sources [372, 373], as well as 
improve cartilage regeneration [341, 374].  The combination of high VEGF-A secretion 
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and low FGF-2 secretion may be the main reason why ASC-secreted factors have 
deleterious effects on chondrocytes and subsequent cartilage regeneration.  
 In addition to enhancing catabolic pathways in chondrocytes, VEGF-signaling has 
been associated with osteophyte formation and osteoarthritis progression in articular 
cartilage [69-71] and blocking VEGF-signaling improves the chondrogenic potential and 
regenerative capacity of muscle-derived stem cells [375, 376].  Additionally, VEGF-A 
directs cartilage vascularization in hyaline cartilage and hypertrophic chondrocyte 
absorption that leads to subsequent ossification [66, 377].  Although chondrocytes 
exposed to ASC-secreted factors did not have increased mRNA levels of RUNX2 or 
increased alkaline phosphatase activity and cartilage defects with ASC pellets did not 
have signs of vascularization, hypertrophic differentiation, or bone formation, longer in 
vitro or in vivo studies may have revealed these effects.  Additionally, ASCs may secrete 
trophic factors that prevent hypertrophic differentiation. 
 Several studies have investigated the effects chondrocyte-stem cell co-cultures 
and chondrocyte secreted factors have on stem cell differentiation [310, 375, 378], but 
few have provided insight into the effects stem cell-mediated paracrine signaling has on 
chondrocytes.  Bian et al. showed that co-culturing chondrocytes with MSCs within the 
same gel reduced hypertrophy and increased compressive moduli, but it appeared that 
these improvements were independent of long-range MSC-paracrine signaling [379].  
Additionally, results from Hildner et al. suggested that co-culturing ASCs and 
chondrocytes in the same matrix moderately increased SOX9, aggrecan, and cartilage 
oligomeric protein mRNA expression when normalized to the initial percentage of 
chondrocytes, but the findings provided little insight into the role of ASC-secreted factors 
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[380].  From the current study, the length of exposure to ASC-secreted factors and the 
ability for trophic factor interchange between ASCs and chondrocytes appear to be 
important variables in regulating chondrocyte phenotype.  Twelve hour exposure to ASC-
conditioned medium appeared to have the most significant effects on SOX9 and 
aggrecan, which are earlier stage markers of chondrogenesis, whereas seven days of ASC 
co-culture exerted the greatest effects on RUNX2, a later stage chondrogenic marker 
[53].  Additionally, 7 day co-culture with ASCs treated with chondrogenic medium 
increased aggrecan expression, possibly due to the interplay of chondrocyte and ASC 
signaling.  
 Although chondrogenic treatment that included both TGF-1 and BMP-6 
eliminated the deleterious effects ASCs secreted factors and ASCs had on chondrocytes 
and cartilage regeneration respectively, ASCs treated with chondrogenic medium did not 
secrete factors that improved chondrocytes’ ability to produce cartilaginous extracellular 
matrix in vitro.  This absence of improvement over baseline may be due to the short 5 day 
chondrogenic medium treatment time as several studies have shown optimal ASC and 
stem cell chondrogenesis to require at least 2 to 6 weeks of chondrogenic treatment [243, 
352].  However, these studies did not investigate the effects varying the temporal 
application of chondrogenic medium had on trophic factor production. 
 
CONCLUSION 
This study showed that ASCs can inhibit cartilage regeneration in a focal hyaline 
cartilage defect in vivo.  In vitro, ASCs monolayers or microbeads cultured in growth 
medium secrete a large amount of VEGF-A which causes chondrocyte apoptosis and 
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reduced proteoglycan synthesis.  Additionally, these ASCs secrete factors that reduce 
chondrogenic gene expression and proliferation.  Treating ASCs with chondrogenic 
medium reduces the secretion of VEGF-A, significantly reduces the deleterious effects 
ASC-secreted factors have on chondrocytes, and eliminates the inhibitory effect ASCs 
have on cartilage regeneration.  Blocking VEGF-A in ASC-conditioned medium 
eliminates the deleterious effects ASC-secreted factors have on chondrocyte phenotype 
and apoptosis.  Adding a high concentration of FGF-2 eliminates the apoptotic effect 
VEGF-A has on chondrocytes and adding both low and high concentrations of FGF-2 
eliminates the detrimental effects VEGF-A has on chondrocyte phenotype.  These results 
have significant implications on how ASCs and possibly other stem cell therapies are 
used for repairing cartilage.  Specifically, these therapies must be pre-treated or modified 








Alginate hydrogels have been used for a wide variety of tissue engineering and 
regenerative medicine applications because they have favorable mass transfer properties 
[197], can be molded into specific shapes [198, 199], have adjustable degradation 
kinetics [200-202], support a range of different cell phenotypes [203-205], can be 
mechanically and biochemically modified [196, 206, 207], support cell differentiation in 
large animal models [208], and are biocompatible for delivery of cells in human trials 
[209].  The most common method of incorporating bioactive molecules or cells into 
alginate matrices is via extrusion, in which an alginate suspension is extruded through a 
needle to form droplets that fall into a solution that contains divalent cations causing 
alginate crosslinking [204, 381-383].  Alginate microspheres can also be created by using 
air flow [210] or high electrostatic potentials [384] to overcome surface tension, and have 
been used to encapsulate and deliver pancreatic islets [204].  In addition to cell delivery, 
hydrogel microspheres have generally been used for spheroid cell culture, drug delivery, 
and as injectable tissue fillers.  The ability of alginate microspheres as an injectable filler 
to deliver encapsulated cells has not been fully characterized, and, to further develop this 
technology, the mass transfer properties and reabsorption kinetics of alginate 
microspheres must be controllable in vivo. 
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Various pre-clinical and clinical studies have reported alginate calcification [31, 
385, 386], which presents a critical challenge in developing large scale applications using 
this hydrogel.  Our preliminary studies have shown that alginate microbeads calcify in 
vivo, which affects mass transfer in and out of the hydrogel while preventing reabsorption 
and creating unwanted mineralization foci within the tissue.  Therefore, it would be 
advantageous to develop methods to prevent alginate calcification.  However, if alginate 
calcification can be regulated temporally and spatially in vivo, this hydrogel could also be 
used as a stimulus for in situ bone repair and formation.  To achieve this type of 
application, a thorough understanding of the mechanism of alginate calcification and 
methods to control it need to be developed.  No study, however, has yet extensively 
characterized alginate calcification nor has any study thoroughly investigated methods to 
control this process. 
The objective of this study was to investigate how alginate beads calcify and to 
develop different methods to control alginate calcification while characterizing the 
mineral formed.  We first hypothesized that calcium-crosslinked alginate calcifies by 
sequestering the surrounding phosphate to form calcium phosphate.  Alginate beads were 
cultured in a phosphate solution, and phosphate content and subsequent mineralization 
were analyzed.  We then hypothesized that calcium-crosslinked alginate has the ability to 
calcify in vivo regardless of the presence of encapsulated cells, delivery method, site of 
delivery, or sex of the animal.  Alginate microbeads seeded with or without human 
adipose stem cells were implanted intramuscularly or injected subcutaneously in male 
and female nude mice and the retrieved implants analyzed for mineral content and 
properties.  Finally, we hypothesized that the type of mineral would be similar to 
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hydroxyapatite found in bone and that this calcification could be eliminated by varying 
divalent cations used to crosslink alginate or by buffering the pH in the beads before 
implantation.  Barium was used as a crosslinking ion since it does not readily interact 
with phosphate ions [348] whereas aledronate was added since it is a bisphosphonate that 
chelates calcium and attaches strongly to hydroxyapatite to prevent crystal growth [387].  
HEPES, an organic zwitterion buffering agent that does not contain phosphate, was used 
to buffer the crosslinking bath below physiological levels since hydroxyapatite crystals 
are stable to neutral to alkaline environments [388].  Implanted alginate microbeads 
created in different cross-linking solutions were retrieved and extensively characterized. 
   
MATERIALS AND METHODS 
In Vitro Phosphorus Content 
To test our first hypothesis that calcium-crosslinked alginate calcifies by 
sequestering surrounding phosphate, an in vitro study was designed to assess the ability 
of calcium-crosslinked alginate to sequester phosphate.  Low viscosity sodium alginate 
[Kelco Corp., Chicago, IL, USA] dissolved in 155 mM sodium chloride at a 
concentration of 12 mg/ml was dropped gently through a 25 gauge needle at a rate of 2-3 
drops per second into a 102 mM calcium chloride bath.  After 10 minutes, the beads (15-
20 beads/10ml alginate) were washed four times with 155 mM NaCl.  The beads were 
suspended in 25 ml 4 mM (NH4)2HPO4 in 0.05 M Tris buffer at pH 7.4, and removed at 
different time points over a 4 hour period (0, 0.5, 1, 2, and 4hrs).  After incubation at 
room temperature, the beads were collected by centrifugation, and the supernatants were 
assayed for phosphorus content using a commercially available kit [Sigma, St. Louis, 
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MO, USA] (n=3 for each experimental group and time).  Beads were then lyophilized, 
mixed with KBr (~1 wt %), and made into KBr pellets for Fourier transform infrared 
spectroscopy (FTIR) analysis as outlined below.  In some cases, the cloudy supernatant 
of the incubation buffer was centrifuged to a pellet, washed with acetone, air dried, and 
analyzed as a KBr pellet via FTIR. 
Cell Isolation and Culture 
To test our second hypothesis that calcium-crosslinked alginate microbeads with 
and without cells would calcify in vivo, adipose stem cells (ASCs) were isolated.  Fat was 
excised from male and female patients less than 18 years of age undergoing cosmetic and 
reconstructive procedures at Children’s Healthcare of Atlanta under an approved IRB 
protocol at Georgia Institute of Technology and Children’s Healthcare of Atlanta.  All 
patients and parents gave written consent to both the procedure and handling of fat 
thereafter.  ASCs were isolated via a collagenase digestion solution as previously 
described [389].  Cells were then seeded at 5,000 cells/cm
2
 and cultured in Lonza 
Mesenchymal Stem Cell Growth Medium [Lonza, Basel, Switzerland] up to second 
passage.   
Alginate Bead and Microbead Fabrication 
To test our hypotheses that alginate calcification can occur independently of how 
and where microbeads were implanted and that it could be eliminated by varying the 
crosslinking method, alginate microbeads were made in different crosslinking solutions.  
Medium molecular weight alginate (240,000 kDa) with a high guluronate to mannuronate 
ratio (69% guluronate) [FMC Biopolymer, Drammen, Norway] was UV light sterilized 
and dissolved in 155 mM sodium chloride [Ricca Chemical, Arlington, TX, USA] at a 
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concentration of 20 mg/ml. Alginate containing ASCs was initially seeded at 1x10
6
 
cells/ml, resulting in a final measured cell number of 40±7 cells per microbead (Figure 
2B).  Microspheres were created using a Nisco Encapsulator VAR V1 LIN-0043 [Nisco 
Engineering AG, Zurich, Switzerland] at a 4ml/hr flow rate, 0.175mm nozzle inner 
diameter, and 6kV electrostatic potential [390].  Microbeads were made in four different 
crosslinking solutions: (i) 50mM CaCl2 and 150mM glucose (non-buffered); (ii) 50mM 
CaCl2 and 150mM glucose with 25M alendronate [Sigma] (bisphosphonate); (iii) 
20mM BaCl2 and 150mM glucose (barium); and (iv) 50mM CaCl2 and 150mM glucose 
with 15mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 [Sigma] 
(HEPES-buffered).  Microbeads made in non-buffered crosslinking solutions were 
washed and stored in 155 mM sodium chloride (saline) while microbeads made in the 
HEPES-buffered crosslinking solution were washed and stored in Dulbecco’s modified 
eagle medium (DMEM) [Invitrogen, Carlsbad, CA, USA] at 37
o
C and 5% CO2 prior to 
implantation to allow for longer term storage of ASC microbeads in future studies.  
Following microencapsulation, microbeads were implanted as described below. 
Cell Viability 
 To determine whether ASCs were viable after microencapsulation in alginate and 
remained viable after injection delivery, microencapsulated ASCs suspended in DMEM 
were injected as described below and cultured for 0, 1, and 2 weeks in Lonza 
Mesenchymal Stem Cell Growth Medium.  Microencapsulated ASCs that were not 
injected were also cultured for comparison (n=6 for each experimental group and time).  
Viability was measured using fluorescent confocal microscopy using a LIVE/DEAD 
Viability Kit following the manufacturer’s protocol [Invitrogen].  Briefly, samples were 
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incubated for 30 minutes in a PBS solution containing 10 mM CaCl2, 4 M ethidium 
homodimer-1, and 2 M calcein and imaged with a LSM 510 confocal microscope [Carl 
Zeiss MicroImaging Inc., Thornwood, NY]. 
Animal Surgeries 
Male and female athymic nude (Nu/Nu) mice were housed in the vivarium in the 
Institute for Bioengineering and Bioscience at the Georgia Institute of Technology and 
handled under a protocol approved by the IACUC committee.  Prior to surgeries, athymic 
mice were anesthetized using isoflurane gas.  Both non-buffered and HEPES-buffered 
microbeads were directly implanted subcutaneously or intramuscularly or injected 
subcutaneously to determine if delivery method affected alginate calcification.  
Bisphosphonate and barium microbeads were only injected subcutaneously to reduce 
animal discomfort and to investigate how the crosslinking solution affects alginate 
calcification.   For intramuscular implants, a small skin incision was made over the calf 
region of the hind limb, a pouch was prepared in the muscle by blunt dissection, and 
approximately 0.1 ml microbeads were inserted directly into the gastrocnemius muscle 
[391].  For all subcutaneous injections, 0.25 ml microbeads were mixed in 0.25 ml 
DMEM and injected via an 18 gauge needle.  Animals were euthanized by CO2 
inhalation at various time points from 1 to 6 months.  Each animal received either 2 
injections or 2 implantations subcutaneously or 2 bilateral intramuscular implantations 
(n=4-6 for each experimental condition).  Samples were harvested and processed for 
subsequent studies as described below. 
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Micro-computed Tomography 
To assess the extent of alginate microbead mineralization, subcutaneous and 
intramuscular samples were excised from nude mice, immediately scanned using a μCT 
40 (Scanco Medical, Switzerland) with a voxel size of 20μm, and analyzed as previously 
described [392].  Calcification was identified using a fixed threshold; individual samples 
were isolated with user-guided contours and three dimensional images were created.  
Samples were then fixed in 10% neutral buffered formalin [Sigma] for histological 
processing or frozen and lyophilized for subsequent materials characterization. 
Histology 
After 48 hours of fixation in formalin, representative undecalcified samples were 
embedded in plastic, and cut into 10-μm thick sections.  Samples were stained with von 
Kossa with a nuclear fast red counter stain as previously described [295].     
Fourier Transform-Infrared Spectroscopy (FTIR) 
To test our hypothesis that alginate calcification mineral was similar to 
hydroxyapatite found in bone, infrared spectroscopy in attenuated total internal reflection 
(ATR) mode [Pike Technologies, Madison, WI, USA] was performed on lyophilized 
samples using a Nexus 870 FT-IR bench [Nicolet Instrument Corporation, Madison, WI, 
USA].  Each spectrum was the mean of two acquisitions (between 1800 and 800 cm-1) of 
at least 64 scans with a spectral resolution of 4 cm
-1
. 
X-Ray Diffraction  
Crystal structure of the samples was identified using an X‘Pert PRO Alpha-1 
diffractometer [PANalytical, Almelo, The Netherlands]. X-ray diffraction (XRD) scans 
were collected using Cu Kα radiation.  A 1° parallel plate collimator, ½ divergence slit 
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and 0.04 rad soller slit were used for controlled axial divergence.  Bragg-Brentano 
parafocusing at 45 kV and 40 mA was used to analyze samples.  The assignment of 
detected peaks to crystalline phases was performed using the database from the 
International Centre for Diffraction Data (ICDD, 2008). 
Scanning Electron Microscopy and Energy Dispersive X-Ray Spectroscopy 
Morphology of the microbeads was qualitatively evaluated using an Ultra 60 field 
emission scanning electron microscope (FESEM) [Carl Zeiss SMT Ltd., Cambridge, UK] 
at an accelerating voltage of 5 kV and different magnifications.  Chemical composition of 
samples was determined using an INCAPentaFET-x3 energy dispersive x-ray 
spectrometer (EDS) [Oxford Instruments, Bucks, UK] at an accelerating voltage of 15 kV 
and a working distance of 8.5 mm. 
 
RESULTS  
In Vitro Calcification 
Upon adding the calcium-crosslinked alginate beads to the phosphate buffer, the 
solution started to become cloudy.  The phosphate concentration in the bath decreased by 
20-35% over the first 4 hours and depended on the amount of alginate that was added 







 (Figure 8.1B) while the FTIR spectrum of 
the phosphate bath pellet had a similar peak between 900-1200cm
-1
 along with peaks 
centered around 1600 and 1400cm
-1
 (Figure 8.1C).   Pure hydroxyapatite had 




 (Figure 8.1D). 
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Figure 8.1: In vitro Study of Alginate Calcification 
(A) Phosphate concentration of buffered bath over time for different amounts of alginate 
added to 25 mls of 4mM (NH4)2HPO4 in 0.05 M Tris buffer at pH 7.4 (n=3 for each 
experimental group and time).  FTIR spectra of (B) lyophilized alginate beads, (C) 
precipitate from the bath, and (D) pure hydroxyapatite. 
 
Visualization of In Vivo Calcification 
Microbeads formed in all crosslinking solutions ranged from 200-350m in 
diameter (Figure 8.2A).  When non-buffered microbeads were either implanted or 
injected subcutaneously into male nude mice, almost every sample showed the presence 
of mineral at all time points examined (1, 3, and 6 months; Table 8.1).  Specifically, 24 of 
24 implanted samples calcified whereas 21 of 24 injected samples calcified.  ASC 
viability prior to implantation or injection was 70±3% (Figure 8.2B), and in vitro studies 
show cell viability increasing to 80±5% two weeks post injection (data not shown), yet 
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the presence of ASCs had no apparent effect on mineralization (Table 8.1). 
Mineralization was demonstrated by light microscopy (Figure 2C) or by visual inspection 
of implanted (Figure 8.2D) and injected (Figure 8.2E) microbeads.   
 
Figure 8.2: Gross-Visualization of Alginate Microbead Mineralization  
(A) Microbeads before implantation or injection under a light microscope (Bar = 100μm).  
(B) Live/dead staining of human ASCs within a single microbead post injection (Bar = 
25μm) (C) Visualization of mineralized microbeads 3 months post-implantation under a 
light microscope (Bar = 100μm).  (D) Mineralized microbeads 3 months post-
implantation.  (E) Mineralized microbeads 1 month post-injection. 
 




1  Implantation: 4/4 Mineralized 
Injection: 3/4 Mineralized 1 
Implantation: 4/4 Mineralized 
Injection: 3/4 Mineralized 
3  Implantation: 4/4 Mineralized 
Injection: 3/4 Mineralized 1 
Implantation: 4/4 Mineralized 
Injection: 4/4 Mineralized 
6  Implantation: 4/4 Mineralized 
Injection: 4/4 Mineralized 
Implantation: 4/4 Mineralized 
Injection: 4/4 Mineralized 
1
Microbeads for one sample disappeared and had no volume retention 
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Modifications to the crosslinking protocol reduced or eliminated calcification as 
detected by von Kossa staining (Table 8.2).  When microbeads were injected 
subcutaneously, no visual calcification was evident when barium chloride was used as the 
crosslinker and the addition of the 25M bisphosphonate to the crosslinking solution 
partially reduced mineralization.  HEPES-buffered (pH 7.3) microbeads injected 
subcutaneously also had no apparent calcification.  When HEPES-buffered samples were 
then directly implanted subcutaneously and intramuscularly, there was no visual 
mineralization.  In contrast, when non-buffered microbeads were implanted a second 
time, all the subcutaneous and two-thirds of the intramuscular samples mineralized. 
The intensity of von Kossa staining for phosphate was very strong in non-buffered 
samples as phosphate was present throughout almost every microbead (Figure 8.3A).  
Barium chloride-treated samples had no detectable presence of von Kossa staining with 
microbeads surrounded by endothelial tissue (Figure 8.3B).  Bisphosphonate-treated 
samples that did calcify only had partially positive staining for phosphate as both the 
intensity of staining and the number of positively stained microbeads was lower 
compared to non-buffered samples (Figure 8.3C, Table 8.2).  HEPES-buffered samples 
had no von Kossa staining and were surrounded by connective tissue (Figure 8.3D).  
Cross-sectional x-ray sections of non-buffered samples via microCT showed 
extensive mineralization that was not just limited to the surfaces of individual microbeads 
or peripheral microbeads of the bolus (Figure 8.4A, B).  Additionally, the intensity of X-
ray attenuation seemed to be comparable to the adjacent bone.  3-D reconstructions 
further demonstrate the extent of calcification of both subcutaneous (Figure 8.4C) and 
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intramuscular (Figure 8.4D) samples.  HEPES-buffered samples were undetectable by 
microCT (data not shown). 
Table 8.2: Regulating Calcification by Modifying the Crosslinking Solution  
 
 





















Injection - 0/4 Calcified 2/4 Calcified 0/4 Calcified 
 
  
Figure 8.3: Histology of in vivo Microbead Samples 
 von Kossa with nuclear fast red counter stain to determine calcification for 
representative (A) non-buffered, (B) barium chloride, (C), bisphosphonate, (D) buffered 
samples in vivo after 2 months.  Bar represents 100μm for all images.   
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Figure 8.4: Micro-CT Images of in vivo Non-buffered Microbead Samples 
(A) Representative X-ray cross-section of subcutaneously implanted non-buffered 
microbeads after 5 weeks in vivo.  (B) 3-D reconstruction of subcutaneously implanted 
non-buffered microbeads after 5 weeks in vivo.  (C) Representative sagittal X-ray cross-
section of intramuscularly implanted non-buffered microbeads near the tibia after 5 
weeks in vivo.  (D) 3-D reconstruction of intramuscular implanted non-buffered 
microbeads along with the tibia after 5 weeks in vivo.  Bar represents 1mm for all 
images. 
 
Characterization of In Vivo Calcification 
Comparison of FTIR spectra of the lyophilized explanted samples presented 
significant differences.  The spectrum of the non-buffered sample (Figure 8.5A) showed 
the characteristic bands of hydroxyapatite around 1400-1550 cm
-1
 and 900-1200 cm
-1
 and 
corresponded well with the spectrum of the pure hydroxyapatite powder.  The spectrum 
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of the HEPES-buffered sample (Figure 8.5B) had no traces of the HEPES spectrum 
(Figure 8.5C), but matched almost perfectly with the spectrum of the pure alginate 
powder (Figure 8.5D).  No presence of hydroxyapatite was noted in the HEPES-buffered 
sample.  
  
Figure 8.5: FTIR of in vivo Microbeads Samples 
Spectra of (A) non-buffered microbeads after 5 weeks in vivo, (B) buffered microbeads 
after 5 weeks in vivo, (C) HEPES powder used to buffer the crosslinking solution, and 
(D) alginate powder used to make the microbeads. 
 
The XRD spectra of the explanted samples showed the presence of monphasic 
crystalline structures (Figure 8.6).  The alginate powder presented no diffraction pattern.  
The non-buffered sample appeared to have the crystal structure of hydroxyapatite, 
whereas the HEPES-buffered sample showed the main peaks of NaCl crystals and 
 156 
incorporated none of the peaks of the HEPES buffer.  The crystalline structures were 
further confirmed with the EDS spectra (Table 8.3), which showed the presence of 10.2 ± 
1.3% Ca and 6.3 ± 0.8% P on the non-buffered sample (Ca/P ratio of 1.6±0.4), and only 
approximately 1% of each on the HEPES-buffered sample.  Conversely, the HEPES-
buffered sample included 14.3 ± 0.7% Na and 13.2 ± 1.8% Cl, and the non-buffered 
sample had < 1% of Na and no traces of Cl.  The main components of both samples were 
C and O, primarily from the alginate polymer.  SEM image of non-buffered microbeads 
that were lyophilized shows an intact spherical structure with surrounding tissue growth 
(Figure 8.7A) whereas HEPES-buffered microbeads that were lyophilized were clearly 
fragmented (Figure 8.7B). 
 
Figure 8.6 XRD of in vivo Microbead Samples 
Spectra of HEPES powder used to buffer the crosslinking solution, alginate powder used 
to make the microbeads, buffered microbeads after 5 weeks in vivo, NaCl from the 










C O Na Mg Al P S Cl Ca K 
Non-buffered 34.0 ± 4.3 47.2 ± 2.0 < 1 < 1 1.2 ± 0.4 6.3 ± 0.8 < 1 - 10.2 ± 1.3 - 
HEPES-
Buffered 
41.6 ± 1.0 27.5 ± 1.9 14.3 ± 0.7 - < 1 1.15 ± 0.1 < 1 13.2 ± 1.8 < 1 < 1 
1 
The values should be evaluated with an error of approximately ± 2% relative. 
2
 Elements that were not present in all measurements of the same sample were not included in 




Figure 8.7: SEM Images of in vivo Microbead Samples 
(A) Lyophilized non-buffered microbeads after 5 weeks in vivo.  (B) Lyophilized 
buffered microbeads after 5 weeks in vivo. 
 
DISCUSSION 
Alginate mineralization has been sporadically reported when used for biomedical 
research and clinical applications [31, 385, 386].  The presence of such calcifications 
hinders soft tissue regeneration; therefore, effective strategies are needed to eliminate 
alginate calcification. This study is the first to characterize the mineralization that occurs, 
propose a mechanism behind alginate calcification, and develop strategies to modulate 
alginate calcification.  It appears that alginate calcification both in vitro and in vivo 
occurs due to the alginate hydrogel providing a bolus of calcium ions that then interacts 
with surrounding phosphate ions to form calcium phosphate salts.  This finding is 
confirmed by our in vitro results in which phosphate is sequestered from the solution into 
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the alginate and by our in vivo results where alginate crosslinked with barium - a divalent 
cation that does not readily interact with phosphate ions [348] - exhibited no 
mineralization, and the addition of alendronate - a bisphosphonate that prevents crystal 
growth at concentrations as low as 10
-6
M [387] -  reduced calcification.  Although barium 
was effective at preventing calcification, it is known to be toxic at high levels [393] and 
hinders the ability for alginate to reabsorb while it significantly retards the delivery of 
soluble proteins [348].  Despite the alendronate’s partial effectiveness, bisphosphonates 
are known to have a wide variety of side effects when treating osteoporosis [394] and 
have been shown to influence differentiation of stem cells [395].  Therefore, another 
method of regulating calcification induced by the alginate beads was investigated.   
Hydroxyapatite crystals are stable to neutral to alkaline environments [388].  
Therefore it was believed that buffering the pH of alginate hydrogels slightly below 
physiological levels with a non-phosphate buffer would help eliminate calcification in 
vivo while minimizing any biological side effects.  HEPES was selected because it does 
not contain phosphate, is commonly used in cell culture, and is also effective for 
maintaining enzyme structure and function below physiological temperatures [396].  
Additionally, instead of washing and storing microbeads in saline, which is the standard 
care for most medical implants, DMEM was used to allow for longer term storage of 
microbeads with encapsulated cells.  MicroCT imaging along with von Kossa staining of 
precipitated phosphate showed extensive mineralization of non-buffered and saline-stored 
samples whereas buffering with HEPES and maintaining the pH of the crosslinking 
solution to pH 7.3, along with washing and storing samples in DMEM, completely 
eliminated mineralization.  Both microCT and histology showed that calcification was 
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not limited to just the surface, suggesting that the calcium crosslinks throughout the 
microbeads play a major role in alginate calcification.   
Further investigation using FTIR, XRD, and EDS showed that hydroxyapatite is 
the most stable crystal phase formed when alginate is calcified.  Explanted non-buffered 
alginate microbeads had similar spectra to pure hydroxyapatite for both FTIR and XRD 
whereas buffered microbeads appeared to be a combination of alginate powder and salt 
crystals when both analytical modalities were used.  Specifically, FTIR spectrum of non-
buffered microbeads closely resembled that of 16-day-old rat calvaria with characteristic 
phosphate (900-1180cm
-1
) and amide I (1580-1750cm
-1
) peaks [397].  Although, the 
broad phosphate peak in the non-buffered microbeads does overlap with aryl-hydroxyl 
(1030-1085 cm
-1
) and carboxylic acid (915-995 cm
-1
) groups found in the HEPES-
buffered microbeads and alginate powder, the disappearance of alginate peaks found at 
lower frequencies, the low intensities of the amide I and II peaks (1405-1420, 1600-1690 
cm
-1
) in the non-buffered samples, and the XRD spectra suggest the formation of 
hydroxyapatite.  To confirm these findings, the Ca/P ratio for non-buffered alginate was 
found to be 1.6±0.4, which closely matches hydroxyapatite found in bone [398].  Non-
buffered microbeads also had traces of Mg, which has been associated with facilitating 
the formation of calcified pathological cardiovascular deposits [399].  HEPES-buffered 
microbeads only had traces of calcium left, suggesting that these samples were starting to 
be reabsorbed.   The presence of sulfur and higher content of carbon in HEPES-buffered 
microbeads compared to non-buffered samples suggest levels of tissue incorporation, 
which was also confirmed with histology.  More studies though are needed to determine 
the ability of injectable microbeads to be used for tissue replacement or regeneration. 
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Cell-mediated mineralization is a complex process, and it is probable that multiple 
factors contribute to alginate calcification and its inhibition.  It is not completely clear 
why buffering the calcium chloride bath with HEPES at a pH slightly below 
physiological levels (7.3) or washing and storing alginate microbeads in basal DMEM 
would prevent mineralization.  Hydroxyapatite does not form de novo at pH less than 6.8 
[388].  More soluble calcium phosphate phases form at lower pH values, hence the 
kinetics for hydroxyapatite mineral deposition would be lessened at the lower pH.  It is 
possible that washing and storing microbeads in DMEM may have deposited amino acids 
such as glutamine or lysine that inhibited growth of any hydroxyapatite nuclei in a similar 
manner to how salivary proteins in supersaturated saliva prevent calcium phosphate 
mineral precipitation by adsorbing active sites of crystallite surfaces [388].    However, 
this explanation does not explain why non-buffered microbeads that were injected in 
DMEM still calcified.  It is likely that making microbeads in HEPES-buffered calcium 
chloride at this lower pH and subsequent washing and storage in media was more 
effective than non-buffered saline alone in removing excess calcium ions and preventing 
hydroxyapatite nuclei from forming.  Additionally, it has been shown that HEPES binds 
calcium ions with a maximum apparent binding of 1.24±0.001 mmol of Ca
2+
/L by 
HEPES at 10mM and pH 7.39 [400].  
Although alginate microbead calcification did not strongly depend on the delivery 
method, delivery site, the presence of cells, or sex of the animal, biological factors can 
play a significant role in mineralizing alginate constructs in vivo.  When bone marrow 
mesenchymal stem cells (MSCs) were treated with 10
-7
 dexamethasone and 10ng/ml 
TGF-1 for more than 1 week, these cells were able to mineralize alginate scaffolds in 
 161 
vivo whereas scaffolds with cells treated for only 1 day had no apparent calcification 
[31].  Osteogenic-induced adipose stem cells are able to calcify collagen scaffolds both in 
vitro and subcutaneously [401], and alginate microbeads containing a combination of 
osteoprogenitor and endothelial cells have been shown to mineralize in a metaphyseal 
femoral bone defect [349].  The final adipose stem cells concentration in our alginate 
microbeads is similar to MSC-seeded alginate constructs in Ma et al (2×10
6
 cells/ml) [31] 
but significantly less than the microencapsulated osteoprogenitor and endothelial cells in 
Grellier et al (20×10
6
 cells/ml) [349].  Regardless, to better utilize alginate microbeads 
for different tissue engineering strategies, more studies are needed to understand the 
exact mechanisms regulating in vivo mineralization of alginate. 
Natural biomineralization systems and previous in vitro experiments have 
suggested that crystal nucleation and growth from organic templates occurs on surfaces 
that expose repetitive patterns of anionic groups [398, 402].  These negatively charged 
groups concentrate and create local supersaturation of inorganic cations, which leads to 
oriented nucleation of crystal formation.  Alginate is a co-polymer with negatively 
charged blocks of (1-4)-linked β-D-mannuronate and (1-4)-linked α-L-guluronate 
residues.  This structure may allow alginate polysaccharide chains to facilitate controlled 
calcification for bone tissue engineering.   Peptide-amphiphile nanofibers modified with 
negatively charged peptides rich in phosphoserine groups have been shown to create 
hydroxyapatite in vitro that was aligned in the same manner as observed in bone [398].  
Injectable, crosslinked-alginate that can then mineralize in situ without the presence of 
other biological or chemical factors may present an advantage over pre-mineralized 
scaffolds or bone morphogenetic proteins in that it avoids adverse immune responses, 
 162 
limits systemic side effects, and is minimally-invasive for simple orthopaedic and 
reconstructive applications.  However, in addition to hydroxyapatite formation and 
alignment, bone tissue engineering via mineralized alginate must also form constructs 
with high porosity and collagen content, osteoconductive properties, bioactivity, and 
mechanical integrity in order for this method of repair to be feasible.  
 
CONCLUSION 
In order to understand the mechanism behind alginate calcification and to develop 
ways to regulate it, studies in vitro and in vivo were performed.  Non-buffered calcium 
crosslinked alginate beads placed in a phosphate buffered bath sequestered the 
surrounding phosphate and calcified, forming traces of hydroxyapatite.  Non-buffered 
calcium crosslinked alginate microbeads with or without ASCs also mineralized when 
implanted subcutaneously or intramuscularly or injected subcutaneously after 1 to 6 
months.  More extensive analysis with microCT, FTIR, XRD, and EDS showed that the 
1.6±0.4 Ca/P ratio of the mineral formed closely matched hydroxyapatite found in bone.  
Incorporating bisphosphonate helped regulate alginate calcification whereas using barium 
chloride as the crosslinking agent eliminated calcification.  Buffering the crosslinking 
solution at pH 7.3 while washing and storing samples in basal media prior to implantation 
also eliminated calcification in vivo.  This study effectively showed that calcium 
throughout the alginate is responsible for bulk hydroxyapatite formation and developed 
methods to partially regulate and eliminate alginate calcification.  
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CHAPTER 9 
OPTIMIZING DELIVERY OF ADIPOSE STEM CELL 
MICROBEADS FOR REPAIRING CARTILAGE FOCAL DEFECTS 
 
INTRODUCTION 
An effective therapy to treat articular cartilage lesions is needed because these 
injuries do not heal themselves [345]. The ineffectiveness of microfracture has been 
documented in human subjects as patients often experience short-term pain relief and 
develop progressive symptoms because of tissue failure [4-6].  Current cell therapies, 
such as autologous chondrocyte implantation, aim to directly regenerate cartilage by 
providing a source of cells that can synthesize new tissue.  However, these therapies are 
used by a limited number of clinicians due to high variability in cartilage quality and 
functional outcomes [3, 4].  Therefore, a new paradigm has emerged in using stem cells, 
like adipose stem cells (ASCs), as growth factor production sources to stimulate diseased 
or damaged cartilage to regenerate itself  [140, 148].   ASC microbeads are highly 
favorable for this new strategy because of their ability to maintain greater than 80% cell 
viability for at least 3 weeks post-injection and to be localized in the desired site in vivo 
for at least 3 months [223].  Additionally, previous studies have shown that ASC 
microbeads could be preconditioned to make growth factor secretion more favorable for 
cartilage regeneration. 
To assess the potential of ASC microbeads to treat articular cartilage lesions, they 
first must be tested in focal cartilage defects.  Additionally, methods need to be 
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developed to maintain the microbeads within the defect.  Finally, a biomaterial approach 
may be needed to facilitate cartilage infiltration into critically-sized defects.  Therefore, 
the objectives of this study were to determine if ASC microbeads could regenerate 
cartilage within a focal defect and if ASC microbeads needed to be combined with a 
functionalized biomaterial to promote cartilage ingrowth.      
 
MATERIALS AND METHODS 
Cell Isolation 
ASCs were isolated from the inguinal fat pads of 125 g male Sprague-Dawley rats 
(Harlan Laboratories, Indianapolis, IN, USA) as previously described in detail  [319, 320] 
and cultured in Lonza Mesenchymal Stem Cell Growth Medium (GM, Lonza, 
Walkersville, MD, USA).  After one passage, these cells were negative for CD45 and 
positive for CD73 and CD271 [320].   
Microencapsulation and Treatment 
Once primary ASCs reached 90% confluence, cells were trypsinized and 
microencapsulated in 20 mg/mL low molecular weight (~150 kDa) alginate (FMC 
BioPolymer, Sandvika, Norway) with a high mannuronate to guluronate ratio (40% 
guluronate) dissolved in saline (Ricca Chemical, Arlington, TX, USA) at a cell 
concentration of 25×10
6
 cells/mL as previously described [322], using a Nisco 
Encapsulator VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) and a 
cross-linking solution of 50 mM CaCl2, 150 mM glucose, and 15 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (pH=7.3, Sigma, St. Louis, MO, USA).  
The microbeads were washed three times in GM and cultured in this medium for 5 days.  
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After 5 days of culture, microbeads were then treated for 5 days with either GM or 
chondrogenic medium (CM) consistent of 4.5 g/L glucose DMEM with 1 mM sodium 
pyruvate (Mediatech, Manassas, VA, USA), 40 μg/ml proline (Sigma), 50 μg/ml 
ascorbate-2-phosphate (Sigma), 1% ITS+ (Sigma), 100 nM dexamethasone (Sigma), 10 
ng/ml recombinant human transforming growth factor beta-1 (TGF-1, R&D Systems, 
Minneapolis, MN, USA) and 100 ng/ml recombinant human bone morphogenic protein-6 
(BMP-6, PeproTech, Rocky Hill, NJ, USA).  After 5 days of treatment, microbeads were 
washed in Dulbecco’s modified Eagle’s medium (DMEM) containing 1% penicillin and 
streptomyocin and stored at 4
o
C prior to implantation.  
RGD-conjugated Hydrogel Preparation 
 One day before the surgeries, 20 mg/mL CaSO4 (Sigma) was autoclaved and 
stored at 4
o
C.  Prior to surgeries, sterile RGD-conjugated alginate (NOVATACH M 
RGD, FMC BioPolymer) was dissolved in DMEM containing 1% penicillin and 
streptomyocin at a concentration of 25 mg/mL.  Using two syringes connected to a luer-
lock 3-way connector the RGD-conjugated alginate and CaSO4 were mixed at a 4:1 
volume ratio.   
Xiphoid Defect 
 To assess if ASC microbeads alone could promote cartilage regeneration, 3 mm 
cylindrical defects were made in the xiphoids of 125 g male Sprague-Dawley rats as 
previously described in detail [369] using a protocol approved by the Institutional Animal 
Care and Use Committee of the Georgia Institute of Technology.  To assess if ASC 
microbeads could promote cartilage ingrowth along an RGD-conjugated hydrogel, 2 mm 
cylindrical defects were made in xiphoids.  For both studies, ASC microbeads 
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preconditioned with MSCGM or CM were implanted into the defect, but were 
immobilized with the RGD-conjugated hydrogel mixture only in the 2 mm defect study.  
Empty defects and empty microbeads served as controls in the 3 mm defect study 
whereas empty defects with the hydrogel mixture and re-implanted excised cartilage 
(autografts) served as controls in the 2 mm study.  All groups were tested in 7 rats.   
35 days post operation, the xiphoids were excised and washed in saline and 
radiographic imaging (Faxitron Bioptics, Lincolnshire, IL, USA) was performed in the 
coronal plane at a voltage of 22 mV and exposure time of 16 s to visualize soft tissue 
penetration as previous described [369].  A blind observer then scored the presence of 
soft tissue penetration with a score of 0 representing no healing, a score of 0.5 
representing partial healing, and a score of 1 representing full healing. 
 Equilibrium partitioning of an ionic contrast agent via micro-computed 
tomography (EPIC-CT) was used to visualize the distribution of proteoglycans within 
the xiphoid defects as previously described [369, 370].  Xiphoids were incubated in 40% 
Hexabrix (Mallinckrodt, St. Louis, MO, USA) in saline containing 1% proteinase 
inhibitor cocktail (CalBiochem, Darmstadt, Germany) overnight and scanned using pre-
determined settings [369].  Low X-ray attenuation (green/yellow) of three-dimensional 
color images corresponded to regions of high proteoglycan concentration and no or high 
X-ray attenuation (black and red/orange) indicated regions of low proteoglycan 
concentration.  To determine cartilage volume, the 1 mm defect was isolated with user-
guided contours and evaluated at a 100 – 250 threshold range.    
After scanning, samples were washed in saline for 2 hours at 37
o
C to equilibrate 
out any excess Hexabrix.  Samples were then fixed in 10% phosphate-buffered formalin 
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(Sigma) for 48 hours and embedded in paraffin.  Sagittal sections of the defect were 
stained with safranin-O using a fast green counter stain to evaluate proteoglycan present.   
RESULTS 
Effects of ASC Microbeads on Cartilage Regeneration 
 X-ray scoring of defects with microbeads showed that although partial healing 
was observed, microbeads with encapsulated ASCs did not perform better than empty 
microbeads (Figure 9.1A).  Histology confirmed these results, showing little to no 
apparent cell infiltration or extracellular matrix deposition (Figure 9.1C).    There were 
also no differences in EPIC-CT measured cartilage volume among all the groups 
(Figure 9.1B).   
Effect of ASC Microbeads and RGD-conjugated Hydrogel on Cartilage Regeneration 
 X-ray scoring of defects showed that defects with GM or CM preconditioned 
ASC microbeads and hydrogel mixture performed better than empty defects with only the 
hydrogel (Figure 9.2A).  Defects with only the hydrogel mixture had no apparent cell 
infiltration, new extracellular matrix (ECM) deposition, or perichondrium as indicated by 
the lack of fast green staining (Figure 9.2C).  Defects with the ASC microbeads 
preconditioned in MSCGM had traces of fast green staining throughout the defect with 
cell infiltration and tissue deposition at the edges of the defect (Figure 9.2C).  Defects 
with ASC microbeads preconditioned in CM had ECM deposition throughout the defect 
with cell infiltration, tissue resembling a perichondrium, and initial proteoglycan 
deposition (Figure 9.2C).  Defects with the autograft had cell infiltration, a 
perichondrium that resembled that of the surrounding xiphoid and proteoglycan 
deposition between the edges of the defect and autograft (Figure 9.2C).  EPIC-CT 
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measured cartilage volume was highest for the autograft group, and no difference in 
cartilage volume was seen in any defect containing the hydrogel mixture (Figure 9.2B). 
 
 
Figure 9.1: ASC Microbeads in Xiphoid Defect 
(A) Radiographic scoring.  (B) 3-D EPIC-CT calculated cartilage volume within defects 




   
 
Figure 9.2: ASC Microbeads and RGD-Hydrogel Mixture in Xiphoid Defect 
(A) Radiographic scoring.  (B) 3-D EPIC-CT calculated cartilage volume within defects 






When implanted in a focal cartilage defect, ASC microbeads alone were unable to 
regenerate tissue any better than empty microbeads.    When ASC microbeads were 
immobilized in a RGD-conjugated hydrogel in a smaller defect, they were able to 
stimulate tissue infiltration from the defect edges and perichondrium while promoting 
proteoglycan deposition. Additionally ASC microbeads preconditioned with 
chondrogenic medium performed better than ASC microbeads preconditioned in growth 
medium.  Despite these initial results, the full potential of the ASC microbeads and 
hydrogel mixture may have been better assessed at time periods longer than 35 days post-
operation.   
Alginate microbeads have previously been used to deliver progenitor cells in bone 
defects [349] and MSCs in the infarcted heart [169].  Additionally, RGD can increase 
expression of FGF-2 in microencapsulated MSCs, but has also been shown to inhibit 
chondrogenesis [238].  RGD’s negative effects on chondrogeneis may be due to its ability 
to promote actin cytoskeleton reorganization.  Actin cytoskeleton disruption via protein 
kinase C-dependent p38 mitogen-activated protein kinase signaling induced 
chondrogenesis [403], and inhibiting ROCK signaling, a well characterized regulator of 
cytoskeletal organization, elevated Sox9 expression and glycosaminoglycan synthesis 
[404].  Additionally, RGD is a biomimetic peptide derived from fibronectin, which is 
known to inhibit chondrogeneis [351].  Although the RGD-conjugated hydrogel did not 
appear to inhibit cartilage ingrowth, secreted factors from ASC microbeads may have 
counteracted this peptide’s negative effects. 
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In these studies, the perichondrium appeared to be the main mediator for tissue 
infiltration and cartilaginous tissue deposition within the defect.  This tissue is known to 
be a rich source of chondroprogenitors and has a central role in mediating the effects of 
TGF-β1 in endochondral bone formation [49].  Perichondrium transferred from ears and 
ribs have been used to resurface articular cartilage with varying levels of success [405, 
406].  Additionally, chondroprogenitor cells isolated from the perichondrium have had 
promising results for cartilage tissue engineering and regeneration [407-409].  Although 
using the paracrine actions of ASCs to stimulate perichondrium-mediated tissue 
regeneration may be beneficial for regenerating hyaline cartilage, articular surfaces have 
no more than a peripheral rim of this tissue.  Furthermore, isolating perichondrium from 
other hyaline surfaces to re-surface articular cartilage would lead to a significantly more 
complicated procedure, though periosteal flaps may provide a viable source of infiltrating 
progenitor cells.  Therefore, when further optimizing ASC microbeads for cartilage 
regeneration, these factors will need to be taken into consideration. 
EPIC-μCT was also performed in this study, but the results from 3-D evaluations 
were contradictory with results from radiographic imaging and histology.  Subsequent 
investigation revealed that a noticeable amount of hexabrix was retained within alginate 
constructs after incubation overnight.  This finding was highly surprising because of 
alginate polymer’s negative charge and because of the ability of alginate microbeads to 
provide extended release of high pI proteins [410].  However, it may be possible that the 
negatively charged hexabrix may have interacted with the calcium crosslinks in alginate 
gels.   Because the ability of EPIC-μCT to visualize and quantify proteoglycan 
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production is dependent on hexabrix exclusion from the anionic tissue, this method may 
not be optimal for detecting neocartilage formation within alginate constructs. 
 
CONCLUSION 
 ASC microbeads were unable to facilitate any observable cartilage regeneration in 
3 mm defects regardless of chondrogenic medium pretreatment.  In 2 mm defects with 
only the RGD-conjugated hydrogel mixture, no apparent cell infiltration, new 
extracellular matrix deposition, or perichondrium formation was observed.  Defects with 
the ASC microbeads preconditioned in GM and immobilized in RGD-conjugated 
hydrogel had cell infiltration and tissue deposition at the edges of the defect.  Defects 
with ASC microbeads preconditioned in chondrogenic medium and RGD-conjugated 
hydrogel had extracellular matrix deposition throughout the defect with cell infiltration, 
tissue resembling a perichondrium, and initial proteoglycan deposition.  Defects with the 
autograft had cell infiltration, a perichondrium that resembled that of the surrounding 
xiphoid, and proteoglycan deposition between the edges of the defect and autograft.  
These results suggest that ASC microbeads may serve as trophic factor production 






CONCLUSION AND FUTURE PERSPECTIVES 
 
 In order to develop cartilage regeneration therapies that harness the paracrine 
actions of ASCs, the first step is to understand the signaling mechanisms that regulate 
temporal morphology and development of cartilaginous tissues.  Tethers present in both 
the growth plates of long bones and synchondroses of the cranial base occurred in 
specific regions that could be mapped.  These tethers thickened and accumulated in 
number with age as the tissue decreased in size.  When the VDR was ablated, tether 
formation was nearly eliminated in both rachitic growth plates and synchondroses.  
Restoring mineral homeostasis with rescue diets restored the overall size of both growth 
centers but only partially restored growth center morphology and tether formation, 
suggesting that tether formation in both growth centers is partially regulated by VDR 
signaling via 1,25-dihydroxy vitamin-D3.  Serial decalcified histological sections 
confirmed the findings from μCT analysis as parameters were significantly correlated 
between the two imaging and analytical techniques.  During post-fetal development from 
2 to 15 weeks of age, tether phenotype had significant relationships to animal weight.  
Synchondrosis and growth plate thicknesses were inversely correlated to weight in wild-
type mice, whereas in both 2 to 15 week old normal mice and 10 week old VDR-/- mice 
with normal and abnormal mineral homeostasis, tether phenotype was tightly linked to 
growth center thickness.  The strong association between tether formation and growth 
center morphology may have implications on normal skeletal development and 
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homeostasis, and further investigation may provide insight into strategies to regulate 
cartilage formation and bone growth. 
Tailoring the secretory profile of ASCs is the next step in using the paracrine 
actions of these therapies to regenerate cartilage.  Rat ASC cultures had high mRNA 
levels of TGF-β and MAPK signaling molecules, and preconditioning ASC cultures with 
chondrogenic medium and its individual components had distinct effects on trophic factor 
production.  For rat ASC cultures in 2-D monolayer and 3-D alginate microbeads, 
chondrogenic medium increased the expression and secretion of IGF-I, TGF-β2, and 
TGF-β3 and decreased the expression and secretion of VEGF-A and FGF-2.  
Microencapsulation alone increased PTHrP expression and IGF-I, TGF-β2, and VEGF-A 
secretion in growth medium, but not necessarily in chondrogenic medium.  Chondrogenic 
medium and microencapsulation had similar effects on human ASCs isolated from 
multiple donors as chondrogenic medium consistently decreased the expression of FGF-2 
and secretion of VEGF-A from ASC microbeads derived from the same donor 
population.  Additionally, microencapsulation alone increased gene expression of PTHrP 
and secretion of IGF-I and TGF-β3. 
In subsequent studies with rat ASC monolayers cultured in growth and 
chondrogenic media, ascorbic acid 2-phosphate decreased FGF-18 expression and 
VEGF-A secretion but increased IGF-I and TGF-β2 secretion.  Meanwhile, 
dexamethasone increased BMP-2 and FGF-18 expression, decreased FGF-2 expression, 
and decreased VEGF-A expression and secretion in growth and chondrogenic media.  
TGF-β1 and BMP-6 increased expression and secretion of TGF-β2 and FGF-18 
expression while TGF-β1 also increased expression and secretion of FGF-2 and VEGF-
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A.  Crosslinking human ASC microbeads in BaCl2 instead of CaCl2 did not eliminate the 
beneficial effects of microencapsulation, but did decrease IGF-I gene expression and 
production.  Increasing the guluronate content of the alginate microbead increased TGF-
β3 expression and IGF-I maintained within.  Decreasing the molecular weight of the 
alginate used eliminated the beneficial effects microencapsulation had on IGF-I secretion 
while increasing the molecular weight of alginate used decrease PTHrP gene expression.  
These studies demonstrated that different components of differentiation media and 
alginate microbeads can be used to tailor the secretome of stem cell therapies and that 
ASC microbeads may be a reliable source for delivering multiple growth factors to 
facilitate cartilage regeneration. 
Before delivering these ASC therapies in vivo, the effect ASC-secreted factors 
have on chondrocyte behavior and cartilage regeneration needs to be determined.  ASCs 
that were preconditioned in growth medium inhibited cartilage regeneration in a focal 
hyaline cartilage defect in vivo.  In vitro, ASCs monolayers or microbeads cultured in 
growth medium secreted a large amount of VEGF-A which caused chondrocyte apoptosis 
and reduced proteoglycan synthesis.  Additionally, these ASCs secrete factors that 
reduced chondrogenic gene expression and proliferation.  Treating ASCs with 
chondrogenic medium reduced the secretion of VEGF-A, significantly reduced the 
deleterious effects ASC-secreted factors have on chondrocytes, and eliminated the 
inhibitory effect ASCs have on cartilage regeneration.  Blocking VEGF-A in ASC-
conditioned medium eliminated the deleterious effects ASC-secreted factors had on 
chondrocyte phenotype and apoptosis.  Adding a high concentration of FGF-2 eliminated 
the apoptotic effect VEGF-A had on chondrocytes and adding both low and high 
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concentrations of FGF-2 eliminated the detrimental effects VEGF-A had on chondrocyte 
phenotype.  These results have significant implications on how ASCs and possibly other 
stem cell therapies are used for repairing cartilage.  Specifically, these therapies must be 
pre-treated or modified to reduce the inhibitory effects of VEGF-A and other secreted 
factors on cartilage regeneration. 
 The final step in exploiting the paracrine actions of ASCs to regenerate cartilage 
is to develop an effective method to deliver them in vivo.  Initial studies showed that ASC 
alginate microbeads calcified after 1 to 6 months regardless if they were implanted 
intramuscularly or injected subcutaneously.  Non-buffered calcium crosslinked alginate 
beads placed in a phosphate buffered bath sequestered the surrounding phosphate and 
calcified, forming traces of hydroxyapatite.  More extensive analysis of calcified 
microbeads delivered in vivo showed that the 1.6±0.4 Ca/P ratio of the mineral formed 
closely matched hydroxyapatite found in bone.  Incorporating bisphosphonate helped 
regulate alginate calcification whereas using barium chloride as the crosslinking agent 
eliminated calcification.  Buffering the crosslinking solution at pH 7.3 while washing and 
storing samples in basal media prior to implantation also eliminated calcification in vivo.  
Once this formulation was optimized, ASC microbeads preconditioned with growth and 
chondrogenic media were implanted in 3 mm xiphoid cartilage defects but were unable to 
facilitate any observable cartilage regeneration.  When ASC microbeads preconditioned 
in growth media were immobilized with an RGD-conjugated hydrogel in 2 mm defects, 
cell infiltration and tissue deposition at the edges of the defect were observed.  Defects 
with ASC microbeads preconditioned in chondrogenic medium and immobilized in 
RGD-conjugated hydrogel had extracellular matrix deposition throughout the defect with 
 176 
cell infiltration, tissue resembling a perichondrium, and initial proteoglycan deposition.  
These results suggest that modifying the crosslinking solution for alginate microbeads 
can regulate bulk hydroxyapatite formation and that ASC microbeads may serve as 
trophic factor production sources to stimulate cartilage regeneration along a biomimetic 
scaffold. 
The strong correlations between tether formation and growth center thickness, 
animal weight, and tissue shrinkage during histological processing suggest that tethers 
may have a fundamental role in growth plate closure, mechanical stability, and their 
interrelationship.  If confirmed, this revelation will contradict decades of growth plate 
development dogma because growth plate closure and changes in mechanical properties 
have long been thought to occur in layers corresponding to the tissue’s different 
hierarchical zones.  Tethers, however, traverse all developmental zones of the growth 
plate.  The closest independent results that may confirm tethers’ role in growth plate 
mechanical stability was disclosed by Sevenler and Bonassar et al. at the 2012 Annual 
Meeting of the Orthopaedic Research Society in San Francisco.  They found that cyclic 
shear strain applied in the anteroposterior direction (γyx) on normal growth plates of 
Sprague-Dawley rats induced significant shear strain in the direction of growth (γxy) 
concentrated in bands located in the interterritorial matrix between chondrons.  These 
bands of shear strain were similar to the periodic nature of tether formation within the 
growth plate.  When the same shear strain was applied on growth plates of vitamin D 
deficient rats, the spacing between the peak strains were twice as large and not periodic, 
consistent with tether formation in VDR null mice.  Whether tether formation forms in 
response to this shear strain or imparts the growth plate with this periodic mechanical 
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property is unknown.  However, further elucidating the relationship between tissue 
microscale mechanical properties and tether formation during normal and abnormal 
growth plate development may revolutionize our understanding of growth plate biology 
and closure.    
 Although preconditioning with chondrogenic medium generally increased 
chondrogenic factors and decreased angiogenic ones, it is unknown what global effects it 
had on other cytokines, growth factors, and enzymes.  Inflammatory cytokines, proteases, 
and inhibitors are important for cartilage regeneration and a better understanding of how 
preconditioning affects these factors is needed.  Additionally, controlling the exact timing 
of different factors’ secretion profiles is critically.  Specifically, anti-inflammatory 
cytokines and growth factors that stimulate mesenchymal condensation and 
chondrogenesis may be critical for initial cartilage regeneration, but their presence during 
subsquent stages of regeneration may be detrimental.  It is unknown whether ASCs 
preconditioned with different treatments will secrete temporally varying amounts of 
growth factors once delivered in vivo.  Additionally, the exact role each ASC-secreted 
factor has in cartilage regeneration is unknown.  To elucidate this may require several in 
vivo studies of varying lengths where multiple ASC populations that underwent different 
pretreatments are delivered. 
 Developing a novel ASC therapy that stimulates cartilage regeneration via its 
paracrine actions may take decades before it is clinically available to any patient.  
However, evaluating and tailoring stem cell therapies for tissue regeneration via its 
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